

UC 577,1; 61

ISSN 0354-3447



JUGOSLOVENSKA MEDICINSKA BIOHEMIJA

Časopis Društva medicinskih biohemičara Srbije i Crne Gore
Official Journal of the Society of Medical Biochemists of Serbia and Montenegro

Godište: 23

Beograd, oktobar – decembar 2004

Broj: 4

SADRŽAJ – CONTENTS

PREGLEDNI ČLANAK – REVIEW ARTICLE

- Danijela Vučević, Tatjana Radosavljević, Gordana Đorđević-Denić*
ULOGA EOZINOFILNIH LEUKOCITA U PATOGENEZI BRONHIJALNE ASTME 333

ORIGINALNI NAUČNI RAD – ORIGINAL PAPER

- Vesna Vučić, Miroslav Adžić, Ana Nićiforović, Nevena Tišma, Sabera Ruždijić, Marija B. Radojčić*
CELL DEATH IN IRRADIATED PROSTATE CANCER CELLS ASSESSED BY FLOW CYTOMETRY 343

- Aleksandra Nikolić, Aleksandra Divac, Nada Bogdanović, Marija Mitić-Milikić, Dragica Radojković*
CFTR GENE ANALYSIS IN PATIENT WITH ATYPICAL CYSTIC FIBROSIS 351

- Aleksandra Perić-Popadić, Mirjana Bogić, Žikica Jovičić, Sanvila Rašković, Vesna Tomić-Spirić, Snežana Kovačević, Jasna Bolpačić, Miodrag Čolić*
THE INFLUENCE OF ATOPY ON sICAM-1 SERUM LEVELS IN PATIENTS WITH ALLERGIC RHINITIS AND BRONCHIAL ASTHMA 355

- Jelena Poznanić, Ljubica Perišić, Jelena Urošević, Branka Petručev, Tatjana Đureinović, Nataša Tošić, Lidija Krivokapić-Dokmanović, Dragana Janić, Milica Čvorkov-Dražić, Gordana Bunjevački, Sonja Pavlović*
BIOCHEMICAL PHENOTYPE AND ORIGIN OF THE THREE MOST COMMON BETA-THALASSEMIA MUTATIONS IN SERBIA 361

- Zorica S. Saičić, Dejan N. Mijalković, Aleksandra L. Nikolić, Duško P. Blagojević, Mihajlo B. Spasić, Vojislav M. Petrović*
EFFECT OF THYROXINE ON GLUTATHIONE-DEPENDENT ANTIOXIDANT ENZYME ACTIVITIES AND GLUTATHIONE CONTENT IN THE INTERSCAPULAR BROWN ADIPOSE TISSUE OF DIFFERENT MATURATED RATS 367

- Ljiljana Petrović-Rackov, Nada Pejnović, Zoran Mijušković, Gordana Ercegović*
INFLAMMATORY RESPONSE IN RHEUMATOID ARTHRITIS 375

- Radmila Maksimović, Ljuba Mandić, Slavica Spasić*
THE BASIC HAEMATOLOGICAL MEASUREMENTS IN PERIPHERAL BLOOD FROM WORKERS EXPOSED TO MERCURY VAPOURS 381

Nastavak na poledini korica (continued on back cover)

YUGOSLAV MEDICAL BIOCHEMISTRY

Volume: 23

Belgrade, October – December 2004

No: 4

STRUČNI RAD – PROFESSIONAL PAPER

Dragica Milenković, Aleksandar Vuksanović, Nataša Lalić, Sanja Simić-Ogrizović, Violeta Dopsaj
NOVI PROTOKOL ZA LABORATORIJSKO ISPITIVANJE PACIJENATA SA KALKULOZOM URINARNOG TRAKTA. . . 387

Nada Kostić, Branislava Brkić, Zorica Čaparević, Verica Milošević
SOMATOSTATIN U OBOLJENJIMA GASTROINTESTINALNOG TRAKTA 393

OBAVEŠTENJA – TECHNICAL REPORTS 397

Jugoslavensku medicinsku biohemiju

referišu: Bowker International Serials Database, Bulletin Scientifique, Chemical Abstracts Service, EMBASE / Excerpta Medica, Elsevier BIOBASE / Current Awareness in Biological Sciences, Current Awareness in Biomedicine
Jugoslavenski Bibliografsko Informacijski Institut, Referativnyi Zhurnal.

Jugoslavenska medicinska biohemija

is covered by the following indexing and abstracting service: Bowker International Serials Database, Bulletin Scientifique, Chemical Abstracts Service, EMBASE / Excerpta Medica, Elsevier BIOBASE / Current Awareness in Biological Sciences, Current Awareness in Biomedicine, Referativnyi Zhurnal, Yugoslav Institute for Bibliography and Information (YUBIN)

JUGOSLOVENSKA MEDICINSKA BIOHEMIJA

YUGOSLAV MEDICAL BIOCHEMISTRY

Jugoslovenska Medicinska Biohemija
is electronic available on <http://www.dmbj.org.yu/jugoslovmedbiohem>

JUGOSLOVENSKA MEDICINSKA BIOHEMIJA

Časopis Društva medicinskih biohemičara Srbije i Crne Gore

YUGOSLAV MEDICAL BIOCHEMISTRY

Official Journal of the Society of Medical Biochemists of Serbia and Montenegro

Adresa uredništva

Jugoslovenska medicinska biohemija,
Društvo medicinskih biohemičara Srbije i Crne Gore, Farmaceutski fakultet
Vojvode Stepe 450, FAH 146, 11221 Beograd, Srbija i Crna Gora
Tel. / Fax: 011-36 15 631
e-mail: dmbj@eunet.yu
www.dmbj.org.yu

Editorial Office

Society of Medical Biochemists of Serbia and Montenegro
Pharmaceutical Faculty, Vojvode Stepe 450, P.O. Box 146
11221 Belgrade, Serbia and Montenegro
Tel. / Fax: +381-11-36 15 631
e-mail: dmbj@eunet.yu
www.dmbj.org.yu

*Izdavanje »Jugoslovenske Medicinske Biohemije« finansira
Ministarstvo za nauku, tehnologije i razvoj Republike Srbije*

*Yugoslav Medical Biochemistry is published by financial support
of Ministry of Science, Technology and Development of Republic of Serbia*

JUGOSLOVENSKA MEDICINSKA BIOHEMIJA

YUGOSLAV MEDICAL BIOCHEMISTRY

GLAVNI I ODGOVORNI UREDNIK
EDITOR - IN - CHIEF

Nada Majkić-Singh

REDAKCIONI ODBOR
EDITORIAL BOARD

Branislava Brkić	Jovan Kavarić
Bogomir Dimitrijević	Gordana Matić
Vidosava B. Đorđević	Ivanka Miletić
Svetlana Ignjatović	Jasmina Mimić-Oka
Jelena Joksimović	Vesna Starčević
Marina Stojanov	

MEĐUNARODNI REDAKCIONI ODBOR
INTERNATIONAL ADVISORY BOARD

Effi Anagnostou-Cacaras Athens, Greece	Armando D'Angelo Milan, Italy
Stoyan Danev Sofia, Bulgaria	Dolphe Kutter Luxemburg
Robert Rej Albany, USA	Susan Schiffman Durham, USA
Jose M. Queraltó Barcelona, Spain	

Editorial Office

Nada Majkić-Singh, Editor-in-Chief

Society of Medical Biochemists of Serbia and Montenegro, Pharmaceutical Faculty,
Vojvode Stepe 450, 11221 Belgrade, P.O. Box 146, Serbia and Montenegro

JUGOSLOVENSKA MEDICINSKA BIOHEMIJA

YUGOSLAV MEDICAL BIOCHEMISTRY

Vol. 23 (2004)

Informacije o časopisu: Časopis izlazi tromesečno. Svako godište sadrži četiri broja. Rukopisi se dostavljaju na adresu uredništva. Autori se izveštavaju o prijemu rukopisa. Svi radovi se recenziraju.

Informacije o pretplati: Pretplata za organizacije i inostranstvo iznosi 50 US \$. Pretplata se šalje na tekući račun Društva medicinskih biohemičara Srbije i Crne Gore. 255-0006390101000-02, Privredna banka Beograd a.d., Beograd (sa naznakom »pretplata za JMB«).

Informacije o oglašavanju: Svi zahtevi koji se odnose na oglašavanje u Jugoslovenskoj medicinskoj biohemiji dostavljaju se na adresu Uredništva.

Informations for contributors: »Jugoslovenska medicinska biohemija« publishes review articles, original research papers and preliminary communications dealing with clinical chemistry, medical biochemistry and related fields. All manuscript should conform to generally accepted usage in composition of scientific papers. For technical requirements, authors should consult a current issue. Contributors in two double-spaced typewritten copies should be addressed to The Editor, Yugoslav Medical Biochemistry, Pharmaceutical Faculty, Department of Medical Biochemistry, Vojvode Stepe 450, P.O. Box 146, 11221 Belgrade, Serbia and Montenegro.

Information to subscribers: Subscribers rate per Volume (containing 4 issue) US \$ 50 including surface postage. Subscription orders and correspondence should be addressed to the Editorial Office, Jugoslovenska medicinska biohemija, Pharmaceutical Faculty, Department of Medical Biochemistry, Vojvode Stepe 450, P.O. Box 146, 11221 Belgrade, Serbia and Montenegro.

ULOGA EOZINOFILNIH LEUKOCITA U PATOGENEZI BRONHIJALNE ASTME

Danijela Vučević, Tatjana Radosavljević, Gordana Đorđević-Denić

Institut za patološku fiziologiju, Medicinski fakultet, Beograd

Kratak sadržaj: Patogeneza bronhijalne astme nije do kraja razjašnjena. U plućima, perifernoj krvi i sputumu astmatičara prisutan je povećan broj eozinofila. Eozinofilija je identifikovana kao faktor rizika za razvoj opstrukcije vazdušnih puteva. Izrazit eozinofilni zapaljenski infiltrat u bronhijalnoj sluznici i korelacija između broja eozinofilnih leukocita i težine bolesti podržava hipotezu prema kojoj su eozinofili glavne inflamacijske ćelije sposobne da izazovu patofiziološke promene karakteristične za astmu. Aktivirani eozinofili sekretuju široki spektar preformiranih i novosintetisanih medijatora koji dovode do oštećenja bronhijalnog epitela, spazma glatkih mišića bronhija, povećanja sekrecije sluzi i vazodilatacije. Dokazano je da se u toku astmatičnog napada povećava proizvodnja oksidanasa. Brojna istraživanja ukazuju da eozinofili u krvi i vazdušnim putevima osoba obolelih od bronhijalne astme stvaraju veću količinu oksidanasa u odnosu na zdrave osobe.

Ključne reči: eozinofilni leukociti, bronhijalna astma, inflamacija, oksidansi

Bronhijalna astma i hronične opstruktivne bolesti pluća

Bronhijalna astma je inflamacijska bolest koju karakteriše preosetljivost vazdušnih puteva sa povremenim periodima bronhospazma. Radi se o spazmu ili dužim kontrakcijama bronhijalne i bronhiolarne glatke muskulature. *Extrinsic* astma (atopijska, alergijska astma) je mnogo češća od *intrinsic* astme (nealergijske, neatopijske, inflamacijske astme). Bronhijalna astma je veoma složeno oboljenje koje podrazumeva biohemijske, autonomne, imunske, infektivne, endokrine i psihičke faktore različitog stepena u različitim osoba (1).

Smatra se da je inflamacija koja nastaje kao posledica preosetljivosti ili hiperosetljivosti vazdušnih puteva osnovni patofiziološki razlog u svim tipovima astme. Oslobođanje medijatora inflamacije dovodi do spazma glatkih mišića bronhija, vaskularne kongestije, povećane propustljivosti krvnih sudova, edema, stvaranja guste, lepljive sluzi i prestanka funkcije (1).

Po mnogima eozinofilni leukociti su ključne efektorne ćelije u patogenezi ove inflamacijske bolesti vazdušnih puteva (2–4, 9, 47, 48–59). Aktivirani eozinofili sekretuju široki spektar preformiranih i novosintetisanih medijatora koji razaraju integritet bronhijalne sluznice, zaustavljaju pokretanje cilija i dovode do oštećenja i jake sekrecije epitelnih ćelija. Oštećenje epitelnih ćelija je u korelaciji sa preosetljivošću vazdušnih puteva (1, 51, 57, 58). Brojni citokini koje proizvode eozinofili obezbeđuju lokalni mehanizam kojim se pojačava i modulira postojeći zapaljenski proces (5, 55, 56). Metaplazija peharastih ćelija, koja nastaje kao posledica inflamacije disajnih puteva, takođe umnogome doprinosi kliničkoj simptomatologiji, opstrukciji disajnih puteva i mortalitetu (6, 47, 51). Bitne patomorfološke karakteristike bronhijalne astme su i subepitelna fibroza, hipertrofija glatkih mišića i formiranje novih krvnih sudova, što u krajnjem ishodu dovodi do remodelovanja zida disajnih puteva (5, 7, 51, 56).

Osim bronhijalne astme, inflamacija je značajna za razvoj hroničnih opstruktivnih bolesti pluća (HOBP). Ipak, inflamacijski odgovor u HOBP se značajno razlikuje od odgovora u astmi, što je prikazano na tabeli 1. Međutim, neki bolesnici imaju istovremeno i HOBP i astmu, pa inflamacija u njihovim plućima može pokazivati karakteristike obe bolesti (8).

Adresa autora:

Danijela Vučević
Institut za patološku fiziologiju Medicinskog fakulteta u Beogradu
Dr Subotića 9
11000 Beograd

Table I Karakteristike inflamacije u bronhijalnoj astmi i HOBP

Bolest pluća	Bronhijalna astma	HOBP
Inflamacijske ćelije	Eozinofili Mali porast broja makrofaga Porast broja CD4+ T limfocita Aktivacija mastocita	Neutrofil Veliki porast broja makrofaga Porast broja CD8+ T limfocita Leukotrien B ₄ (LTB ₄)
Medijatori inflamacije	Leukotrien D ₄ (LTD ₄) Interleukin-4 (IL-4) Interleukin-5 (IL-5) Mnogi drugi medijatori	Interleukin-8 (IL-8) Faktor nekroze tumora α (TNF α) Mnogi drugi medijatori Skvamozna metaplazija epitela
Posledice	Fragilan epitel Zadebljanje bazalne membrane Metaplazija sluzi Uvećanje žlezda	Destrukcija parenhima Metaplazija sluzi Uvećanje žlezda
Odgovor na terapiju	Glikokortikoidi inhibiraju inflamaciju	Glikokortikoidi imaju mali efekat ili ne ispoljavaju svoje dejstvo

Table II Diferencijalna dijagnoza bronhijalne astme i HOBP

Bolest pluća	Znaci koji ukazuju na bolest
Bronhijalna astma	Početak u mladosti (često u detinjstvu) Simptomi se menjaju iz dana u dan Simptomi se javljaju noću ili rano ujutru Česta pridruženost alergije, rinitisa i/ili ekcema Pozitivna porodična anamneza za astmu Uglavnom reverzibilno ograničenje protoka vazduha
HOBP	Početak u srednjem životnom dobu Spora progresija simptoma Anamneza o dugotrajnom pušenju Dispnoja pri fizičkom naporu Uglavnom ireverzibilno ograničenje protoka vazduha

Table III Proteinski sadržaj eozinofilnih granula

Protein	Vrsta granula
Glavni osnovni protein (MBP-major basic protein)	Sekundarne (specifične) granule
Eozinofilni katjonski protein	Sekundarne (specifične) granule
Eozinofilni neurotoksin	Sekundarne (specifične) granule
Eozinofilna peroksidaza	Sekundarne (specifične) granule
Lizozim	Sekundarne (specifične) granule
Kisela fosfataza	Sekundarne (specifične) granule
Arilsulfataza B	Sekundarne (specifične) granule
Katalaza	Sekundarne (specifične) granule
Enoil-CoA hidrataza	Sekundarne (specifične) granule
3-ketoacil-CoA tiolaza	Sekundarne (specifične) granule
β -glukuronidaza	Sekundarne (specifične) granule
Katepsin D	Sekundarne (specifične) granule
Elastaza	Sekundarne (specifične) granule
Granulocitno-monocitni faktor rasta (GM-CSF)	Sekundarne (specifične) granule
Interleukin-2 (IL-2)	Sekundarne (specifične) granule
Interleukin-4 (IL-4)	Sekundarne (specifične) granule
Interleukin-5 (IL-5)	Sekundarne (specifične) granule
Interleukin-6 (IL-6)	Sekundarne (specifične) granule
Faktor nekroze tumora α (TNF α)	Sekundarne (specifične) granule
RANTES	Sekundarne (specifične) granule
Tip II fosfolipaza A ₂	Sekundarne (specifične) granule
Baktericidni protein koji povećava permeabilnost	Sekundarne (specifične) granule
Kisela fosfataza	Male granule
Arilsulfataza B	Male granule
Katalaza	Male granule
Citohrom b ₅₅₈	Male granule
Elastaza	Male granule
Eozinofilni katjonski protein	Male granule
Lizofosfolipaza (Charcot-Leyden kristalni protein)	Primarne (nespecifične granule)
Ciklooksigenaza	Lipidna telašca
5-lipoksigenaza	Lipidna telašca
15-lipoksigenaza	Lipidna telašca
Leukotrien C ₄ sintetaza	Lipidna telašca
Eozinofilna peroksidaza	Lipidna telašca
Esteraza	Lipidna telašca

U nekih bolesnika s hroničnom bronhijalnom astmom jasno razlikovanje ove bolesti od HOBP nije moguće korišćenjem savremenih metoda za imidžing pluća i ispitivanje plućne funkcije. Znaci karakteristični za bronhijalnu astmu i HOBP, koji su važni za diferencijalnu dijagnozu ovih bolesti prikazani su na tabeli II. Međutim, ovi znaci se ne sreću kod svih bolesnika. Na primer, osoba koja nikad nije pušila može da se razboli od HOBP. Takođe, astma može da se razvije u odraslih, pa čak i u starijih osoba (8).

Eozinofilni leukociti i zapaljenje mukoze disajnih puteva

Postoje dokazi o akutnoj i hroničnoj inflamaciji koje su nepravilno raspoređene u disajnim putevima astmatičara (9). Opšte je prihvaćeno da su eozinofili dominantne efektorne ćelije u hroničnoj inflamaciji (2–4, 9, 47, 48–59). Svoju ulogu ostvaruju u toku procesa degranulacije oslobađanjem čitavog niza medijatora i faktora rasta (Tabela III–V).

Table IV Eozinofilni lipidni medijatori

Faktor aktivacije trombocita (PAF-platelet activation factor)
Leukotrien B ₄ (LTB ₄)
Leukotrien C ₄ (LTC ₄)
Tromboksan A ₂ (TXA ₂)
Prostaglandin E ₂ (PGE ₂)
Prostaglandin G ₂ (PGG ₂)
Prostaglandin F _{2α} (PGF _{2α})
Prostaglandin I ₂ (PGI ₂)
5-hidroksieikosatetraenoična kiselina (5-HETE)
12-hidroksieikosatetraenoična kiselina (12-HETE)
15-hidroksieikosatetraenoična kiselina (15-HETE)
5,15-dihidroksieikosatetraenoična kiselina (5,15-diHETE)
8,15-dihidroksieikosatetraenoična kiselina (8,15-diHETE)
14,15-dihidroksieikosatetraenoična kiselina (14,15-diHETE)
Lipoksin A ₄ (LXA ₄)
Lipoksin C ₄ (LXC ₄)
13-hidroksilinolesna kiselina (13-HODE)

Table V Eozinofilni faktori rasta

Faktor nekroze tumora α (TNFα – tumor necrosis factor α)
Faktor nekroze tumora β (TNFβ – tumor necrosis factor β)
Faktor rasta poreklom iz trombocita (PDGF – platelet-derived growth factor)
Faktor rasta vaskularnog endotela (VEGF – vascular endothelial growth factor)
Heparin vezujući epidermski faktor rasta (HB-EGF → heparin-binding epidermal growth factor)
Nervni faktor rasta (NGF – nerve growth factor)
Endotelin (ET – endothelin)

Iz granula eozinofila oslobađaju se katjonski proteini (eozinofilni katjonski protein, eozinofilna peroksidaza, eozinofilni neurotoksin, i dr.), enzimi (fosfolipaza A₂, eozinofilna kolagenaza, katalaza, kiselna fosfataza, histaminaza, itd.) i neuropeptidi (supstanca P, vazoaktivni intestinalni peptid – VIP, i dr.). Najzastupljeniji protein u granulama eozinofila (MBP – major basic protein), deluje toksično na epitel vazdušnih puteva. Pokazano je da MBP izaziva oštećenje pneu-

Tabela VI Eozinofilni receptori za hemokine i njihovi endogeni ligandi

Subfamilija hemokina	Nomenklatura	Endogeni ligandi
CXC hemokini	CXCR1	Interleukin-8 (IL-8)
CXC hemokini	CXCR1	Granulocitni protein hemotakse-2 (GCP-2 → granulocyte chemotactic protein-2)
CXC hemokini	CXCR2	Interleukin-8 (IL-8)
CXC hemokini	CXCR2	Granulocitni protein hemotakse-2 (GCP-2 → granulocyte chemotactic protein-2)
CC hemokini	CCR1	Makrofagni inflamacijski protein 1α (MIP1α)
CC hemokini	CCR1	RANTES
CC hemokini	CCR1	Monocitni protein hemotakse-2 (MCP-2 → monocyte chemotactic protein-2)
CC hemokini	CCR1	Monocitni protein hemotakse-3 (MCP-3 → monocyte chemotactic protein-3)
CC hemokini	CCR1	Monocitni protein hemotakse-5 (MCP-5 → monocyte chemotactic protein-5)
CC hemokini	CCR1	Leukotaktin-1
CC hemokini	CCR3	Eotaksin I
CC hemokini	CCR3	Eotaksin II
CC hemokini	CCR3	Leukotaktin-1
CC hemokini	CCR3	Monocitni protein hemotakse-3 (MCP-3 → monocyte chemotactic protein-3)
CC hemokini	CCR3	Monocitni protein hemotakse-4 (MCP-4 → monocyte chemotactic protein-4)
CC hemokini	CCR3	RANTES

mocita (10, 11) i deskvamaciju epitela respiracijskog trakta (12, 13). MBP narušava transport jona u epitelu traheje, što može da izmeni zapreminu i sastav tečnosti koja oblaže vazdušne puteve (14).

Nezaobilazni element aktivacije i efektorne funkcije eozinofila su i novosintetisani lipidni medijatori ciklooksigenaznog puta (prostaglandini i tromboksan A_2) i lipoksigenaznog puta (leukotrieni, lipoksini i dr.). Osim toga, eozinofili stvaraju i citokine (eokine), i to pre svega interleukin-3 (IL-3), IL-5 i granulocitno-monocitni faktor rasta (GM-CSF), koji svojim autokrinim dejstvom održavaju i intenziviraju inflamaciju. U granulama eozinofila utvrđeno je i prisustvo IL-10, IL-11, IL-12, IL-16, interferona γ (INF γ) i faktora koji inhibira migraciju makrofaga (MIF – macrophage migration inhibitory factor). Zapaljenski proces moduliraju i eokini akutne inflamacije (IL-1 α , IL-6, i faktor nekroze tumora α – TNF α), faktor aktivacije trombocita (PAF), kao i hemokini (IL-8, makrofagni inflamacijski protein 1 α – MIF1 α , i dr.) (2–4, 9, 47, 48–59).

Inflamacijski odgovor predstavlja kaskadu događaja koja se manifestuje sekvencionalnom akcijom integrina, selektina, superfamilije imunoglobulina, kadherina, adresina i drugih familija adhezivnih molekula i njihovih receptora. Zapaljenske ćelije se kotrljaju preko endotela posredstvom mehanizama koje obezbeđuju selektini (L, E i P selektini). Zahvaljujući integrinima ostvaruje se čvrsto vezivanje inflamacijskih ćelija za endotel. Naime, na neaktiviranim leukocitima integrini se nalaze u mirujućem stanju i eksprimiraju se na bazalnom nivou. Aktivacijom ćelija stimuliše se i ispoljavanje i aktivacioni status ovih glikoproteinskih membranskih molekula, kao i sekrecija L-selektina. Integrini su uključeni i u kontakte leukocita sa proteinima ekstracelularnog matriksa. Najznačajniji ligandi integrina među proteinima ekstracelularnog matriksa su kolagen, laminin, fibronektin i vitronektin (15, 67).

Eozinofili na svojoj površini ispoljavaju adhezivne molekule važne za povezivanje ovih leukocita u nastanku imunskog odgovora, za usmeravanje njihovog kretanja kroz krvne sudove i za interakciju sa ekstracelularnim matriksom. Subfamiliji β_1 integrina (raniji naziv VLA antigeni – very late activation) pripadaju VLA-4, VLA-5 i VLA-6. U β_2 subfamiliju integrina svrstani su Mac-1 (macrophage-1 antigen koji se još označava i kao CD11b/CD18), leukocitni funkcionalni antigen-1 (skraćeno označen kao LFA-1 ili CD11a/CD18) i p150/95 (CD11c/CD18). $\alpha_4\beta_7$ je takođe integrin ćelijske membrane eozinofila. Na površini eozinofila ispoljeni su i L-selektin i sijaloglikoprotein (Sialil Lewis X). PECAM-1, koji je dobio naziv od početnih slova engleskih reči platelet endothelium cellular adhesion molecule-1, i intercelularni adhezivni molekul-1 (ICAM-1) predstavljaju adhezivne molekule iz superfamilije imunoglobulina takođe ekspimirane na eozinofilima (2, 4, 67).

Eozinofili vezuju imunoglobuline (Ig) preko površinskih receptora. Tako se IgE i IgG vezuju za Fc γ RI, Fc γ RII i Mac-2 receptore, dok se IgA vezuje za Fc α R (4).

Svoje specifične receptore na površini eozinofila imaju i C5a, CR1, CR3 i C1q komponenta komplemента (4).

Brojni površinski receptori eozinofila olakšavaju interakciju ovih ćelija sa citokinima. Na ovaj način svoje delovanje ostvaruju IL-2, CD25, IL-3, IL-5, IL-13, GM-CSF, interferon α (INF α), INF β , INF γ , TNF α , i transformišući faktor rasta β (TGF β) (4, 16).

Na površini eozinofila se mogu uočiti i receptori za hemokine. Vezivanjem za ove receptore hemokini učestvuju u migracijskim kretanjima eozinofila, aktivaciji integrina, indukciji respiracijskog praska, transkripciji citokina (neki od njih), angiogenezi, stvaranju kolagena i proliferaciji hematopoetskih prekursora. Najnovija istraživanja pokazuju da je RANTES (hemokin čiji naziv predstavlja kovanicu dobijenu od početnih slova engleskih reči *regulated upon activation normal T cell expressed and secreted*) pravi hemotaktički faktor u bolesnika sa alergijskom astmom, dok je IL-5 neophodan kofaktor (4, 17).

Eozinofili i njihovi produkti su prisutni u krvi, disajnim putevima, pljuvački i u bronhoalveolarnom lavatu (BAL) osoba obolelih od bronhijalne astme. U astmatičara eozinofilija je u korelaciji sa stepenom opstrukcije i težinom bolesti (2, 4).

O procesima koji dovode do aktivacije eozinofila *in vivo* još uvek se relativno malo zna. Osnovna karakteristika eozinofilne funkcije je da je za nju neophodan »priming« eozinofila, što prevedeno sa engleskog jezika znači »prvi sloj, prvo premazivanje«. *Priming* bi mogao da se posmatra kao međusobni uticaj modulacijskih i aktivacijskih signala. Aktivacija eozinofilnih receptora preko adhezivnih molekula, komponenti komplemента i imunoglobulina bi mogla da bude uključena u ove događaje. Receptori eozinofila su potentni signalni molekuli *in vitro*, ali svoju optimalnu funkciju postižu tek nakon priminga sa citokinima i hemotaksinima. IL-5 i GM-CSF priming eozinofila neophodan je za odgovore ovih ćelija, uključujući sintezu i oslobađanje bioaktivnih medijatora, što doprinosi povećanoj bronhijalnoj reaktivnosti (18). Smatra se da cirkulišući eozinofili dobijaju povećanu sposobnost da sekretuju IL-5 kad stignu u pluća, gde su stimulisani i drugim citokinima, kao što su IL-2 i IL-4 (19).

Migracija eozinofila iz cirkulacije u plućno tkivo se odigrava nakon njihove adhezije za vaskularne endotelne ćelije, komponente ekstracelularnog matriksa i tkivne ćelije. Kretanje ćelija u zapaljensko područje se sastoji iz rolovanja (kotrljanja), čvrste adhezije i transendotelne migracije. Eozinofilna dijapeza na mesto inflamacije je regulisana citokinima podstaknutom i pojačanom ekspresijom endotelnih ad-

hezivnih molekula. Na površini endotelnih ćelija utvrđeno je prisustvo vaskularnog adhezivnog molekula-1 (VCAM-1), ICAM-1, ICAM-2, PECAM-1, E-selektina, P-selektina, fibronektina i laminina (20). Svaki od ovih molekula ima svoj odgovarajući ligand na eozinofilima i bazofilima (LFA-1, Mac-1, VLA-4, L-selektin) (21). Specifična ekspresija VLA-4 na eozinofilima i limfocitima, i njeno odsustvo na neutrofilima doveli su do hipoteze da je VCAM-1 predominantni endotelni regulator hronične inflamacije bronhijalne mukoze (22). IL-4 dovodi do povećane ekspresije VCAM-1 na endotelnim ćelijama (23). Povećana endotelna ekspresija VCAM-1, E-selektina i ICAM-1 je povezana sa alergijskim zapaljenjem pluća (2). Lutman i saradnici (24) su eksperimentalno pokazali da IL-4 i IL-13 pojačavaju efekat TNF α na eozinofilnu aktivaciju, kao i sinergistički efekat ovih citokina sa IL-5 na eozinofilnu aktivaciju.

IL-5 pojačava adheziju humanih eozinofila za vaskularni endotel i dovodi do hiperreaktivnosti donjih disajnih puteva (25). Receptor IL-5 pripada familiji tipa 1 citokinskih receptora. α subjedinica (β c lanac koji koriste i IL-3 i GM-CSF za signalnu transdukciju) ovog visokoafinitetnog receptora se aktivira nakon vezivanja IL-5 za receptorski IL-5 α lanac (IL-5R α), i time započinje serija intracelularnih događaja. Na ovaj način tirozinskom fosforilacijom Janus kinaze 2 (JAK2) i proteina STAT1 α (signal transducer and activators of transcription 1 α) aktivira se JAK-STAT put. Familiju STAT proteina čini sedam članova (STAT 1 α , STAT 1 β i STAT 2–6). Osim JAK2, IL-5 aktivira i druge tirozin kinaze (lyn, hck, yes, btk, tec, c-fes). JAK2 i c-fes su direktno udružene sa β c subjedinicom GM-CSF/IL-3/IL-5 receptora, sugerišući da je njihova aktivacija rani događaj citokinske signalizacije (26, 27). JAK kinaze su neophodne za aktivaciju STAT proteina koji se nalaze u latentnom obliku u citoplazmi. Nakon aktivacije, odnosno fosforilacije, STAT proteini formiraju homodimere i heterodimere, translociraju se u jedro, vezuju za određenu sekvencu dezoksiribonukleinske kiseline (DNK) i regulišu transkripciju. U humanim eozinofilima IL-5 indukuje dva DNK-vezujuća kompleksa koji sadrže tirozin fosforilisane proteine. Jedan od ova dva DNK-vezujuća kompleksa sadrži STAT1 α verovatno kao dimer. Međutim, IL-5 pored indukcije STAT proteina indukuje i mnoge druge nuklearne proteine. Dugotrajna stimulacija ovim citokinom dovodi do indukcije transkripcionog faktora c-myc u humanim eozinofilima. IL-5 preko ras puta indukuje transkripcione faktore c-fos i c-jun, p21 ras, raf, MAPKK (p41 i p45) i MAPK (p44). S obzirom da do sada nije identifikovan apsolutno eozinofilni specifični regulacijski DNK element i transkripcioni faktor, moguće je da je specifična signalizacija rezultat specifične kombinacije transkripcionih faktora (25).


Eozinofilna apoptoza u hroničnoj inflamaciji bronhijalne mukoze

Broj eozinofila *in vivo* je regulisan ne samo produkcijom eozinofila u kostnoj srži, već i stepenom eozinofilne apoptoze, koja predstavlja najčešći oblik fiziološke ćelijske smrti. Bcl-2 (B-cell leukemia oncogene-2) familija gena kodira heterogenu grupu proteina koji predstavljaju ključne intracelularne modulatore (regulatore) ćelijskog umiranja po tipu apoptoze (28, 29). Otkrićem Bcl 2 gena, Bcl 2 familija proteina postaje posebno istraživana oblast zbog izuzetnog značaja za razumevanje molekulsko-bioloških mehanizama koji leže u osnovi procesa apoptoze. Poslednjih godina naročito se istražuju antiapoptozni članovi Bcl 2 familije proteina (29–34).

Odložena eozinofilna apoptoza se smatra jednim od najodgovornijih mehanizama koji doprinose eozinofiliji. U ljudi izgleda da je IL-5 specifičan faktor preživljavanja eozinofila, pa nije iznenađujuća činjenica da su eozinofilija i visoka ekspresija IL-5 udružene u hroničnoj inflamaciji bronhijalne mukoze. Eozinofilna apoptoza može biti odložena IL-om 5 kojeg sekretuju susedne ćelije, ali i autokrinom produkcijom ovog citokina. Izgleda da stimulacija eozinofila IL-om 5 dovodi do indukcije Bcl-xl (Bcl-2-regulated factor xl), koji je važan antiapoptotski gen. Postoje istraživanja gde je verifikovana povećana ekspresija Bcl-2 nakon tretiranja eozinofila IL-om 5 (35). Antiapoptozno dejstvo Bcl 2 proteina zasniva se na mogućnosti da veže Bax (Bcl 2-associated x) protein u formi heterodimera i tako onemogućuje stvaranje proapoptoznih Bax/Bax homodimera. Tokom indukcije procesa apoptoze, homodimeri Bax proteina formiraju kanale na membranama mitohondrija. Putem ovih kanala mitohondrije napuštaju molekuli citohroma c, koji su od posebne važnosti za aktivaciju izvršne faze procesa apoptoze (36). Na osnovu ovih saznanja, većina autora kao glavnu biološku ulogu Bcl 2 proteina u inhibiciji procesa apoptoze smatra njegovu sposobnost vezivanja za Bax protein i heterodimerizacionu neutralizaciju njegovog proapoptoznog dejstva (37–39). U *in vitro* uslovima je dokazano da je preživljavanje eozinofila produženo kada se inkubiraju u kulturama sa eozinofilnim citokinima kao što su IL-3, IL-5 i GM-CSF (35).

Eozinofilni leukociti i oksidacijsko oštećenje u bronhijalnoj astmi

Pluća predstavljaju primarno ciljano tkivo za oksidacijsko oštećenje zbog svoje lokalizacije, anatomije i funkcije. Kod naglog povećanja broja i količine oksidansa, u uslovima tzv. oksidacijskog stresa, prirodni zaštitni mehanizmi popuštaju. Dokazano je da se u toku astmatičnog napada povećava proizvodnja oksidansa. Brojna istraživanja ukazuju da eozinofili u krvi i vazдушnim putevima osoba obolelih od bronhijalne astme stvaraju veću količinu reaktivnih kiseoničkih



Slika 1 Reaktivne kiseoničke vrste i plućni antioksidacijski mehanizmi

vrsta (RKV) u odnosu na zdrave osobe (4, 8, 46, 50, 51, 57, 58, 61–66, 68, 69). Metaboliti kiseonika čiji izvor su i eozinofili, direktno oštećuju proteinske plućnog matriksa i/ili slabe funkciju antiproteaza i/ili inaktiviraju enzime uključene u sintezu elastina i obnovu plućnog tkiva. RKV eozinofila podstiču sekreciju sluzi i bronhokonstrikciju. Tako npr., vodonik peroksid (H_2O_2) kontrahuje glatki mišić disajnih puteva *in vitro*, a izoprostan $F_{2\alpha}$ -III, koji se stvara delovanjem slobodnih radikala u toku peroksidacije arahidonske kiseline, je snažan konstriktor disajnih puteva čoveka (8, 40, 41).

U izdahnutom vazduhu astmatičara zabeležene su povišene vrednosti H_2O_2 i azot monoksida (NO) (42, 43). NO je veoma reaktivan i nestabilan oksidans. U sintezi NO učestvuje enzim NO sintetaza (NOS). Inducibilna forma ovog enzima (iNOS), koja je odgovorna za citotoksične i biocidne efekte NO, prisutna je u eozinofilnim leukocitima. Aktivira se bakterijskim lipopolisaharidima i određenim citokinima (INF_γ , $TNF\alpha$ i $IL1\beta$). Inducibilnoj NOS je za maksimalnu produkciju NO potrebno 8–12 sati, a količine NO koje se tom prilikom produkuju su znatne (15, 44).

Oksidansi eozinofila mogu da reaguju i sa lipidima i nukleinskim kiselinama, što može da dovede do disfunkcije ili smrti ćelije. Takođe, u uslovima oksidacijskog stresa aktivacijom transkripcionog faktora NF-kappaB koji upravlja ekspresijom različitih infla-

macijskih gena važnih za bronhijalnu astmu, kao što su IL-8 i $TNF\alpha$, dodatno se podstiče zapaljenski proces (8, 60).

Singlet kiseonik (1O_2), superoksid anjon ($O_2^{\cdot-}$), H_2O_2 i hidroksil radikal ($OH\cdot$) su RKV koje eozinofili stvaraju u toku respiracijskog praska. U prisustvu H_2O_2 katalitičkim dejstvom eozinofilne peroksidaze dolazi do oksidacije halogenih elemenata i stvaranja reaktivnih kiselina (hipobromne, bromovodonične i jodovodonične kiseline) (16). Istraživanje na miševima inficiranim Toksokarom kanis (*Toxocara canis*) je pokazalo da se eozinofilna peroksidaza taloži u plućnom parenhimu i miokardu, što može da dovede do oštećenja srca i pluća (45).

Zaključak

Patogeneza bronhijalne astme nije do kraja razjašnjena. Ono što se sa sigurnošću zna je da eozinofili bitno doprinose njenom nastanku. Kompleksan patofiziološki supstrat ove bolesti otkriva nova polja istraživanja interakcija eozinofilnih medijatora i citokina sa medijatorima i citokinima drugih inflamacijskih ćelija. Takođe, nameće se potreba za dodatnim proučavanjem kako inhibicije aktivnosti IL-4 i IL-5, tako i pojačavanja aktivnosti IL-10, IL-12 i INF_γ , tj. što uspešnijeg imitiranja njihovih dejstava u cilju pronalazanja efikasnijih lekova u terapiji bronhijalne astme.

THE ROLE OF EOSINOPHILIC LEUKOCYTES IN PATHOGENESIS OF BRONCHIAL ASTHMA

Danijela Vučević, Tatjana Radosavljević, Gordana Đorđević-Denić

Institut za patološku fiziologiju, Medicinski fakultet, Beograd

Summary: Pathogenesis of bronchial asthma has not been completely understood. Eosinophilic leukocytes accumulate in high numbers in the lungs, blood and sputum of asthmatic patients. Peripheral blood eosinophilia has been identified as a risk factor for the development of airway obstruction. Prominent eosinophilic inflammatory infiltrate in the bronchial mucosa and correlation between eosinophil numbers and disease severity supports the hypothesis that eosinophils are central inflammatory cells capable of inducing pathophysiological features of asthma. Activated eosinophils secrete a wide range of preformed and newly generated mediators that damage the bronchial epithelium, contract smooth muscle, increase mucous secretion and cause vasodilation. There is ample evidence that oxidants generation is increased during an asthma exacerbation. Many investigations indicate that airway and blood eosinophils produce more oxidants in asthmatic patients compared with control subjects.

Key words: eosinophilic leukocytes, bronchial asthma, inflammation, oxidants

Literatura

- Đorđević-Denić G. Patološka fiziologija respiracijskog sistema. U: Beleslin BB., Protić S, Đorđević-Denić G (ured.) i saradnici. Specijalna patološka fiziologija, Zbornik za udžbenike i nastavna sredstva, Beograd, 2003: 119–42.
- Ulfman LH, Kuijper PHM, Van der Linden JAM, Lammers JJ, Zwaginga JJ, Koenderman L. Characterization of eosinophil to TNF- α -activated endothelium under flow conditions: α_4 integrins mediate initial attachment and E-selectin mediates rolling. *J Immunol* 1999; 163: 343–50.
- Nakajima H. CD4-positive T-lymphocytes and interleukin-5 mediate antigen-induced eosinophil infiltration into the mouse trachea. *Am Rev Respir Dis* 1992; 146: 374.
- Adolphson CR, Gleich GJ. Eosinophils. In: Holgate S, Church K (eds). *Allergy*. Gower Medical, London, 1993: 6.1–6.12.
- Savić N. Određivanje koncentracije interleukina-4 i interleukina-5 u serumu bolesnika sa bronhijalnom astmom i njihov dijagnostički i prognostički značaj. Magistarska teza, Beograd, Univerzitet u Beogradu, 2001.
- Hawker KM, Johnson PRA, Hughes JM, Black JL. Interleukin-4 inhibits mitogen-induced proliferation of human airway smooth muscle in culture. *Am J Physiol* 1998; 275: 469–77.
- Đorđević-Denić G. Medijatori anafilaktičke reakcije u toku plućnih bolesti. *Deč Pulm* 1993; 1, 1–2: 11–16.
- Lenfant C, Khaltaev N. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: National heart, lung and blood institute/World health organization (NHLBI/WHO) Workshop 2001; 2701: 28–57.
- Jovičić Ž. Chronic inflammation in bronchial asthma. *Medicinska istraživanja* 1999; 33 (3): 15–20.
- Ayars GH. Eosinophil-and eosinophil granule-mediated pneumocyte injury. *J Allergy Clin Immunol* 1985; 76: 595.
- Hisamatsu K. Cytotoxicity of human eosinophil granule major basic protein to the human nasal sinus mucosa in vitro. *J Allergy Clin Immunol* 1990; 86: 52.
- Frigas E, Loegering DA, Gleich GJ. Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. *Lab Invest* 1980; 42: 35.
- Motojima S. Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. *Am Rev Respir Dis* 1989; 139: 801.
- Jacoby DB. Effect of human eosinophil major basic protein on ion transport in dog tracheal epithelium. *Am Rev Respir Dis* 1988; 137: 13.
- Maravić-Stojković V, Radak Đ, Dimković S. Endotel u aterosklerozi. U: Radak Đ, Maravić-Stojković V. ured. *Limnologija u genezi i terapiji ateroskleroze*. Beograd, 2004: 31–41.
- Litchfield MT, Lee TH. Asthma cells and cytokines. *J Asthma* 1992; 29(3): 181–91.
- Venge J, Lampinen M, Hakansson L, Rak S, Venge P. Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung. *J Allerg Clin Immunol* 1996; 97: 1110–15.
- Bracke M, Dubois GR, Bolt K, Bruijnzeel PLB, Vaerman JP, Lammers JWJ. Differential effects of the T helper cell type 2-derived cytokines IL-4 and IL-5 on ligand binding to IgG and IgA receptors expressed by human eosinophils. *J Immunol* 1997; 159: 1459–65.

19. Lai CKW, Ho ASS, Chan CHS, Tang J, Leung JCK, Lai KN. Interleukin-5 messenger RNA expression in peripheral blood CD4+ cells in asthma. *J Allergy Clin Immunol* 1996; 97: 1320–6.
20. Bochner BS, Schleimer RP. The role of adhesion molecules in human eosinophil and basophil recruitment. *J Allergy Clin Immunol* 1994; 94: 427–38.
21. Wardlaw AJ, Symon FS, Walsh GM. Eosinophil adhesion in allergic inflammation. *J Allergy Clin Immunol* 1994; 94: 1183–9.
22. Barks JL, McQuillan JJ, Iadernasco MF. TNF- α and IL-4 synergistically increase vascular cell adhesion molecule-1 expression in cultured vascular smooth muscle cells. *J Immunol* 1997; 159: 4532–8.
23. Dickensheets HL, Donnelly PR. IFN- γ and IL-10 inhibit induction of IL-1 receptor type I and type II gene expression by IL-4 and IL-13 in human monocytes. *J Immunol* 1997; 159: 6226–33.
24. Lutmann W, Matthiesen T, Matthys H, Virchow JC Jr. Synergistic effects of interleukin-4 or interleukin-13 and tumor necrosis factor-alpha on eosinophilic activation in vitro. *Am J Resp Cell Mol Biol* 1999; 20(3): 474–80.
25. Wang P, Wu P, Cheewatrakoolpon G, Myers JG, Egan RW, Billah MM. Selective inhibition of IL-5 receptor α -chain gene transcription by IL-5, IL-13 and granulocyte-macrophage colony stimulating factor in human blood eosinophils. *J Immunol* 1998; 160: 4427–32.
26. Abbas KA. Cellular and molecular immunology, W.B. Saunders Company, 1997: 249–78.
27. Van der Bruggen T, Koenderman L. Signal transduction in eosinophils. *Clin and Exp Allergy* 1996; 26: 880–91.
28. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. *Science* 1998; 281 (5381): 1322–26.
29. Brajušković G, Škaro Milić A, Cerović S, Marjanović S, Knežević Ušaj S, Čizmić M, et al. Familija Bcl 2 proteina kod malignih bolesti. *Vojnosanit Pregl* 2004; 61(3): 305–10.
30. Makin G, Hickman JA. Apoptosis and cancer chemotherapy. *Cell Tissue Res* 2000; 301 (1): 143–52.
31. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. *Science* 1995; 267 (5203): 1456–62.
32. Katoch B, Sebastian S, Sahdev S, Padh H, Hasnain SE, Begum R. Programmed cell death and its clinical implications. *Indian J Exp Biol* 2002; 40(5): 513–24.
33. Rutledge SE, Chin JW, Schepartz A. A view to a kill: ligands for Bcl-2 family proteins. *Curr Opin Chem Biol* 2002; 6 (4): 479–85.
34. Mareel M, Leroy A. Clinical, cellular and molecular aspects of cancer invasion. *Physiol Rev* 2003; 83(2): 337–76.
35. Adachi T, Motojima S, Hirata A, Fukuda T, Kihara N, Kosaku A. Eosinophil apoptosis caused by theophylline, glucocorticoids and macrolides after stimulation with IL-5. *J Allergy Clin Immunol* 1996; 6 (98): 207–15.
36. Korsmeyer SJ. Bcl-2 gene family and the regulation of programmed cell death. *Cancer Res* 1999; 59 (7 suppl): 1693s–700s.
37. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl 2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. *Semin Cancer Biol* 1993; 4(6): 327–32.
38. Reed JC, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S. Bcl-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. *J Cell Biochem* 1996; 60(1): 23–32.
39. Murphy KM, Ranganathan V, Farnsworth ML, Kavallaris M, Lock RB. Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. *Cell Death Differ* 2000; 7(1): 102–11.
40. Pratico D, Basili S, Vieri M, Cordova C, Violi F, Fitzgerald GA. Chronic obstructive pulmonary disease is associated with an increase of isoprostane F2 α -III, an index of oxidant stress. *Am J Respir Crit Care Med* 1998; 158:1709–14.
41. Montuschi P, Collins JV, Ciabattini G, Lazzeri N, Corradi M, Kharitonov SA, et al. Exhaled 8-isoprostane as an *in vivo* biomarker of lung oxidative stress in patients with COPD and healthy smokers. *Am J Respir Crit Care Med* 2000; 162:1175–7.
42. Dekhuijzen PN, Aben KK, Dekker I, Aarts LP, Wielders PL, Van Herwaarden CL, et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1996; 154: 813–16.
43. Maziak W, Loukides S, Culpitt S, Sullivan P, Kharitonov SA, Barnes PJ. Exhaled nitric oxide in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998; 157: 998–1002.
44. Jukema JW. New insights into atherosclerosis. *Cardiologie* 2000; 7: 37–40.
45. Dimayuga E, Stober M, Kayes SG. Eosinophil peroxidase levels in hearts and lungs of mice infected with *Toxocara canis*. *J Parasitol* 1991; 77: 461.
46. Bowler RP, Crapo JD. Oxidative stress in allergic respiratory diseases. *J Allergy Clin Immunol* 2002; 110: 349–56.
47. Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. *Immunology* 2002; 2: 787–95.
48. Domachowske JB, Bonville CA, Easton AJ, Rosenberg HF. Pulmonary eosinophilia in mice devoid of interleukin-30. *J Leukoc Biol* 2002; 71: 966–72.

49. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HAM, Postma DS, et al. Effect of SCH55700, a humanized antihuman interleukin-5 antibody in severe persistent asthma. *Am J Res Crit Care Med* 2003; 167: 1655–59.
50. Williams TJ. The eosinophil enigma. *J Clin Invest* 2004; 113 (4): 507–9.
51. Tobin MJ. Asthma, airway biology, and nasal disorders in AJRCCM 2003. *Am J Res Crit Care Med* 2004; 169 (2): 265–76.
52. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatic. *J Clin Invest* 2003; 112 (7): 1029–36.
53. Kay BA, Menzies-Gow. Eosinophils and interleukin-5: the debate continues. *Am J Respir Crit Care Med* 2003; 167 (12): 1586–7.
54. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. *Am J Respir Crit Care Med* 2003; 167: 199–204.
55. Kanazawa H, Nomura S, Yoshikawa J. Role of microvascular permeability on physiologic differences in asthma and eosinophilic bronchitis. *Am J Respir Crit Care Med* 2004; 169 (10): 1125–30.
56. Grootendorst DC, Rabe KF. Mechanisms of bronchial hyperreactivity in asthma and chronic obstructive pulmonary disease. *Proceedings of the ATS* 2004; 1 (2): 77–87.
57. Brightling CE, Pavord ID, Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophils in asthma and airway hyperresponsiveness. *Am J Respir Crit Care Med* 2004; 169 (1): 131–3.
58. Busse WW, Kelly AEB. Is the eosinophil a »humpty dumpty« cell in asthma? *Am J Respir Crit Care Med* 2003; 167 (2): 102–3.
59. Liu LY, Sedgwick JB, Bates ME, Vrtis RF, Gern JE, Kita H, et al. Decreased expression of membrane IL-5 receptor α on human eosinophils: I. Loss of membrane IL-5 receptor α on airway eosinophils and increased soluble IL-5 receptor α in the airway after allergen. *J Immunol* 2002; 169: 6452–58.
60. Gagliardo R, Chanez P, Mathieu M, Bruno A, Costanzo G, Gougat C, et al. Persistent activation of nuclear factor-kappaB signaling pathway in severe uncontrolled asthma. *Am J Respir Crit Care Med* 2003; 168: 1190–8.
61. Rahman I. Oxidative stress, transcription factors and chromatin remodelling in lung inflammation. *Biochem Pharm* 2002; 64: 935–42.
62. Chow CW, Abreu MTH, Suzuki T, Downey GP. Oxidative stress and acute lung injury. *Am J Respir Cell Mol Biol* 2003; 29: 427–31.
63. Urso ML, Clarkson PM. Oxidative stress, exercise and antioxidant supplementation. *Toxicology* 2003; 189: 41–54.
64. Heunks LMA, Dekhuijzen PNR. Respiratory muscle function and free radicals: from cell to COPD. *Thorax* 2000; 55: 704–16.
65. Del Donno M, Verduri A. Oxidants and antioxidants in pulmonary diseases. *European Respiratory News supplemental issue* 2000: 1–48.
66. Dröge W. Free radicals in the physiological control of cell function. *Physiol Rev* 2002; 82: 47–930.
67. Popper HH, Pailer S, Wurzinger G, Feldner H, Hesse C, Eber E. Expression of adhesion molecules in allergic lung diseases. *Virchows Arch* 2002; 440 (2): 172–80.
68. Piotrowski WJ, Marezak J. Cellular sources of oxidants in the lung. *Int J Occup Med Environ Health* 2000; 13 (4): 369–830.
69. Klings ES, Farber HW. Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease. *Respir Res* 2001; 2: 280–5.

Rad primljen: 9. 8. 2004

Prihvaćen za štampu: 25. 8. 2004

CELL DEATH IN IRRADIATED PROSTATE CANCER CELLS ASSESSED BY FLOW CYTOMETRY

Vesna Vučić¹, Miroslav Adžić¹, Ana Nićiforović¹, Nevena Tišma²,
Savera Ruždijić³, Marija B. Radojčić¹

¹Laboratory of Molecular Biology and Endocrinology,
VINČA Institute of Nuclear Sciences, Belgrade, Serbia and Montenegro

²Institute of Oncology and Radiology of Serbia, Belgrade, Serbia and Montenegro

³Laboratory of Molecular Neurobiology, Department of Neurobiology and Immunology,
Institute for Biological Research, Belgrade, Serbia and Montenegro

Summary: Despite the significant advances in cancer chemotherapy, radiotherapy still remains a method of choice for treatment of metastatic human prostate cancer. This study presents quantitative analysis of ⁶⁰Co gamma-radiation effects on cell growth and cell death of metastatic human prostate cancer PC-3 cell line, performed in time (24–72h) and dose (2–20 Gy) dependent manner. The irradiated PC-3 cells were mostly dying by necrosis at late time intervals (72h), while apoptotic cell death was negligible. The EC₅₀ or 50% of cytotoxicity was not achieved within the radiation doses used (2–20 Gy), but significant cell growth inhibition with IC₅₀ of 10.4 Gy was observed. It is concluded that the increase in the radiation dose may have an important cytostatic effect, but for the complete eradication of metastatic prostate cancer novel cytotoxic drugs and radiosensitizers should be introduced as adjuvant.

Key words: human prostate cancer, cell death, gamma-rays, flow-cytometry

Introduction

Despite the significant advances in the area of cancer chemotherapy, radiotherapy, applied either alone or as adjuvant, still remains a method of choice for treatment of many malignant diseases. One of them is prostate cancer, the most frequent cancer in men population, which unfortunately shows a continual casualty increase (1). The ultimate aim of radiotherapy is to efficiently eradicate tumor cells with minimal deleterious effects to the surrounding normal tissues and to the whole organism. In that view, induction of apoptosis is very desirable therapeutic endpoint

(2, 3). However, much is yet to be learned about either systemic or individual biological effects of both conventional (gamma-, x-ray) or accelerated particle (proton, etc.) ionizing radiation in order to optimize clinical results of treatment of human prostate cancer.

Regardless of the routine use of simple test for prostate specific antigen in sera, that can detect disease at an early stage (4, 5), the number of men with metastatic prostate cancer is still high. The early stages of disease are usually managed by ionizing radiation and/or hormone therapy, but there is no successful therapy for metastatic prostate carcinoma. Advanced disease is mostly treated by radiation therapy, sometimes in combination with hormone or chemotherapy, but hormone withdrawal often leads to selection of hormone-independent clones (6). Dose-escalated (*i.e.* 70–80 Gy) radiotherapy is an important treatment option especially for men with intermediate-risk prostate cancer (7). On the other hand, radiotherapy is often inefficient due to radioresistance of prostate cancer cells.

Address for correspondence:

Marija B. Radojčić, Ph.D., Res.Assoc.
VINČA Institute of Nuclear Sciences
P.O. Box 522–090, 11001 Belgrade,
Serbia and Montenegro
tel. +381 (11) 245–82–22 ext.304
fax +381 (11) 344–01–00
www.vin.bg.ac.yu
marija@rt270.vin.bg.ac.yu

Recent studies suggest that some prostate cancer cells can undergo apoptosis (8). The response to ionizing radiation, depends on a number of factors such as the stage of differentiation, mutations in specific genes (such as p-53 and bcl-2) that will determine the ability of the target cells to enter apoptosis (9, 10). For clinical purposes (*i.e.* eradication of the tumor, but prevention of undesired inflammatory *sequelae*, radiation sickness and fibrosis), it is useful to investigate whether the cells of certain types are susceptible to apoptosis or necrosis, as well as to determine the time and dose dependence of the process. In addition to cell killing, radiation can also lead to cell cycle arrest and stopping of proliferation with significant decrease in cell growth (11).

The purpose of this study is to investigate radiation induced cell death in PC-3 prostate cancer cell line in time- and dose-dependent manner. The changes in cell growth following irradiation were also determined.

Materials and Methods

Cell lines. Human prostate cancer cell line PC-3 was purchased from American Type Culture Collection (CRL 1435, Rockville, MD). They are androgen independent and were established from bone metastasis, which is the most usual place for metastatic prostate cancer. PC-3 were maintained in RPMI 1640 medium supplemented by 10% heat inactivated fetal calf serum, 100 IU/mL penicillin/streptomycin and 2 mmol/L L-glutamine (Sigma Aldrich Chemie GmbH, Germany), at 37 °C under 5% CO₂ atmosphere. Cells were grown as monolayers in 75 cm² culture bottles supplied with 15 mL RPMI, and after a few passages cells were transferred in 25 cm² culture bottles (Nunk, Nalgene, Danmark).

Cell Irradiation. For investigation of radiation induced effects on PC-3, 3×10⁵ cells were seeded in 25 cm² culture flasks, and after 72 hours were irradiated at room temperature with 2, 10 or 20 Gy gamma-rays from ⁶⁰Co gamma-source, at the dose rate of 20 Gy/h. The effects of irradiation on cell viability, morphology and genomic DNA structure were determined 24-, 48-, and 72 h after irradiation.

Trypan blue exclusion assay. For analysis of cell growth and spontaneous cell death in culture, cells were seeded at a density of 12×10³ cells/cm² in 25 cm² culture flasks. Cell growth, viability and morphology were followed for 8 consecutive days, by trypan blue exclusion (TBE) assay. Medium from each bottle was collected, cells were harvested by trypsinization (1 mL 0.25% / 0.02% trypsin/EDTA, Sigma Aldrich, per bottle) and pooled with the medium. Cells were washed twice in phosphate buffered saline (PBS) and pelleted at 1800 rpm for 5 min at room temperature. Pellets were resuspended in fresh media and the number of viable (trypan blue negative), dead (trypan blue positive) and total cells (viable + dead) was counted in

five squares at 320× magnification using Neubauer haemocytometer and Leitz-Wetzlar Orthoplan microscope. Cell viability was determined as % of cells that excluded trypan blue stain. The doubling time (td) was calculated according to the following formula:

$$td = \frac{\ln 2}{\mu}$$

$$\mu = (\ln x - \ln x_0)/t$$

where x represents cell number in time t, and x₀ cell number in time t₀.

The same assay was used for determination of viable, dead and total cell number in irradiated samples 24-, 48- and 72 h post-irradiation. The viability index (Vi) of each sample was calculated related to appropriate, unirradiated control, which was used as viability index 1 (100%).

Cell death analysis by flow cytometry. Double staining of cells by Annexin and propidium iodide (PI) enabled estimation of cell viability after irradiation and discrimination between two ways of cell death – apoptosis and necrosis. After trypsinization and centrifugation of cells, approximately 10⁵ cells of each sample were mixed with 100 μL of Annexin V-FITC reagent (Travigen Inc., Gaithersburg, MD, USA) containing 5 μg/mL Annexin V-FITC and 5 μg/mL propidium iodide, and incubated at room temperature for 15 minutes in dark and then diluted with 400 μL of binding buffer. Multiparameter measurement of the cell sample in order to detect radiation-induced cell death was performed using a FACS-calibur flow cytometer (Becton Dickinson, San Jose, CA, USA) with 488 nm, 15 mW argon-ion laser. Staining of the cells with Annexin V-FITC (Annexin) permitted identification of cells in early apoptosis, while staining of the cells with Annexin and PI permitted quantification of cells in the late apoptosis and necrosis. Data were acquired immediately after staining by analyzing about 20,000 cells/sample. The data were further processed by Becton Dickinson LYSIS II software.

DNA fragmentation assay. This assay was used for confirmation of necrosis, detected by double staining and flow cytometry analysis. It was performed as previously described with minor modifications (12). Cells were incubated in one volume of digestion buffer (100 mmol/L NaCl, 25 mmol/L EDTA, 10 mmol/L Tris-HCl, pH 8.0, 0.5% SDS and 0.5 mg/mL RNA-se A) for 2 h at 50 °C, followed by the addition of proteinase K (0.6 mg/mL) and digestion was continued overnight. DNA was deproteinised using the phenol/chloroform/isoamyl-alcohol reagent, for three times. The aqueous layer was transferred to a new tube and precipitated with one volume of isopropanol and 1/10 volume of ammonium acetate overnight at 4 °C. The DNA pellet was washed three times with ice-cold 95% ethanol and dried at room temperature. The final DNA pellet was resuspended in 20 μL TE buffer (10 mmol/L Tris, pH 7.4, 1 mmol/L EDTA) and the concentration

of DNA was determined spectrophotometrically. Electrophoresis of 4–10 µg of each DNA sample, was carried out for 60 min at 60 V at room temperature on 1% agarose gel containing 1 µg/mL ethidium bromide. Gels were scanned by GelDoc apparatus.

Statistical analysis. For statistical analysis of time- and dose- dependent changes in viability index and flow-cytometric determination, two-way ANOVA was used. If a statistical significance was found, Tukey post-hoc test was used to determine which groups differ from each other. Statistical significance was accepted if $p < 0.05$.

Results

Analysis of cell growth and spontaneous cell death in culture

PC-3 cells were plated in 25 cm² culture flasks, at the density of 12×10^3 cells/cm² (e.g. 3×10^5 cells per bottle), and cell growth, viability and morphology were monitored for 8 consecutive days (Figure 1). During the first day post plating the viable cell number increase from 12×10^3 cells/cm² to almost 13.5×10^3 cells/cm², suggesting that plating efficiency was very high. The log phase of cell growth occurred between 2nd and 6th day post plating. The confluence was reached on the 6th day at the cell density of about 116×10^3 cells/cm². Further incubation led to the slightly decrease in cell number. TBE assay showed that approximately 2–8% of all cells were TB positive at all time points, indicating that cell viability was high during the whole experiment. We also calculated PC-3 cell doubling time, which was 32.9 ± 2.8 h under conditions maintained in our laboratory.




Figure 1. Growth and viability of PC-3 cells in culture determined by TBE assay. Data are the mean SEM from 2 distinct experiments.

Cell growth of irradiated PC-3 human prostate cancer cells

Effects of gamma-ionizing radiation on PC-3 growth were evaluated by TBE assay. The test is convenient for determination of Viability (V) and Viability index (Vi) after radiation treatment. TBE assay was performed 24-, 48- and 72 h after irradiation by 2-, 10- and 20 Gy. The obtained results (Table 1 and Figure 2) showed significant decrease in cell number and Viability Index (Vi), comparing with appropriate control, both by dose (F 190.1, $p < 0.001$) and time (F 45.2, $p < 0.001$) as determined by two-way ANOVA. This effect was most pronounced 72 h after treatment with 20 Gy, when the Vi decreased from 1, established in control, to 0.35. The radiation dose which caused decrease in cell Vi from 1 to 0.5, termed IC₅₀ (mitotic cell death dose), was 10.4 ± 0.4 Gy. The dose dependent Vi (e.g. viable cell number) decrease was significant for all experimental points (Table 1). The statistical differences between groups were analyzed by Tukey post hoc test, comparing irradiated samples with the control from the same time point, and significance was established at $*p < 0.05$. The number of TB positive cells, indicating cytotoxicity (actual cell death), was relatively low (up to 20 %, data not shown), which was in agreement with cytometric quantification of necrotic cells determined after double Annexin V-FITC/PI staining (Figure 3).

Table 1 Number of viable cells in the control and ⁶⁰Co gamma-irradiated human prostate cancer cells PC-3 measured by TBE assay 24–72 h post-irradiation. Data are the mean ± SEM from 3 distinct experiments. Statistical time- and dose-dependent differences were determined by two way ANOVA and Tukey post hoc test. ** $p < 0.01$, *** $p < 0.001$.

Dose → Time (h) ↓	control (0 Gy)	2 Gy	10 Gy	10 Gy
		**	***	***
24	57.3 ± 1.6	43.7 ± 2.8	40.9 ± 4.4	40.9 ± 4.4
48	92.4 ± 4.9	49.9 ± 9.7	46.8 ± 5.9	46.8 ± 5.9
72	84.6 ± 3.9	69.6 ± 1.4	44.7 ± 5.3	44.7 ± 5.3

Radiation-induced cell death analysis by flow cytometry

All samples analyzed by TBE, were also stained by Annexin V-FITC and PI, and analyzed by FACS-Calibur flow cytometer. The results of quantification of cells in different states, such as viable cells, cells in early apoptosis, cells in late apoptosis or necrotic cells, and necrotic cells or cell aggregates, are presented in Figure 3 A–D. Figure 3A represents a flow cytometry scatter plot and the dots represent cells in different




Figure 2. Time course of viable cells number in the control and ⁶⁰Co gamma-irradiated human prostate cancer cells PC-3 (A) and Viability index calculated according to the related control from the same time point (B) as measured in TBE assay. Error bars represent standard error of the mean (SEM). Data are the mean SEM from 3 distinct experiments.

states, depending on the place in scatter plot. Cells in early apoptosis were Annexin positive, while PI staining indicated late apoptosis or necrosis (Figure 3A). As it may be observed from Figure 3B, cell viability of the samples decreased with the increase in the radiation dose and with the period of incubation. Radiation-induced decrease of viability showed dose-dependent significance which was judged by two-way ANOVA analysis at $p < 0.05$ ($F 9.12$, $p < 0.001$), but not time-dependent significance ($F 2.06$, $p = 0.142$). The Tukey post hoc test, used for comparison of irradiated samples with appropriate control, showed that only radia-

tion dose of 20 Gy induced significant viability decrease, 48 and 72 h post irradiation. The evidence for apoptosis was minimal in either control or irradiated PC-3 cells. With the increase in the radiation dose, the percentage of cells in the state of early apoptosis increased from 0.2% up to 0.8% (Figure 3C), but there were neither time- nor dose-dependent significance ($F 1.35$, $p = 0.33$ and $F 1.42$, $p = 0.33$ respectively).

The radiation dose and time dependent increase in number of PI positive cells in the late apoptosis or necrosis was also observed. The dose dependent increase in necrotic cells was significant ($F 7.85$, $p < 0.001$), but time-dependence was not statistically significant ($F 1.9$, $p = 0.17$). The Tukey post hoc analysis showed significant increase in number of dead cells after irradiation with 20 Gy, 48 and 72 h after treatment (Figure 3D).

Electrophoretic analysis of purified genomic DNA from irradiated cells

The genomic DNA from control and irradiated samples, including attached and floating cells, was analyzed on 1% agarose gel containing 1 μ g/mL ethidium bromide. As it may be observed in Figure 4 the initial fragmentation of PC-3 cell DNA to a high molecular size band (> 10 Kb) was visible in all samples. In the case of irradiated samples, in addition to the fragmentation of PC-3 cell DNA to a high molecular size band (> 10 Kb), smaller fragments ($1 < Kb$) also appeared. The observed smear is most pronounced 72 h post irradiation with doses of 10 and 20 Gy. It correlated well with the highest percent of dead cells obtained by cytometry (Figure 3D). DNA ladder was not observed in examined samples, confirming flow cytometric data, that PC-3 do not die by apoptosis after gamma-irradiation.

Discussion

The hormone-independent metastatic prostate cancer is incurable at present. In the lack of efficient chemotherapeutic agents, ionizing radiation therapy still remains as a method of choice for the disease cure. It is known that apoptotic cell death plays an important role in the death of both normal prostate and androgen-dependent malignant prostate tissue following androgen withdrawal. Cancer cell death is leading to a decrease in either glandular or tumor volume, respectively. However, recent data indicate that apoptosis may not be the dominant form of cell death following radio- and chemotherapy in epithelial tissues (7, 13). Disruption of the pathways that lead to apoptosis is one of the major mechanism by which cancer cells become resistant to radiation or chemotherapy (14).

In this paper, we have analyzed ⁶⁰Co gamma-radiation-induced death of PC-3 human prostate cancer cells. PC-3 cells originates from epithelial cells.




Figure 3. Time course of percent changes in PC-3 cell viability and death after ⁶⁰Co gamma-irradiation as determined by flow cytometry. Viable cells (A), early apoptosis (B) or late apoptotic/necrotic cells (C). Data are the mean (n=3) and the error bars represent SEM. Statistical differences were determined by two-way ANOVA followed by Tukey post hoc analysis. ** p<0.01, *** p<0.001.

They are hormone-refractory cells derived from human bone metastasis of prostate adenocarcinoma, representing advanced prostate cancer (15). For these experiments, we chose doses of 2 and 10 Gy, to be representative of the 1.8–2 Gy daily clinical fractions given during curative radiotherapy and the 8–10 Gy single doses given in palliative radiotherapy, as well as the dose of 20 Gy which is in the range of cumulative curative dose for prostate carcinomas (70–80 Gy).

The growth curve of PC-3 cells showed sigmoid-like shape, with the population doubling time about 33 h. The viability of PC-3 cells was 92–98 % throughout the log phase of growth. The culture reach confluence 6th days post plating, at the density of 120 × 10³ cells/cm², which is considerable less than other epithelial prostate cancer cell line, DU 145 (180 × 10³ cells/cm²), suggesting that PC-3 are bigger than DU

145 (to be published). After day 6th, number of cells slightly decreased, retaining surprisingly high viability (97–98%). Based on data from cell growth curve, all irradiation experiments were performed in the log phase of cell growth. Cells were irradiated with 2–20 Gy from ⁶⁰Co-source at the dose rate of 20 Gy/h. The irradiated PC-3 cell cultures were followed for three consecutive days *i.e.* through approximately two proliferation cycles. The data obtained by the TBE assay, showed significant decrease in cell Viability index, e.g. in the number of viable cells in irradiated samples relative to the control from the same time point. The process was dependent both on the radiation dose and on the incubation time. On the other hand, the number of TBE positive cells remained relatively low, indicating that radiation caused cell cycle arrest and blocking of cell proliferation, rather than actual cell




Figure 4. Agarose gel electrophoresis of genomic DNA extracted from ^{60}Co gamma-irradiated PC-3 cells. Lane S: DNA standard molecular size markers; lanes 1–12: genomic DNA pattern of samples irradiated with 0, 2-, 10 and 20 Gy respectively, isolated 24 hours (lines 1–4), 48 h (lines 5–8) or 72 h (lines 9–12) post-irradiation.

death. The obtained data enabled determination of doses which induced 50% of cell growth inhibition (named IC_{50}) and 50% of cytotoxicity, i.e. dose which induced 50% of trypan blue positive cells (EC_{50}). IC_{50} was achieved at the dose of 10.4 Gy, but EC_{50} was higher than applied doses, as 20 Gy induced only 20% of trypan blue positive cells. This indicated that the radiation treatment in the clinically relevant dose interval would predominantly inhibit PC-3 growth rather than induce cell killing. The similar results were obtained for other hormone-refractory epithelial prostate cancer cell line DU 145, derived from brain metastasis (to be published), but in the case of cervix epithelial cancer cells HeLa S3, the same doses of ionizing radiation induced cell death in up to 45% of irradiated cells (16). This comparison suggests that prostate cancer cells are much radioresistant than HeLa S3 cell line.

In order to determine the form of radiation-induced PC-3 cell death two different techniques were used: flow-cytometry analysis of cell morphological features after double staining with propidium iodide and Annexin-V-FITC, and DNA electrophoresis of purified DNA. Simultaneous staining of cells with Annexin V-FITC and propidium iodide enabled distinction of early apoptosis from late apoptosis and/or necrosis. After dou-

ble staining and flow-cytometry analysis of control and irradiated samples, the most of dead cells were in late apoptosis or necrosis (Annexin V+, PI+ cells). The early apoptosis (Annexin V+, PI- cells) occurred in insignificant number of cells, less than 1% of total cell number in each sample, and there were no significant changes in percent of apoptotic cells depending on time or dose. On the contrary, the cell necrosis was dose dependent, as determined by two-way ANOVA, and was most pronounced 72 hours post treatment. These results suggest that the prevailing form of ^{60}Co gamma radiation-induced PC-3 cell death was necrosis.

As it was not possible to distinguish the necrosis from the late apoptosis by double staining, it was necessary to perform the gel electrophoresis of purified genomic DNA from PC-3 cells. DNA fragmentation assay confirmed the presence of the necrosis process, showing the absence of DNA ladder characteristic for apoptosis in control (17), as well as in irradiated samples. One explanation for the absence of apoptosis following radiotherapy in PC-3 cell line is that these cells have mutant p53 gene. However, the impairment of other mechanisms necessary for initiation of the apoptotic process is not excluded. Namely, recent investigation showed that gamma-radiation activates acidic sphingomyelinase to produce ceramide, a catabolic product of membrane sphingolipids that is a cell death signal (14, 18, 19). It was suggested that the other epithelial prostate carcinoma LNCaP cells are highly resistant to induction of apoptosis by gamma-radiation due to a defect in ceramide generation (14, 20, 21). Likewise, resistance to apoptosis involves a defect in ceramide generation in the PC-3 prostate cancer cell line (20, 22).

In summary, the obtained results suggests that ^{60}Co gamma-ionizing radiation caused notable human prostate cancer PC-3 cell killing. The irradiated PC-3 cells were mostly dying by necrosis, while apoptotic cell death was negligible. Although within the radiation doses used in this study (2–20 Gy) the EC_{50} i.e. 50% of cytotoxicity was not achieved, we found significant cell growth inhibition with IC_{50} of 10.4 Gy. Thus, this *in vitro* study suggests, that the increase in radiation dose may have an important cytostatic effect, rather than eradicating the advanced prostatic carcinoma. It also suggests that, in addition to gamma irradiation, current antitumor strategies should introduce novel cytotoxic adjuvant or radiosensitizers, in order to achieve complete eradication of metastatic human prostate cancer.

Acknowledgment. This study was supported by the Ministry for Science, Technology and Development of Serbia, grant No. BOI-1953

ĆELIJSKA SMRT U OZRAČENIM ĆELIJAMA KANCERA PROSTATE ANALIZIRANA PROTOČNOM CITOMETRIJOM

Vesna Vučić¹, Miroslav Adžić¹, Ana Nićiforović¹, Nevena Tišma²,
Savera Ruždžić³, Marija B. Radojčić¹

¹Laboratorija za molekularnu biologiju i endokrinologiju,
VINČA Institut za nuklearne nauke, Beograd, Srbija i Crna Gora

²Institut za onkologiju i radiologiju Srbije, Beograd, Srbija i Crna Gora

³Laboratorija za molekularnu neurobiologiju, Institut za biološka istraživanja, Beograd

Kratak sadržaj: Uprkos značajnom napretku u hemoterapiji kancera, radioterapija ostaje metod izbora u tretmanu metastaziranog kancera prostate. Ovaj rad predstavlja kvantitativnu analizu efekata ⁶⁰Co gama zračenja na ćelijski rasti i ćelijsku smrt PC-3 ćelijske linije humanog kancera prostate, pri čemu je praćena vremenska (2–72h) i dozna zavisnost (2–20 Gy). Ozračene PC-3 ćelije su uglavnom umirale nekrozom u kasnijem vremenskom intervalu (72h), dok je apoptoza bila zanemarljiva. Vrednost EC₅₀ odnosno 50% citotoksičnosti nije dostignuta primenjenim dozama, ali je ustanovljena značajna inhibicija ćelijskog rasta, sa vrednošću IC₅₀ od 10.4 Gy. Zaključeno je da povećanje doze može imati značajan citostatički efekat ali da je za kompletno odstranjivanje metastaziranog kancera prostate neophodno uvođenje novih citotoksičnih agenasa ili radiosenzitera kao adjuvanata.

Ključne reči: humani kancer prostate, ćelijska smrt, gama zračenje, protočna citometrija

References

- Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. *CA Cancer J Clin* 2002; 52: 23–47.
- Crompton NEA. Programmed Cellular Response in Radiation Oncology. *Acta Oncol* 1998; Suppl 11: 1–49.
- Ross GM. Induction of cell death by radiotherapy. *Endocr Relat Cancer* 1999; 6: 41–4.
- Marinović V, Čuperlović M, Hajduković-Dragojlović Lj. Prostate-specific antigen: biochemical characteristics, biological functions and diagnostic potential in prostate cancer screening. *Jug Med Biohem* 1997; 16: 129–36.
- Marinović V, Nedić O, Stanojević N, Baričević I, Pavlica S. Investigation of the relationship between two major prostate tumour markers. *Jug Med Biohem* 2000; 19: 407–10.
- Raghavan D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. *Semin Oncol* 1998; 15: 371–89.
- Bromfield GP, Meng A, Warde P, Bristow RG. Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. *Prostate Cancer and Prostatic Diseases* 2003; 6: 73–85.
- Algan O, Stobbe CC, Helt AM, Hanks GE, Chapman JD. Radiation inactivation of human prostate cancer cells: The role of apoptosis. *Radiation Res* 1996; 146: 267–75.
- Szumiel I. Ionizing radiation- induced cell death. *Int J Radiat Biol* 1994; 66: 329–41.
- Kyprianou N, King DE, Bradbury D, Rhee J. Bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. *Int J Cancer* 1997; 70: 341–8.
- Hartwell LH, Kastan MB. Cell cycle control and cancer. *Science* 1994; 266: 1821–8.
- Armstrong K, Isaacs JT, Ottaviano YL, Davidson NE. Programmed cell death in an estrogen independent human breast cancer cell line, MDA-MB-468. *Cancer Res* 1992; 52: 3418–24.
- Olive PL, Vikse CM, Vanderbyl S. Increase in the fraction of necrotic, not apoptotic, cells in SiHa xenograft tumours shortly after irradiation. *Radiother Oncol* 1999; 50: 113–9.
- Kimura K, Bowen C, Spiegel S, Gelmann EP. Tumor Necrosis Factor- sensitizes prostate cancer cells to Gamma-Irradiation-induced apoptosis. *Cancer Res* 1999; 59: 1606–14.
- Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). *Invest Urol* 1979; 17: 16–23.
- Nićiforović A, Zarić B, Dakić A, Tišma N, Radojčić MB. Flow Cytometry Evaluation of HeLa S3 Cell Death Induced by Gamma-Radiation. *Jug Med Biohem* 2004; 23: 1–8.
- Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE. Apoptotic death in epithelial cells. cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. *EMBO J* 1993; 12: 3679–84.
- Haimovitz-Friedman A, Kan CC, Ehleiter D, Persaud RS, McLoughlin M, Fuks Z et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. *J Exp Med* 1994; 180: 525–35.
- Lee JM, Bernstein A. p53 mutations increase resistance

- to ionizing radiation. Proc Natl Acad Sci USA 1993; 90: 5742–6.
20. Nava VE, Cuvillier O, Edsall LC, Kimura K, Milstien S, Gelmann EP et al. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res 2000; 60: 4468–74.
21. Garzotto M, White-Jones M, Jiang Y, Ehleiter D, Liao WC, Haimovitz-Friedman A, et al. 12-O-Tetradecanoyl-phorbol-13-acetate-induced apoptosis in LNCaP cells is mediated through ceramide synthase. Cancer Res 1998; 58: 2260–4.
22. Wang XZ, Beebe JR, Pwiti L, Bielawska A, Smyth MJ. Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy. Cancer Res 1999; 59: 5842–8.

Received: April 1, 2004

Accepted: August 5, 2004

CFTR GENE ANALYSIS IN PATIENT WITH ATYPICAL CYSTIC FIBROSIS

Aleksandra Nikolić¹, Aleksandra Divac¹, Nada Bogdanović², Marija Mitić-Milikić², Dragica Radojković¹

¹Institute of Molecular Genetics and Genetic Engineering, Belgrade

²Institute of Tuberculosis and Lung Disease, Clinical Center of Serbia, Belgrade

Summary: This paper reports a case of a patient presenting with atypical cystic fibrosis whose sweat test shows borderline values. In vast majority of cases the sweat test is essential diagnostic tool for establishing the diagnosis of cystic fibrosis, but only after the molecular genetic testing the diagnosis can be confirmed. The patient was found to be compound heterozygote for two CFTR mutations, F508del and D1152H. The presence of F508del mutation was analyzed by PSM method, while the screening for the second mutation was performed using DGGE. The strategy of mutation detection in cystic fibrosis patients, especially those with atypical presentations who carry less frequent mutations, should include both direct and indirect methods of molecular diagnostics.

Key words: atypical cystic fibrosis, CFTR gene, DGGE, molecular diagnostics

Introduction

Cystic fibrosis is one of the most common life-threatening autosomal recessive disorders that is usually estimated to affect 1 in 2000–3000 Caucasian newborns, with a carrier frequency of 1 in 26 individuals (1). In its classic and most common form, cystic fibrosis manifests with chronic obstructive lung disease, exocrine pancreatic insufficiency, elevated sweat chloride concentration and in males infertility due to obstructive azoospermia (2).

Cystic fibrosis is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, spanning 250kb at chromosomal region 7q31.3 and consisting of 27 exons. The gene was discovered in 1989, and it encodes a protein expressed at the apical membrane of exocrine epithelial cells (3).

CFTR protein functions principally as a cAMP-induced chloride channel and appears capable of regulating other ion channels.

The most common mutation in the CFTR gene is F508del located in exon 10, and it is present on approximately two-thirds (66%) of all cystic fibrosis chromosomes. However, there is great mutational heterogeneity in the remaining one-third of all alleles. Nearly 1300 mutations within CFTR have been identified to date, and reported to Cystic Fibrosis Genetic Analysis Consortium (4). Although these mutations vary greatly in their frequency and distribution, the vast majority are present in either single individual or small number of individuals.

Mutations affect CFTR through a variety of molecular mechanisms which can produce little or no functional CFTR at the apical membrane. The phenotypic spectrum associated with mutations in the CFTR gene extends beyond the classically defined cystic fibrosis. Besides patients with atypical cystic fibrosis, there are large numbers of so-called monosymptomatic diseases, such as various forms of obstructive azoospermia, idiopathic pancreatitis or disseminated bronchiectasis associated with CFTR mutations uncharacteristic for cystic fibrosis (5).

Address for correspondence:

Aleksandra Nikolić
Institute of Molecular Genetics and Genetic Engineering
Vojvode Stepe 444a
p. fah 446
11001 Belgrade
Serbia and Montenegro
Phone: +381 11 3976658
Fax: +381 11 3975808
E-mail: qwert@eunet.yu

This paper reports a case of atypical cystic fibrosis that was diagnosed by the combination of direct and indirect mutation detection methods. It is shown that the patient is a compound heterozygote for two CFTR mutations.

Materials and Methods

Case history

Patient is a 38 year-old woman presented with a diagnosis of bronchiectasis. Her past medical history was noteworthy for the onset of respiratory symptoms such as: recurrent pneumonia and periods of cough and haemoptysis. Sweat test performed at the age of 6 showed borderline values. At the age of 33, computed tomography (CT) has shown the presence of bronchiectasis. At the age of 38, she presented with lung disease progression, which was observed by CT, and was referred for molecular testing for cystic fibrosis.

Methods

DNA was extracted from peripheral blood using GFX™ Genomic Blood DNA Purification Kit (Amersham Biosciences).

The presence of the most frequent CFTR mutation – F508del was detected by PCR-Mediated Site-Directed Mutagenesis (PSM) method (6). The 219bp long fragment was amplified with the following primers: 5'-GCACCATTAAGAAAATATGAT-3' and 5'-CATTACAGTAGCTTACCCA-3', and digested with *Mbo*I. Products were analyzed on 10% polyacrilamide gel.

The screening for the presence of variations in CFTR exons was performed by Denaturing Gradient Gel Electrophoresis (DGGE) method, as previously described (7). Exon 18 was amplified with the following primers: 5'-GTAGATGCTGTGATGAACTG-3' and 5'-GTGGCTATCTATGAGAAGGA-3' and sequenced with the primer 5'-TGCCCTAGGAGAAGTGTG-3' using Thermo Sequenase Cy™5 Dye Terminator Kit (Amersham Pharmacia Biotech).

Results and Discussion

The presence of CFTR F508del mutation was analyzed by PSM method. After digestion with *Mbo*I normal allele is digested giving fragments 202bp and 17bp long, while mutant allele remains undigested. This analysis has shown that the patient is heterozygous for F508del mutation (Figure 1).

The screening for the second mutation was performed using DGGE. After DGGE analysis was performed for several CFTR exons, altered band pattern was seen in exon 18. Mixing of the patient sample with

control samples heterozygous for two mutations in exon 18, has shown that the mutation present in patient's sample is D1152H. Mixing with M1137V/N control gives extra heteroduplex bands, while no extra bands are seen after mixing with D1152H/N control (Figure 2).

The presence of D1152H mutation was confirmed by direct DNA sequencing (Figure 3).




Figure 1. PSM analysis of patient's CFTR gene for the presence of F508del mutation:
1. Heterozygote for F508del
2. Homozygote for normal allele
3. Patient (heterozygote for F508del)
4. Homozygote for F508del




Figure 2. DGGE analysis of patient's CFTR gene for the presence of variations in exon 18:
1. patient's sample
2. control D1152H/N (heterozygote for D1152H)
3. control M1137V/N (heterozygote for M1137V)
4. mixed patient's sample and control D1152H/N
5. mixed patient's sample and control M1137V/N




Figure 3. The part of the patient's CFTR gene exon 18 sequence containing D1152H mutation in heterozygous state (S = C/G)

The described patient, presenting with atypical cystic fibrosis, was found to be compound heterozygote for two CFTR mutations, F508del and D1152H. It has been previously reported that the F508del/D1152H genotype is associated with mild CF phenotype (8).

The CFTR mutation D1152H is caused by point mutation G to C at position 3586. Patients carrying D1152H mutation are usually diagnosed at advanced age, present mild pulmonary disease and pancreatic sufficiency. The mutation D1152H was found to be associated with normal sweat chloride values (9). Characterization at the protein and at the electrophysiological level has shown that this mutation does not alter the permeability sequence of the CFTR channels (10). However, it significantly reduces the whole cell cAMP activated chloride currents, indicating that this mutation interferes with the proper gating of the chloride channels.

In vast majority of cases, the sweat test remains the essential diagnostic tool for establishing the diagnosis of CF. Although the threshold of 60 mmol/L for

the sweat chloride concentration has proven to be discriminating and useful in clinical practice, in described patient a borderline value was observed. Only after the molecular genetic testing, the diagnosis of cystic fibrosis was confirmed. In our opinion in borderline sweat chloride results, clinician should consider molecular genetics testing for cystic fibrosis. Further exhaustive genetic analysis is justified in patients with symptoms suggestive of CF and borderline sweat chloride concentration.

Although methods for direct detection of the most frequent CFTR mutations remain essential, methods for the screening of the whole gene are increasingly used for the purposes of cystic fibrosis molecular diagnostics. In our experience, the denaturing gradient gel electrophoresis is a method of choice, due to its reliability and sensitivity. It is followed by direct DNA sequencing, used for characterization of the detected aberrant pattern. The strategy of mutation detection in analysis of CF patients, especially those with atypical presentations who carry less frequent mutations, should include both direct and indirect methods of molecular diagnostics.

ANALIZA CFTR GENA KOD PACIJENTA SA ATIPIČNOM CISTIČNOM FIBROZOM

Aleksandra Nikolić¹, Aleksandra Divac¹, Nada Bogdanović², Marija Mitić-Milikić², Dragica Radojković¹

¹Institut za molekularnu genetiku i genetičko inženjerstvo, Beograd
²Institut za plućne bolesti i tuberkulozu, Klinički centar Srbije, Beograd

Kratak sadržaj: U ovom radu je prikazan slučaj atipične cistične fibroze sa graničnom vrednošću znojnog testa. U većini slučajeva znojni test je glavni dijagnostički parametar za dijagnostikovanje cistične fibroze, ali se dijagnoza može potvrditi samo na osnovu rezultata molekularno-genetičkog testiranja. Utvrđeno je da je pacijent složeni heterozigot za dve CFTR mutacije, F508del i D1152H. Prisustvo mutacije F508del detektovano je PSM metodom, dok je za analizu prisustva druge mutacije korišćena DGGE metoda. Strategija detekcije mutacija kod pacijenata sa cističnom fibrozom, naročito onih sa atipičnim prezentacijama bolesti koji nose rede mutacije, trebalo bi da uključuje i direktne i indirektne metode molekularne dijagnostike.

Cljučne reči: atipična cistična fibroza, CFTR gen, DGGE, molekularna dijagnostika

References

- Bobadilla JL, Macek MJr, Fine JP, Farrell PM. Cystic fibrosis: A worldwide analysis of CFTR mutations – correlation with incidence data and application to screening. *Hum Mutat* 2002; 19: 575–606.
- Zielenski J. Genotype and phenotype in cystic fibrosis. *Respiration* 2000; 67: 117–33.
- Riordan JR, Rommens JM, Kerem BS, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. *Science* 1989; 245: 1066–73.
- Cystic Fibrosis Genetic Analysis Consortium: www.genet.sickkids.on.ca/cftr
- Noon PG, Knowels MR. »CFTR-opathies«: Disease phenotypes associated with cystic fibrosis transmembrane conductance regulator gene mutations. *Respiration research* 2001, 2: 328–32.
- Friedman KJ, Highsmith WEJr, Silverman LM. Detecting multiple cystic fibrosis mutations by Polymerase Chain Reaction-Mediated Site-Directed Mutagenesis. *Clin Chem* 1991; 37 (5): 753–5.
- Fanen P, Ghanem N, Vidaud M, Besmond C, Martin J, Costes B et al. Molecular characterization of cystic fibrosis: 16 novel mutations identified by analysis of the whole Cystic Fibrosis Conductance Transmembrane Regu-

- lator (CFTR) coding regions and splice site junctions. *Genomics* 1992; 13: 770–6.
8. Lebecque P, Leal T, De Boeck C, Jaspers M, Cuppens H, Cassiman JJ. Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children. *Am J Respir Crit Care Med* 2002; 165: 757–61.
 9. Feldmann D, Couderc R, Audrezet MP, Ferec C, Bienvenu T, Desgeorges M et al. CFTR genotypes in patients with normal or borderline sweat chloride levels. *Hum Mutat* 2003; 22 (4): 340.
 10. Vankeerberghen A, Wei L, Teng H, Jaspers M, Cassiman JJ, Nilius B et al. Characterization of mutations located in exon 18 of the CFTR gene. *FEBS Letters* 1998; 437 (1–2): 1–4.

Received: March 19, 2004

Accepted: August 5, 2004

THE INFLUENCE OF ATOPY ON sICAM-1 SERUM LEVELS IN PATIENTS WITH ALLERGIC RHINITIS AND BRONCHIAL ASTHMA

Aleksandra Perić-Popadić¹, Mirjana Bogić¹, Žikica Jovičić¹, Sanvila Rašković¹, Vesna Tomić-Spirić¹,
Snežana Kovačević², Jasna Bolpačić¹, Miodrag Čolić³

¹Institute of Allergology and Immunology, Clinical Center of Serbia, Belgrade, Serbia and Montenegro

²Internal Medicine, »Dr Laza Lazarević« General Hospital, Šabac

³Institute of Medical Research, MMA, Belgrade

Summary: It has been shown that adhesive molecules are involved in inflammatory diseases of the lungs such as bronchial asthma. The purpose of the study was to measure and establish possible difference in serum levels of soluble ICAM-1 in 42 atopic patients (patients with allergic rhinitis and patients with bronchial asthma) in comparison with 28 patients without atopy (patients with asthma without rhinitis); whether there is a difference in sICAM-1 levels between groups of 26 patients with allergic rhinitis and asthma in comparison with group of 16 patients with allergic rhinitis only and also in comparison with 10 healthy controls. Results of the study have substantiated statistically significant difference in sICAM-1 levels between all groups of patients in comparison to healthy control, but no statistically significant difference in sICAM-1 levels between patients with and without atopy ($Z=-1.738$) or between patients with allergic rhinitis and bronchial asthma in comparison with group of patients with allergic rhinitis only ($Z=0.00$). ICAM-1 is an important marker of inflammation in patients with allergic rhinitis as well as in those with bronchial asthma. Atopic status does not influence differences in sICAM-1 levels. Although mean sICAM-1 levels were higher in patients with allergic rhinitis and bronchial asthma (312.71 ng/mL) in comparison with mean sICAM-1 levels in patients with allergic rhinitis only (279.69 ng/mL), no statistically significant difference was noted in sICAM-1 levels between these groups of subjects, i.e. asthma itself did not contribute to statistically significant increase of sICAM-1 levels.

Key words: intercellular adhesive molecule 1, allergic rhinitis, bronchial asthma, atopy

Introduction

Preliminary studies have suggested that intercellular adhesive molecule 1 (ICAM-1; CD54) may be involved in pathogenesis of asthma (1). Soluble form of the intercellular adhesive molecule 1 (sICAM-1) was detected in elevated levels in the sera of adult patients with some inflammatory, immune or malignant diseases (1). It originates from proteolytic cleavage of membrane ICAM-1 (m ICAM-1) (2). In asthmatic patients epithelial cells of airways may express increased amounts of ICAM-1 molecule, which is one of the responses to different stimuli such as local cytokines, infectious agents, air pollutants, allergens. Their res-

ponse to these stimuli alters the immune and inflammatory environment that is critical in diseases such as bronchial asthma.

The aim of the study was to measure and establish the possible difference in sICAM-1 levels in sera of patients with atopy (patients with allergic rhinitis and patients with allergic rhinitis and bronchial asthma) in comparison with the group of patients without atopy (patients with asthma without rhinitis) as well as possible differences in sICAM-1 levels between groups of patients with allergic rhinitis and asthma in comparison with patients with allergic rhinitis only.

Material and Methods

Our study comprised patients with allergic rhinitis and bronchial asthma. The diagnosis of bronchial asthma was established following the guidelines for diagnosis and treatment of asthma of the international expert group of the National Institute of Health and

Address for correspondence:

Aleksandra Perić-Popadić
Institute of Allergology and Immunology, Clinical Center of Serbia,
Koste Todorovića 2, 11000 Belgrade, Serbia and Montenegro
Phone: 361 7777 37/00
e-mail: popealeksandra@yahoo.com

National Institute of Heart, Lungs and Blood, Bethesda, May 1997, suppl. 2002 (3). All patients had positive results of metacholine and/or Ventolin test. Sensitization to standard inhaling allergens was tested by skin prick test in all patients.

All patients were subjected to physical medical examination. Pulmonary function before blood sampling was measured using Autospir Discom-14 Chest Corporation Tokyo, Japan. In addition to history, skin tests and determination of serum IgE, patients with allergic rhinitis were subjected to *in vivo* specific rhino-provocative tests to evidence the presence of allergic rhinitis.

The sICAM-1 levels were measured in blood samples obtained after the cubital vein puncture using vacutainer, without EDTA addition. The sample was left to coagulate at room temperature for 60–120 minutes. After that the samples were centrifuged at 1300 g for 10 minutes at room temperature. The separated serum was stored at -20°C until the actual analysis. ELISA was used for the sICAM-1 serum level determination. The commercial Parameter human sICAM-1 immunoassay (ELISA, R&D Systems Inc. Minneapolis, USA) was used. The sICAM-1 serum levels were expressed in ng/mL. The lowest detectable value of serum sICAM-1 was 0.35 ng/mL (following the manufacturers instructions).

The subjects were classified into following groups: 16 with allergic rhinitis, 26 with allergic rhinitis and bronchial asthma (all of them combined composed the group with atopy); 28 patients bronchial asthma without allergic rhinitis (composing the group without atopy). The control group was composed of 10 healthy volunteers, mean age 37 years without history of allergy, asthma, allergic rhinitis, atopic dermatitis or any other significant disease.

Statistical analysis was conducted using EPI INFO ver. 10 program package. Statistical differences were calculated using non-parametric Mann-Whitney and Kruskal-Wallis tests. Correlations among different parameters were conducted using the Spearman's rank correlation coefficient (4, 5).

Results

The control group of healthy subjects had mean sICAM-1 values of 226.64 ng/mL, coinciding with control values stated by the manufacturer (R&D Systems). The mean sICAM-1 levels in patients with and without atopy were 300.10 ng/mL and 315.00 ng/mL, respectively. The correlation coefficient of sICAM-1 levels between groups of healthy subjects and patients with and without atopy was $H=12.072$, $p<0.01$, suggesting statistically significant difference of sICAM-1 levels between the groups of subjects.

The correlation coefficient of sICAM-1 levels between groups with atopy (patients with allergic rhinitis

and patients with asthma and allergic rhinitis) and healthy subjects was $Z_1=-2.670$, $p<0.01$, suggesting highly statistically significant difference between the groups, i.e. sICAM-1 level was significantly higher in patients with atopy than in healthy controls.

The correlation coefficient of sICAM-1 levels between groups without atopy (patients with bronchial asthma without allergic rhinitis and negative skin prick test) and healthy subjects was $Z_2=-3.166$, $p<0.01$, suggesting highly statistically significant difference between the sICAM-1 levels in the groups, i.e. sICAM-1 level was significantly higher in patients with asthma without atopy than in healthy controls. The correlation coefficient of sICAM-1 levels between groups with and without atopy was $Z_3=-1.738$, $p>0.05$, suggesting no statistically significant difference between the sICAM-1 levels in the groups, i.e. sICAM-1 serum levels were similar in patients with atopy (allergic rhinitis only and allergic rhinitis with bronchial asthma) and those without atopy (patients with bronchial asthma only), (Table I).

The mean value of sICAM-1 levels in patients with allergic rhinitis was 279.62 ng/mL, while in patients with allergic rhinitis and asthma the level of 312.71 ng/mL was recorded. The mean sICAM-1 level

Table I Mean values of sICAM concentrations in our studies groups

		Group		
		healthy	atopy	atopy free
ICAM-1 (ng/mL)	Valid N	N=10	N=42	N=28
	Mean	226.6	300.10	315.00
	Std Dev.	32.94	136.34	79.26
	Min.	197.0	167.05	190.04
	Max.	301.9	930.65	488.89
H=12.072		p<0.01		
$Z_1=-2.670$		p<0.01		
$Z_2=-3.166$		p<0.01		
$Z_3=-1.738$		p<0.05		

Table II Mean values of sICAM concentrations in our studies groups

		Group		
		healthy	rhinitis	asthma and rhinitis
ICAM-1 (ng/mL)	Valid N	N=10	N=16	N=26
	Mean	226.6	279.62	312.71
	Std Dev.	32.94	136.34	168.66
	Min.	197.0	183.14	167.05
	Max.	301.9	376.63	930.65
H=12.072		p<0.01		
$Z_1=-2.670$		p<0.01		
$Z_2=-3.166$		p<0.01		
$Z_3=-1.738$		p<0.05		

in healthy subjects was 226.64 ng/mL. The correlation coefficient of sICAM-1 levels between the groups was $H=7.172$, $p<0.05$, suggesting the statistically significant difference in sICAM-1 levels between the groups. The correlation coefficient of sICAM-1 levels between the groups of patients with allergic rhinitis and healthy controls was $Z_4=-2.821$, $p<0.01$, suggesting the statistically significant difference between the groups, i.e. patients with allergic rhinitis had statistically significantly higher sICAM-1 levels than the healthy controls. The correlation coefficient of sICAM-1 levels between the groups of patients with allergic rhinitis and asthma on one hand and healthy controls on the other was $Z_5=-2.172$, $p<0.05$, suggesting the statistically significant difference between the groups, i.e. patients with allergic rhinitis and asthma had higher sICAM-1 levels than the healthy controls. The correlation coefficient of sICAM-1 levels between the groups of patients with allergic rhinitis on one hand and bronchial asthma and allergic rhinitis on the other was $Z_6=0.00$, $p>0.05$, suggesting no statistically significant difference between the groups, i.e. sICAM-1 levels were similar in patients with allergic rhinitis only and those suffering from both allergic rhinitis and bronchial asthma (Table II).

Discussion

Nowadays, there is a general consensus that inflammation is crucial in pathophysiology of respiratory allergic diseases (6). The level of soluble adhesive molecules in the serum reflects the degree of systemic inflammation, but the dynamics of these molecules in the pathogenesis of allergic diseases and their evolution in the course of treatment remain to be evidenced. ICAM-1 may be induced on various cell types using miscellaneous inflammation stimuli (7). Allergic inflammation is associated with ICAM-1 expression on the surface of different cells such as the endothelium, bronchial epithelium and eosinophilic leukocytes (8-11). Induction of expression of these molecules takes place under the influence of various proinflammatory cytokines such as IFN-gamma, IL-1, TNF-alpha and others.

The purpose of the study was to measure and compare levels of soluble ICAM-1 in the sera of atopic patients non-atopic patients and to compare the levels with the sICAM-1 levels in healthy controls. The mean sICAM-1 levels in healthy controls was 226.64 ng/mL. Shiota and associates reported somewhat higher mean sICAM-1 value in healthy volunteers, i.e. 260.90 ng/mL. It is possible that the difference in the number of healthy volunteers (10 vs. 39) contributed to the difference in the value obtained.

The mean value of sICAM-1 levels in our atopic patients (all patients with allergic rhinitis and patients with both allergic rhinitis and bronchial asthma) was 300.10 ng/mL as compared with 315.00 ng/mL meas-

ured non-atopic patients (bronchial asthma without rhinitis). Similar values in asthmatic patients were reported by Shiota and associates (12). Analysis of the levels of sICAM-1 between the groups of atopic patients and healthy controls as well as the difference between non-atopic group and healthy controls has revealed the presence of statistically significant difference. This actually means that atopic and non-atopic patients had statistically significant levels of sICAM-1 in the sera in comparison with healthy controls. This finding is in concert with referential data (1, 13, 14), substantiating the hypothesis on ICAM-1 as a marker of inflammation in respiratory diseases. However, analysis of correlation of sICAM-1 levels between groups of atopic vs. non-atopic patients failed to substantiate the statistically significant difference, i.e., both atopic and non-atopic patients had similar sICAM-1 levels in the respective sera. Laan and associates (15) obtained similar values in pediatric population, and Figen Do'Egu and associates (16) failed to identify any statistically significant differences in sICAM-1 levels between atopic and non-atopic children.

Results of our study have substantiated the presence of statistically significant difference in sICAM-1 values of patients with allergic rhinitis in comparison with healthy controls. In a study on a group of patients with allergic rhinoconjunctivitis Turgay et al. (17) reported no statistically significant difference between their sICAM-1 levels and healthy controls, but men with allergic rhinoconjunctivitis had higher values of sICAM-1 levels than in women, and in comparison with healthy controls. The sICAM-1 levels were higher in patients with allergic rhinoconjunctivitis that had higher symptom score (17). Kato and associates (18) reported that the level of sICAM-1 in the sera of patients with polynosis was up-regulated in the early season in comparison with healthy control. However, Chia-Ming Liu and associates (19) found overlapping values in sICAM-1 levels of patients with allergic perennial rhinitis and healthy controls. He explained the phenomenon by the target organ size (the nose) that is substantially lower in comparison with target surfaces of other organs such as the lungs and skin.

The reason for the differences in sICAM-1 levels in our allergic rhinitis patients in comparison with healthy control may lie in the »minimum persistent inflammation« present in patients hypersensitive to mite, that have it all the year round even in absence of symptoms (20). Also, the minimum exposure to allergens in natural conditions may lead to the occurrence of differences in sICAM-1 levels.

Our study has also substantiated the presence of statistically significant difference in sICAM-1 levels between groups of patients with atopy (allergic rhinitis and allergic rhinitis combined with asthma) and group of healthy volunteers, complying with referential data. However, in spite of the notable difference in mean sICAM-1 levels in patients with asthma versus patients

with allergic rhinitis only (312.71 ng/mL vs. 279.62 ng/mL) there was no statistically significant difference in sICAM-1 levels between these groups of patients. The reason may lie in heterogeneous composition of the groups where patients with bronchial asthma mainly used the therapy of inhaling glyocorticosteroids that may affect the down-regulation of ICAM-1 molecules (13, 16, 21–23).

The results of the study have substantiated that sICAM-1 is a marker of inflammation in both patients with bronchial asthma and those with allergic rhinitis, but that atopy itself does not influence the higher sICAM-1 levels in comparison with non-atopic patients. Also, in our study asthma did not contribute significantly to the total sICAM-1 levels. Naturally, future studies are necessitated for better elucidation of the function and regulatory mechanisms of serum ICAM-1.

UTICAJ ATOPIJE NA NIVO sICAM-1 U SERUMU KOD PACIJENATA SA ALERGIJSKIM RINITISOM I BRONHIJALNOM ASTMOM

Aleksandra Perić-Popadić¹, Mirjana Bogić¹, Žikica Jovičić¹, Sanvila Rašković¹, Vesna Tomić-Spirić¹, Snežana Kovačević², Jasna Bolpačić¹, Miodrag Čolić³

¹Institute za alergologiju i imunologiju, Klinički centar Srbije, Beograd

²Interna medicina, Opšta bolnica »Dr Laza Lazarević«, Šabac

³Institut za medicinska istraživanja, VMA, Beograd

Kratak sadržaj: Poznato je da su adhezivni molekuli uključeni u inflamacione bolesti pluća kao što je bronhijalna astma. Cilj ovog rada je bio da se izmeri i utvrdi da li postoji razlika u koncentracijama solubilnog ICAM-1 u serumu 42 bolesnika sa atopijom (bolesnici sa alergijskim rinitisom i bolesnici sa bronhijalnom astmom) u odnosu na grupu od 28 bolesnika bez atopije (bolesnici sa astmom bez rinitisa) da li postoji razlika u koncentracijama sICAM-1 među grupama od 26 bolesnika sa alergijskim rinitisom i astmom u odnosu na 16 bolesnika samo sa alergijskim rinitisom kao i u odnosu na 10 zdravih kontrola. Rezultati rada su pokazali da postoji statistički značajna razlika u koncentracijama sICAM-1 svih pomenutih grupa ispitanika u odnosu na zdravu kontrolu, ali da ne postoji statistički značajna razlika koncentracija sICAM-1 među grupama bolesnika sa atopijom i bez atopije ($Z = -1,738$) kao ni među grupama ispitanika sa alergijskim rinitisom i bronhijalnom astmom u odnosu na grupu ispitanika samo sa alergijskim rinitisom ($Z = 0,00$). sICAM-1 predstavlja značajan marker inflamacije i kod bolesnika sa alergijskim rinitisom kao i kod onih sa bronhijalnom astmom. Atopijski status ne utiče na razlike u koncentracijama sICAM-1. Iako su srednje vrednosti koncentracija sICAM-1 bile više kod bolesnika sa alergijskim rinitisom i bronhijalnom astmom (312,71 ng/mL) u odnosu na srednje koncentracije sICAM-1 kod bolesnika samo sa alergijskim rinitisom (279,62 ng/mL), nije postojala statistički značajna razlika u koncentracijama sICAM-1 među ovim grupama ispitanika, tj. sama astma nije doprinosila statistički značajnijem povećanju koncentracija sICAM-1.

Ključne reči: intercelularni adhezivni molekul 1, alergijski rinitis, bronhijalna astma, atopija

References

1. El-Sawy-IH, Badr-El-Din-Om, El-Azzouni-OE, Motawae-HA. Soluble intercellular adhesion molecule-1 in sera of children with bronchial asthma exacerbation. *Int Arch Allergy Immunol* 1999; 119 (2): 126–32.
2. Van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1 (ICAM-1). *J Mol Med* 1996; 74 (1): 13–33.
3. Global Strategy for Asthma Management and Prevention. National Heart Lung and Blood Institute National Institutes of Health. NHLBI/WHO Workshop Report NIH Pub No 95–3659, 1995, Revised 2002, 2.
4. Jekel JF, Elmore JG, Katz DL. *Epidemiology Biostatistics and Preventive Medicine*. Philadelphia, WB Saunders Company, 1996.
5. Eric-Marinković J, Dotlić R, Janošević S, Kocev N, Gajić M, Ille T, Stanisavljević D, Babić D. *Statistics for researchers in the field of medical science*, Belgrade, School of Medicine 2001.
6. Howarth PH, Bradding P, Montefort S, et al. Mucosal inflammation and asthma. *Am J Resp Crit Care Med* 1994; 150: s 18–22.
7. Wegner CD, Gundel RH, Reilly P, Haynes N, Letts G, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. *Science* 1990; 247: 456–9.
8. Springer T. Adhesion receptors of immune system. *Nature* 1990; 346: 425–33.
9. Smith CW, Marlin SD, Rothlein R, Toman C, Anderson DC. Cooperative interactions of LFA-1 AND Mac-1 with intercellular adhesion molecule-1 in facilitating transendothelial migration of human eosinophils in vitro. *J Clin Invest* 1989; 83: 2008–17.
10. Paolieri F, Battifora M, Riccio AM, Pesce G, Canonica GW, Bagnasco M. Intercellular adhesion molecule-1 on cultured human epithelial cell lines: influence of proinflammatory cytokines. *Allergy* 1997; 52: 521–31.
11. Ciprandi G, Buscaglia S, Pesce GP, Bagnasco M, Canonica GW. ICAM-1/CD54 expression on conjunctival epithelium during pollen season. *Allergy* 1995; 50: 184–7.
12. Shiota Z, Wilson JG, Marukawa M, Ono T, Kaji M. Soluble intercellular adhesion molecule 1 (ICAM-1) antigen in sera of bronchial asthmatics. *Chest* 1996; 109 (1): 94–9.
13. Kobayashi T, Hashimoto S, Imai K, Amemiya E, Yamaguchi M, Yachi A, Horie T. Elevation of serum soluble intercellular adhesion molecule-1 (sICAM-1) and sE-selectin levels in bronchial asthma. *Clin Exp Immunol* 1994; 96 (1): 110–5.
14. Kokuludag A, Sin A, Terzioğlu E, Saydam G, Sebik F. Elevation of serum eosinophil cationic protein, soluble tumor necrosis factor receptors and soluble intercellular adhesion molecule-1 levels in acute bronchial asthma. *J Investig Allergol Clin Immunol* 2002; 12 (3): 211–4.
15. Laan MP, Koning H, Baert MR, Oranje AP, Buurman WA, Savelkoul HF, Neijens HJ. Levels of soluble intercellular adhesion molecule-1, soluble E-selectin, tumor necrosis factor-alpha, and soluble tumor necrosis factor receptor p55 and p75 in atopic children. *Allergy* 1998; 53 (1): 51–8.
16. Do'Egu F, Ikincio Egullari A, Eegin Y, Babacan E. Circulating Adhesion Molecule Levels in Childhood Asthma. *Ind Pediatr* 2002; 39: 1017–21.
17. Turgay M, Keskin G, Kminkli G, Senturk T, Tutkak H, Duman M. Intercellular adhesion molecule-1 (sICAM-1) in patients with allergic rhinoconjunctivitis. *Allergol Immunopathol* 1996; 24 (3): 129–31.
18. Kato M, Hattori T, Matsumoto Z, Nakashima I. Dynamics of soluble adhesion molecule levels in patients with pollinosis. *Arch Otolaryngol Head Neck Surg* 1996; 122 (12): 1398–400.
19. Liu C-M, Shun C-T, Cheng Y-K. Soluble adhesion molecules and cytokines in perennial allergic rhinitis. *Annals of Allergy, Asthma & Immunology* 1998; 81: 176–180.
20. Passalacqua G, Ciprandi G, Canonica GW. United airways disease: therapeutic implication. *Thorax* 2000; 55: 26–7.
21. Bogić M, Perić-Popadić A, Jovičić Z, Kovačević S, Rašković S, Tomić-Spirić V, Savić N, Čolić M. Is soluble intercellular adhesion molecule-1 a marker of disease activity in bronchial asthma? *Jugoslav Med Biochem* 2004; 23 (1): 55–58.
22. Shiota Z, Sato T, Ono T. Serum levels of soluble ICAM-1 in asthmatic patients. *Arerugi* 1993; 42 (12): 1782–7.
23. Van der Saag PT, Caldenhoven E, van de Stolpe A. Molecular mechanisms of steroid action a novel type of cross-talk between glucocorticoids and NF-kappa B transcription factors. *Eur Respir J Suppl*. 1996; 22: 146s–153s.

Received: April 15, 2004

Accepted: May 5, 2004

BIOCHEMICAL PHENOTYPE AND ORIGIN OF THE THREE MOST COMMON BETA-THALASSEMIA MUTATIONS IN SERBIA

Jelena Poznanić¹, Ljubica Perišić¹, Jelena Urošević¹, Branka Petručev¹, Tatjana Đureinović¹, Nataša Tošić¹, Lidija Krivokapić-Dokmanović², Dragana Janić², Milica Cvorkov-Dražić³, Gordana Bunjevački³, Sonja Pavlović¹

¹Institute of Molecular Genetics and Genetic Engineering, Belgrade, Serbia and Montenegro

²University Children's Hospital, Belgrade, Serbia and Montenegro

³Mother and Child Health Care Institute of Serbia »Dr Vukan Čupić«, Belgrade, Serbia and Montenegro

Summary: Molecular (DNA) characterization of thalassemia is the most reliable methodology for the diagnosis of this group of diseases. As thalassemias are very heterogeneous, hematological data and additional biochemical analysis are essential for their differential diagnosis. In this paper we present hematological and biochemical characteristics of the carriers of three most common beta-thalassemia mutations in Serbia (Hb Lepore, $\beta^{\circ}39$ and $\beta^+IVS-I-110$), to be taken into consideration as the initial step of the diagnostic approach to the thalassemia patients. Also, this paper represents a detailed survey of the diversity of β -globin gene haplotypes in carriers of the most common β -thalassemia mutations and normal betaA/betaA individuals of Serbian descent. A novel haplotype associated with Hb Lepore-Boston-Washington gene has been identified in Serbian population. These data support the hypothesis of multicentric origin of this mutation. The mutation has arisen *de novo* in the chromosomal background characteristic for Serbian population. Additionally, we have shown that two most common Mediterranean mutations, $\beta^{\circ}39$ and $\beta^+IVS-I-110$, have probably been introduced into Serbian population from Italy and Turkey, respectively, through historically documented migrations and settlements.

Key words: β -thalassemia, haplotype, Hb Lepore

Introduction

The β -globin gene cluster is located on chromosome 11. The alignment of genes in human β -globin locus represents the order of gene expression during ontogenic development: embryonal genes (ϵ) are located at the 5' end, then fetal genes ($A\gamma$, $G\gamma$) and finally, at the 3' end, adult genes (δ , β). Thalassemia syndromes are a group of hereditary disorders generally caused by mutations in globin genes. In Serbia, thalassemia syndromes are less frequent than in adjacent Mediterranean countries. The overall frequency of thalassemia syndromes in Serbia is 1.9% (1).

Since 1998 thalassemia syndromes have been systematically characterized on molecular level in the population of Serbia (2). Nine different mutations have been detected: seven β -thalassemic mutations and two thalassemic hemoglobin (Hb) variants (Hb Lepore, Hb Sabine), among which 70% were Hb Lepore, $\beta^{\circ}39$ and $\beta^+IVS-I-110$ (2). Two studies showed that Hb Lepore is the most common cause of thalassemia in Serbia (30%) (1, 2).

Hb Lepore is an abnormal thalassemic hemoglobin variant, which consists of normal α -globin chains and fused $\delta\beta$ -globin chains. The $\delta\beta$ -globin chain is a product of an unequal recombination that joins the proximal end of the δ -globin gene with the distal end of the β -globin gene (3). Three types of Hb Lepore, that differ in the position at which the transition from δ to β DNA occurs, have been described: Hb Lepore-Hollandia, Hb Lepore-Baltimore and Hb Lepore-Boston-Washington (Hb Lepore BW) (3).

Substitution (C→T) alters codon 39 to a stop codon. Such chain termination (nonsense) mutation

Address for correspondence:

Sonja Pavlović
Institute of Molecular Genetics and Genetic Engineering
Vojvode Stepe 444a, 11000 Belgrade, Serbia and Montenegro
Tel: +381 11 3976 445
Fax: +381 11 3975 808
E-mail: sonya@sezampro.yu

aborts mRNA translation and leads to synthesis of a truncated polypeptide (4). Therefore, codon 39 results in β^0 thalassemic phenotype. Substitution (G→A) at position 110 in intron I (IVS-I-110) creates an alternative splice site. The incorrectly spliced mRNA leads to premature termination of translation but allows accumulation of some amount of normal globin mRNA (β^+ thalassemic phenotype) (5).

In this study we have analyzed hematological data and Hb content (Hb A, Hb A₂ and Hb F) in carriers of three most common beta-thalassemia mutations in Serbia. Also, we present a detailed study of the diversity of β -globin gene haplotypes in normal betaA/betaA and thalassemic individuals of Serbian descent, conducted with the aim of defining the origin of beta-thalassemia in Serbia.

The β -globin gene cluster is highly polymorphic. The pattern or combination of polymorphic restriction sites in β -globin locus for any chromosome is called a haplotype (6). There are nine common haplotypes (I-IX) known to be present in different Mediterranean populations with significant percentage (6). Additionally, four beta globin intragenic single base polymorphisms have led to the definition of three different beta globin gene frameworks (6). Haplotypes and frameworks of β -globin gene cluster are widely used nowadays to determine the chromosomal background on which a mutation arose, as well as its geographical pattern.

Material and Methods

Forty-five Serbian patients from 20 unrelated families affected with β -thalassemia, were studied: 21 Hb Lepore BW β -thalassemic variant carriers (from 8 unrelated families), 14 β^0 39 β -thalassemia mutation carriers (from 7 unrelated families) and 10 β^+ IVS-I-110 mutation carriers (from 5 unrelated families). Healthy subjects related to the carriers were also analyzed.

Hematological parameters were obtained using an automated cell counter. Abnormal hemoglobin was detected by electrophoresis on cellulose acetate in Tris-borate-EDTA (pH 8.4) (7). Hb F was quantified by standard methods (8, 9) and Hb A₂ and Hb Lepore were estimated by elution from celogel electrophoretic strips.

DNA was extracted from peripheral blood collected with sodium citrate or EDTA as an anticoagulant (10). DNA samples were used as templates in polymerase chain reaction (PCR). For each sample eight PCR-RFLPs were performed, one for each polymorphism (*HincII/ε*, *XmnI/5'Gγ*, *HindIII/Gγ*, *HindIII/Aγ*, *HincII/ψβ*, *HincII/3'ψβ*, *Avall/β*, *BamHI/3'β*). The conditions for PCR amplification were as described previously (11, 12), with changes in temperature of annealing for ϵ , 5'G γ , G γ , A γ , $\psi\beta$, 3'ψβ, β, 3'β DNA

fragments containing β -globin gene cluster polymorphic sites: 55, 55, 60, 55, 61, 61, 57 and 53 °C respectively. For haplotype analysis the polymorphic restriction enzyme sites were determined by digestion of PCR amplified fragments using the methodology of Sutton et al (12). Polymorphic sites were detected by agarose gel electrophoresis. The framework base substitutions were identified by dideoxy chain termination method using fluorescently labeled dideoxy nucleotides (Pharmacia Biotech, Uppsala, Sweden) on an automated DNA sequencer (ALFexpress DNA Sequencer, Pharmacia Biotech) using the primer 5'-AA TCA TTC GTC TGT TTC CCA-3'.

Results

All carriers of Hb Lepore had a clinical phenotype of thalassemia trait. Their MCV and MCH values were reduced (Table I). Hb A₂ level was normal or decreased, while Hb F was slightly increased. Hb analysis by electrophoresis on cellulose acetate revealed the presence of an abnormal Hb fraction, later characterized as Hb Lepore by PCR analysis. Heterozygous carriers of β^0 39 mutation had evident anemia, but unusually mild microcytosis and hypochromia for this type of mutation (β^0). As expected, Hb A₂ and Hb F were markedly elevated (5% and 3.2%, respectively). All carriers of β^+ IVS-I-110 mutation were clinically asymptomatic. They presented with relatively mild anemia and moderately reduced MCV and MCH values. Both Hb A₂ and Hb F levels were slightly elevated.

In order to elucidate the origin of the most common thalassemic mutations in the population of Serbia, haplotype analysis of Hb Lepore BW, β^0 39 and β^+ IVS-I-110 mutation carriers was performed. We have studied eight linked polymorphic restriction sites along β -globin gene cluster (Figure 1). In order to establish the haplotype of thalassemic chromosomes with certainty, nonaffected relatives were included in the study.

Four different haplotypes associated with β -thalassemia mutations were detected: two of them were typical of Mediterranean countries (I and V), and two autochthonous haplotypes, specific for Serbian population, were discovered as well (haplotypes A and B) (Table II).

Table I Hematological data (average values and standard deviations), Hb A₂ and Hb F values for β -thalassemia heterozygotes

Mutation	Gender	No.	Hb (g/L)	MCV (fL)	MCH (pg)	Hb A ₂ (%)	HbF (%)
Hb Lepore (β fusion)	M	11	114.5 ± 9.02	66.2 ± 3.51	20.35 ± 1.50	1.95 ± 0.82	2.15 ± 0.60
	F	10	108.5 ± 5.22	66.0 ± 1.53	20.55 ± 1.75	1.84 ± 0.62	2.16 ± 0.51
Codon 39 (C→T)	M	7	109.0 ± 1.50	67.4 ± 3.90	22.6 ± 0.98	5.0 ± 0.25	4.20 ± 4.08
	F	7	91.0 ± 0.73	67.0 ± 0.33	22.1 ± 0.33	4.6 ± 0.50	3.87 ± 0.43
IVS I-110 (G→A)	M	5	128.5 ± 0.50	66.1 ± 1.66	20.8 ± 0.50	4.3 ± 0.15	2.33 ± 0.77
	F	5	126.0 ± 0.90	64.1 ± 3.35	20.9 ± 1.05	4.2 ± 0.20	2.30 ± 0.60

Table II Haplotypes detected in the healthy and thalassemic population of Serbia

	5' subhaplotype						3' subhaplotype	
	ϵ	5'G γ	G γ	A γ	$\psi\beta_1$	3' $\psi\beta$	β	3' β
Haplotype I [4]	+	-	-	-	-	-	+	+
Haplotype V [4]	+	-	-	-	-	-	+	-
Haplotype A	+	-	-	+	-	-	+	-
Haplotype B	+	-	-	+	-	-	+	+

Polymorphic restriction sites: *HincII*/ ϵ , *XmnI*/5'G γ , *HindIII*/G γ , *HindIII*/A γ , *HincII*/ $\psi\beta_1$, *HincII*/3' $\psi\beta$, *AvaI*/ β , *BamHI*/3' β




Figure 1. The location of eight polymorphic restriction sites in the β -globin gene cluster. Sites are numbered from 5' to 3': 1-*HincII*/ ϵ , 2-*XmnI*/5'G γ , 3- *HindIII*/G γ , 4-*HindIII*/A γ , 5-*HincII*/ $\psi\beta_1$, 6-*HincII*/3' $\psi\beta$, 7-*AvaI*/ β , 8-*BamHI*/3' β ; 5' and 3' subhaplotypes are defined by restriction sites 1-6 and 7, 8, respectively.




Figure 2. Detection of *HindIII*/A γ polymorphic site by 1% agarose gel electrophoresis. 1. λ /*HindIII*/*EcoRI* DNA marker; 2. undigested PCR fragment; 3. homozygote for *HindIII*/A γ polymorphism; 2690bp indicates pUC19 plasmid DNA digested with *HindIII* (control of the restriction enzyme activity)

All analyzed Lepore chromosomes were of the identical haplotype: haplotype A. Comparing this haplotype with Hb Lepore BW haplotypes reported to date showed that it differs from all of them. Thus, in this study a novel haplotype associated with Hb Lepore BW mutation was identified. The specificity of this haplotype is the presence of *HindIII*/A γ restriction site (Figure 2).

Haplotype analysis revealed that β^0 39 thalassemia mutation is mostly associated with haplotype I and framework 1. However, in one family, β^0 39 chromosomes were found to be associated with framework 2. Two different haplotypes were associated with β^+ IVS-I-110 thalassemic mutation: haplotype I and haplotype B. Also, we have detected the presence of haplotypes I and V, as well as haplotypes A and B specific for Serbian population, in normal betaA/betaA individuals.

Discussion

The results presented in this paper may help the clinicians as a guideline for differential diagnostics of thalassemia trait. The hematological values of particular importance are: MCV lower than 70fL and MCH lower than 24pg. If these values are consistently decreased (despite Fe supplementation therapy) in anemic patient, hemoglobin electrophoresis is recommended, followed by DNA analysis.

Haplotype analyses we present in this paper have been carried out on β -thalassemia carriers of common Mediterranean mutations (Hb Lepore BW, β^0 39, β^+ IVS-I-110). A number of similar studies have already provided insights into origin and distribution of these mutations. Beta-globin gene haplotypes associated with thalassemic mutations were sporadically studied in former Yugoslavia, too (13). However, chromosomal background of β -thalassemia mutations in Serbian population demonstrates specificity, not previously reported.

In this paper we present a novel haplotype associated with Hb Lepore BW gene. Hb Lepore BW is common in Mediterranean countries. Up to date, 6 haplotypes associated with Hb Lepore BW chromosomes were identified: haplotype V in 34 families of Spanish, Yugoslavian and Italian origin (14-16), haplotype I in 23 Italian families (15), haplotypes VI and VII in Italian families (15) and two unique haplotypes (in a Hungarian individual and in one Black family) (15). A multicentric origin of this mutation has been suggested (16). In order to elucidate the origin of Hb Lepore BW mutation in Serbia, the 5' and 3' subhaplotypes were taken into consideration as independent entities (see Figure 1). We have detected two different 5' subhaplotypes: the first one, typical for both I and V haplotypes, and the second, autochthonous 5' subhaplotype present in both haplotypes A and B. There were also two 3' subhaplotypes: the one typical

for haplotype I and the other typical for haplotype V (see *Table II*).

All Serbian Hb Lepore BW genes are associated with autochthonous 5' subhaplotype and 3' subhaplotype typical for haplotype V. We have previously shown that they are also associated with framework 2 (17). The Hb Lepore BW gene associated with haplotype V and framework 2 was virtually the only type found in Eastern Italy and former Yugoslavia (13, 16). Considering the fact that two different haplotypes containing autochthonous 5' subhaplotype (A and B) as well as haplotype V were detected in healthy Serbian population, two possible hypotheses could explain the origin of Hb Lepore BW mutation on a novel chromosomal background.

There is a possibility that unequal recombination or gene conversion occurred between two chromosomes with haplotypes A or B and Hb Lepore mutation associated with haplotype V, respectively, producing new chromosomal background for Hb Lepore mutation. The fact that the probable site of recombination could have been in the 9,1 kb segment, which has been defined by Chakravarti *et al.* (18) as a hot spot region for nonuniform recombination in β -globin gene cluster, supports this hypothesis.

However, the mutation might have arisen *de novo*, by a single independent mutational event in a healthy individual with haplotype A and spread in the population. The high frequency of Hb Lepore BW hemoglobin variant in Serbian population, the homogeneity of Hb Lepore BW haplotype (no haplotype V was detected), as well as its uniqueness, suggest its independent origin. The finding that Hb Lepore BW chromosomes are concentrated in particular geographical region of Serbia also supports this hypothesis.

It has been proposed that $\beta^{\circ}39$ mutation originates from Italy (19). Our data suggest Western Me-

diterranean (Italian) origin of this mutation in Serbia. Chromosomal background of $\beta^{\circ}39$ mutation in our population is similar to the one found in other Mediterranean countries. However, in one family $\beta^{\circ}39$ chromosomes are found to be associated with framework 2. Although mutation spread almost never involves a change of β -globin gene framework, the exception has been detected (19). To the best of our knowledge, this is the first report of the association between framework 2 and $\beta^{\circ}39$ mutation. This example of mutation spread from one beta-globin gene framework to another, within a population, may be due to inter-allelic gene conversion events or recurrent mutation (19).

β^+ IVS-I-110 mutation is previously reported to be of Eastern Mediterranean (Turkish) origin and associated with haplotype I (20). In this study, β^+ IVS-I-110 mutation is found to be associated with two different haplotypes. Actually, these two haplotypes differ only in their 5' subhaplotypes: one is typical for haplotype I, and the other is 5' subhaplotype from haplotypes A or B. The likelihood that this haplotype dimorphism associated with the same β -thalassemia mutation is a consequence of random mutation is very low. The diversity of haplotypes associated with β^+ IVS-I-110 mutation, would then be generated by recombination events (crossing-over or gene conversion) between the original β -thalassemic chromosome (haplotype I) and the 5' subhaplotype characteristic for normal population of Serbia.

Although thalassemia syndromes are sporadic disorders in Serbia, they reflect numerous historically documented migrations over Balkan Peninsula and yet show autochthonous features.

Acknowledgements. This work was supported by grant 1417 from Ministry for Science and Technology of Serbia.

BIOHEMIJSKI FENOTIP I POREKLO TRI NAJČEŠĆE BETA-TALASEMIJSKE MUTACIJE U SRBIJI

Jelena Poznanić¹, Ljubica Perišić¹, Jelena Urošević¹, Branka Petručev¹, Tatjana Đureinović¹,
Nataša Tošić¹, Lidija Krivokapić-Dokmanović², Dragana Janić², Milica Cvorkov-Dražić³,
Gordana Bunjevački³, Sonja Paulović¹

¹Institut za molekularnu genetiku i genetičko inženjerstvo,
Beograd, Srbija i Crna Gora

²Univerzitetska dečja klinika, Beograd, Srbija i Crna Gora

³Institut za zdravstvenu zaštitu majke i deteta »Dr Vukan Čupić«,
Beograd, Srbija i Crna Gora

Kratak sadržaj: Molekularna (DNK) karakterizacija talasemija je najpouzdaniji metod za dijagnostiku ove grupe oboljenja. Kako su talasemije vrlo heterogene, hematološki podaci i dodatne biohemijske analize su od esencijalne važnosti za njihovu diferencijalnu dijagnostiku. U ovom radu su prikazani hematološki parametri i biohemijske karakteristike nosilaca tri najčešće β -talasemijske mutacije u Srbiji (Hb Lepore, $\beta^{\circ}39$ i $\beta^{+IVS-I-110}$) koje je neophodno uzeti u obzir u početnom koraku postavljanja dijagnoze kod talasemičnih pacijenata. Pored toga, ovaj rad predstavlja detaljnu analizu diverziteta haplotipova β -globinskog lokusa kod nosilaca najčešćih β -talasemijskih mutacija i zdravih betaA/betaA osoba u Srbiji. Identifikovan je novi haplotip asociiran sa Hb Lepore-Boston-Vašington genom u srpskoj populaciji. Ovi podaci idu u prilog hipotezi o multicentričnom poreklu ove mutacije. Mutacija je nastala *de novo* u hromozomskom kontekstu koji je karakterističan za populaciju u Srbiji. Takođe je pokazano da su dve najčešće mediteranske mutacije, $\beta^{\circ}39$ i $\beta^{+IVS-I-110}$, verovatno »uvezene« u populaciju Srbije iz Italije, odnosno Turske, istorijskim migracijama i seobama naroda.

Ključne reči: β -talasemija, haplotip, Hb Lepore

References

1. Beksedić D, Cuharska T, Stojimirović E, Dinić B. In Hemoglobin and Hemoglobinopathies, (ed) Serbian Blood Transfusion Centre, 1980: 122–7.
2. Pavlović S. Molecular genetics of thalassemia syndromes: genotype-phenotype correlation. Doctoral Thesis. University of Belgrade, Belgrade, FR Yugoslavia, 2001: 136–7.
3. Baglioni C. The fusion of two peptide chains in Hemoglobin Lepore and its interpretation as a genetic deletion. Proc Natl Acad Sci USA 1962; 48: 1880–6.
4. Trecartin RF, Liebhaber SA, Chang JC. Beta^o-thalassemia in Sardinia is caused by a nonsense mutation. J Clin Invest 1981; 68: 1012–15.
5. Spritz RA, Jagadeeswaran P, Choudary PW. Base substitution in an intervening sequence of a beta⁺-thalassemic human globin gene. Proc Natl Acad Sci USA 1981; 78: 2455–62.
6. Orkin SH, Kazazian HH Jr, Antonarakis SE, Goff SC, Boehm CD, Sexton JP, Weber PG, Giardina PJV. Linkage of β -thalassemia mutations and β -globin polymorphisms with DNA polymorphisms in human β -globin gene cluster. Nature 1982; 296: 627–31.
7. Marengo-Rowe AJ. Rapid electrophoresis and quantitation of haemoglobin on cellulose acetate. J Clin Pathol 1965; 18: 790–2.
8. Pembrey ME, McWade P, Weatherall DJ. Reliable routine estimation of small amounts of foetal haemoglobin by alkali denaturation. J of Clin Pathol 1972; 25: 738–40.
9. Molden DP, Alexander NM, Neely WE. Fetal hemoglobin: optimum conditions for its estimation by alkali denaturation. Am J Clin Pathol 1982; 77: 568–72.
10. Poncz M, Solowiejczk D, Harpel B, Mory Y, Schwartz E, Surrey S. Construction of human gene libraries from small amounts of peripheral blood: analysis of β -like globin genes. Hemoglobin 1982; 6: 27–36.
11. Simjanovska L, Petkov GT, Stojanovski N, Basak AN, Efremov GD. The origin of Hb O-Arab in the Balkan countries. Balkan Journal of Medical Genetic 1998; 1 (1): 8–12.
12. Sutton M, Bouhassira EE, Nagel RL. Polymerase chain reaction amplification applied to the determination of β -like globin gene cluster haplotypes. Am J Hematol 1989; 32: 66–9.
13. Efremov GD. Hemoglobinopathies in Yugoslavia: an update. Hemoglobin 1992; 16: 531–44.
14. Ribeiro ML, Cunha E, Goncalves P, Matrin Nunez G, Fernandez Galan MA, Tamagnini GP, Smetanina NS, Gu L-H, Huisman THJ. Hb Lepore-Baltimore and Hb Lepore-Washington-Boston in Central Portugal and Spanish Alta Extremadura. Hum Genet 1997; 99: 669–73.
15. Lanclos KD, Patterson J, Efremov GD, Wong SC, Villegas A, Ojwang PJ, Wilson JB, Kutlar F, Huisman THJ. Characterization of chromosomes with hybrid genes for

- Hb Lepore-Washington, Hb Lepore-Baltimore, Hb P-
Nilotic and Hb Kenya. *Hum Genet* 1987; 77: 40–5.
16. Fioretti G, De Angioletti M, Masciangelo F, Lacerra G, Scarallo A, de Bonis C, Pagano L, Guarino E, De Rosa L, Salvati F, Carestia C. Origin heterogeneity of Hb Lepore-Boston gene in Italy. *Am J Hum Genet* 1992; 50: 781–6.
 17. Urošević J, Đureinović T, Poznanić J, Čvorkov-Dražić M, Bunjevački G, Janić D, Krivokapić-Dokmanović L, Popović Z, Pavlović S. Homogeneity of Hb Lepore gene in FR Yugoslavia. *Balkan Journal of Medical Genetics* 2001; 4 (1&2): 29–32.
 18. Chakravarti A, Buetov KH, Antonarakis SE, Water PG, Boehm CD, Kazazian HH. Nonuniform recombination within the β -globin gene cluster. *Am J Hum Genet* 1984; 36: 212–7.
 19. Kazazian HH Jr, Orkin SH, Markham AF, Chapman CR, Youssoufian H, Waber PG. Quantification of the close association between DNA haplotypes and specific β -thalassemia mutations in Mediterranean. *Nature* 1984; 310: 152–4.
 20. Tadmouri GO, Garguier N, Demont J, Perrin P, Basak AN. History and origin of beta-thalassemia in Turkey: Sequence haplotype diversity of the beta-globin gene. *Hum Biol* 2001; 73: 661–74.

Received: June 22, 2004

Accepted: August 4, 2004

EFFECT OF THYROXINE ON GLUTATHIONE-DEPENDENT ANTIOXIDANT ENZYME ACTIVITIES AND GLUTATHIONE CONTENT IN THE INTERSCAPULAR BROWN ADIPOSE TISSUE OF DIFFERENT MATURATED RATS

Zorica S. Saičić, Dejan N. Mijalković, Aleksandra L. Nikolić,
Duško P. Blagojević, Mihajlo B. Spasić, Vojislav M. Petrović

*Institute for Biological Research »Siniša Stanković«, Department of Physiology,
Belgrade, Serbia, Serbia and Montenegro*

Summary: Effect of thyroxine on glutathione-dependent antioxidant enzyme activities and glutathione (GSH) content in the interscapular brown adipose tissue (IBAT) of different aged rats were studied. Male Mill Hill hybrid hooded rats aged 15, 45 and 75 days were treated with L-thyroxine, T₄ (40 µg/100 g body mass), s.c., one dose per day, 14 days (finally aged 30, 60 and 90 days, respectively). Effect of T₄ on GSH-dependent antioxidant enzyme activities in the IBAT differs with respect to age. T₄ treatment gradually decrease activities of all GSH-dependent antioxidant enzymes in 60 and 90 days old rats in comparison to young ones. GSH content in animals of 30 and 60 days old rats are lower in comparison with 90 days old rats, but the effects are opposite. L-thyroxine treatment significantly increase GSH content in 30 days old rats ($p < 0.001$) in respect with corresponding controls, while decrease in 60 and 90 days old animals were detected ($p < 0.01$). Different response of non-mature rats to thyroxine comparing to older rats could be attributed to the difference in thyroxine metabolism and developmental phase of regulatory physiological systems maturation including antioxidative.

Key words: thyroxine, glutathione-dependent antioxidant enzymes, glutathione, interscapular brown adipose tissue, rats

Introduction

Thermogenesis is the major function of interscapular brown adipose tissue (IBAT) which is found in small mammals. Thyroid hormone (TH) is essential for normal development in vertebrate species. Normal thyroid gland activity is concerned mainly with energy metabolism in nearly all tissues of the body. TH is a major regulator of energy homeostasis with hyperthyroidism increasing basal metabolic rate and body temperature. The development of a hyperthyroid state in vertebrates elevates basal metabolic rate due to increments in the rate of O₂ consumption in target tissues (1) an effect accomplished by both

(a) short-term mechanism activating mitochondrial cytochrome c oxidase and (b) long-term pathway involving changes in nuclear and mitochondrial gene expression through 3,3,5-triiodothyronine signaling. In the latter mechanism, respiratory genes may be upregulated through liganded TH receptor which binds to a TH-responsive element in the promoter regions (2). In IBAT, as well as in other aerobic tissues acceleration of aerobic metabolism by thyroxine enhances the generation of reactive oxygen species (ROS) in mitochondrial and microsomal sites (3). These conditions determine a higher consumption of cellular antioxidants (4, 5) and inactivation of antioxidant enzymes (6) thus inducing oxidative stress (7) with the concomitant increase in lipid peroxides and protein oxidation (1).

The data concerning changes in the amount of low molecular antioxidants such as glutathione (GSH), (8, 9), as well as the activity of antioxidative enzymes in different hyperthyroid rat tissues were investigated by Petrović et al. (10), Asayama et al. (8), Mijalković (11), Saičić et al. (12, 13).

Address for correspondence:

Dr Zorica S. Saičić, Leading scientist
Institute for Biological Research »Siniša Stanković«
Department of Physiology
Bulevar despota Stefana 142,
11060 Belgrade, Serbia, Serbia and Montenegro
Tel: (+ 381) 11 2078 325
Fax: (+ 381) 11 761 433
E-mail: zorica.saicic@ibiss.bg.ac.yu

GSH represents a major non-enzymatic antioxidant and the most abundant non-protein thiol source in the cell (14, 15). GSH serves as a substrate for glutathione peroxidase (GSH-Px) and glutathione-S-transferase (GST) and under physiological conditions, glutathione reductase (GR) will rapidly reduce any oxidized glutathione (GSSG) to reduced form (GSH). Glutathione has several major functions: it detoxifies ROS under normal and impaired homeostasis, detoxifies drugs and maintains an essential thiol status of proteins and other molecules and provides the main molecular form in which cysteine can be stored within the organism and used for transfer between tissues (16, 17).

TH are known to act directly on multiple sites in vertebrate cells, but it seems that mitochondria are the most striking target. IBAT is very rich with mitochondria and potentially important source of free radicals.

In the present work we examine the effect of L-thyroxine, T_4 on total glutathione content (GSH, reduced + GSSG, oxidized) and glutathione-dependent antioxidant enzyme activities: glutathione peroxidase (GSH-Px, EC 1.11.1.9), glutathione-S-transferase (GST, EC 2.5.1.18) and glutathione reductase (GR, EC 1.6.4.2.) in IBAT of different aged rats, 30, 60 and 90 days.

Materials and Methods

The experiments were carried out with the male *Mill Hill hybrid hooded* rats. Animals were housed from birth to 30th day of age near by their mothers. After 30 days they were transferred to individual cages (four animals per cage). All animals were held under controlled conditions of illumination (lights on: 5 a.m.-5 p.m.) and temperature (23 °C) and were allowed free access to water and food. Animals at the 15th, 45th and 75th day of age were treated with L-thyroxine, T_4 (40 mg dissolved in 9 mmol/L NaOH/100 g body mass), s.c., one dose per day, during the next 14 days before sacrificing (finally aged 30, 60 and 90 days, n=31) as performed earlier by Wooten and Cascarino (18). The study was performed using double control group protocol. One control group was consisted of non-treated (intact) animals (n=29). The second control group received 9 mmol/L NaOH/100 g body mass, the same way as T_4 treated animals (n=26).

All animals were sacrificed by decapitation always between 8 and 10 a.m. to avoid any possible rhythmic variations in the antioxidant enzyme level. Immediately after the decapitation IBAT were extracted and washed out with saline solutions (154 mmol/L NaCl). Homogenization was performed with a Janke and Kunkel (Staufen, Germany) Ika-Werk Ultra-Turrax homogenizer at 0–4 °C in 0.25 mol/L sucrose, 1 mmol/L EDTA and 0.05 mol/L TRIS-HCl solution, pH

7.4 (19, 20). The homogenates were sonicated for 30s at 10 kHz on ice to release enzymes (21) and used to determine the content of total glutathione (GSH + GSSG). The remaining sonicates were centrifuged (90 min, 85000 × g, 4 °C) and the supernatant was used for GSH-dependent antioxidant enzyme activity assays and total protein determination. All chemicals were Sigma (St. Louis, MO, U.S.A.) products.

GSH-Px activity was assayed using t-butyl hydroperoxide as substrate (22, 23) and the activity was expressed in nanomoles of NADPH oxidized/min/mg protein. For the determination of GST activity, 1-chloro-2,4-dinitro benzene (CDNB) was used as a substrate (24) and the activity was expressed in nmol GSH used/min/mg protein. GR activity was measured as suggested by Glatzle et al. (25) and expressed in nmol oxidized NADPH/min/mg protein. For the GSH assay sonicated samples were deproteinized by 10% sulfosalicylic acid (2:1, v/v) and centrifuged 10 min on 3020 × g. Content of total GSH (GSH, reduced + GSSG, oxidized) was determined by enzymatic method suggested by Tietze (26) as modified by Griffith (27) and expressed as nmol GSH/g wet mass. All GSH-dependent antioxidant enzyme assays were performed at 25 °C and expressed as specific activity (units per mg protein) and as total activity (units per g wet mass). Protein content was measured by the method of Lowry et al. (28) using bovine serum albumin as a reference.

Statistical analysis was performed using protocols suggested by Hinkle et al. (29). In experimental design here applied treatment was performed on different matured rats, thereby the effects were statistically analyzed considering two factors: treatment and age using two-way analysis of variance (two-way ANOVA).

Results

The GSH-dependent antioxidant enzyme activities after T_4 treatment were presented in *Table I* (activity expressed both per mg protein – as specific and per g wet mass – as total). Statistical data are presented in *Tables II* and *III*.

GSH-Px specific activity was significantly increased ($p < 0.01$) in T_4 treated 90 days aged rats (33.3 ± 3.2) in comparison with corresponding controls (22.4 ± 2.0). At the same time, the activity of GSH-Px in 30 and 60 days aged rats did not show any differences between compared groups (*Table I*). On the other hand, when activity of GSH-Px expressed both as specific and as total (*Table I*) decrease during development in rats (significant age effect- (A); $p < 0.001$; *Tables II* and *III*). This effect is evident in 30 days aged rats in respect to old ones.

We observed the similar effect in GST activity which is not statistically significant, but shows the

Table I The activities of glutathione peroxidase (GSH-Px), glutathione-S-transferase (GST) and glutathione reductase (GR) in the IBAT of 30, 60 and 90 days old rats treated with L-thyroxine (T₄), internal controls (Ki) and controls (K). Enzyme activities are expressed in units per mg protein as specific and in units per g wet mass as total. The results are presented as Mean ± SD.

	30 days			60 days			90 days		
	Controls (K)	Internal Controls (Ki)	Treatment (T ₄)	Controls (K)	Internal Controls (Ki)	Treatment (T ₄)	Controls (K)	Internal Controls (Ki)	Treatment (T ₄)
Specific activity									
GSH-Px	34.4 ± 16.4	44.0 ± 14.3	44.2 ± 14.5	12.8 ± 4.2	22.4 ± 7.7	14.0 ± 2.9	22.4 ± 4.4	23.4 ± 6.9	33.3 ± 6.5
GST	53.9 ± 20.9	54.3 ± 15.3	53.5 ± 13.1	31.3 ± 7.7	41.1 ± 11.2	37.3 ± 7.2	36.6 ± 3.4	36.5 ± 7.7	43.7 ± 11.3
GR	113.5 ± 38.3	98.9 ± 29.0	91.7 ± 34.8	50.5 ± 5.9	51.8 ± 16.3	51.1 ± 9.4	61.1 ± 8.5	69.4 ± 5.9	60.4 ± 8.7
Total activity									
GSH-Px	548 ± 305	880 ± 625	873 ± 313	576 ± 223	940 ± 181	424 ± 91	807 ± 178	798 ± 201	1244 ± 264
GST	966 ± 532	951 ± 603	1072 ± 338	1380 ± 255	1586 ± 345	1133 ± 257	1314 ± 32	1304 ± 239	1681 ± 607
GR	1749 ± 714	1740 ± 748	1632 ± 311	2156 ± 252	2078 ± 720	1523 ± 135	2281 ± 152	2392 ± 236	2240 ± 260

Table II Two-way analysis of variance (ANOVA) for GSH-dependent antioxidant enzyme activities in rats of different age treated with T₄ or corresponding controls. Results are presented as specific activity and expressed in units per mg protein. Df – degree of freedom, MS – mean square. *** p < 0.001

		(A)	(T)	A × T	Error
GSH-Px	Df	2	2	4	65
	MS	3935	353	138	139
	F	28.4***	2.54	1.00	
GST	Df	2	2	4	62
	MS	2304	106	78.9	175
	F	13.2***	0.61	0.45	
GR	Df	2	2	4	71
	MS	20656	329	512	692
	F	29.9***	0.48	0.74	

Table III Two-way analysis of variance (ANOVA) for GSH-dependent antioxidant enzyme activities and GSH content in rats of different age treated with T₄ or corresponding controls. Results are presented as total activity and expressed in units per g wet tissue. Df – degree of freedom, MS – mean square. *** p < 0.001 * p < 0.05

		Age (A)	Treatment (T)	A × T	Error
GSH-Px	Df	2	2	4	65
	MS	403970	335015	375831	119516
	F	3.38*	2.8	3.14*	
GST	Df	2	2	4	62
	MS	1392245	33731	295041	179740
	F	7.75***	0.19	1.64	
GR	Df	2	2	4	74
	MS	2072760	542947	233355	260631
	F	7.95***	2.08	0.9	
GSH	Df	2	2	4	36
	MS	44867	10605	44686	1194
	F	37.6***	8.88***	37.4**	




Figure 1. Glutathione content (GSH) in the IBAT of 30, 60 and 90 days old rats treated with L-thyroxine (T₄), internal controls (Ki) and controls (K) expressed in nmol GSH per g wet mass. Columns represent mean values and vertical bars are S.E.M. ** p < 0.01 *** p < 0.001

same trend, e.g. decreasing during development (significant age effect – (A); p<0.001; Tables II and III).

At the same time, specific GR activity appeared to be lower (p<0.05) in T₄ treated 30 days aged rats (91.7 ± 9.3) in comparison with the corresponding controls (113.5 ± 10.6). GR activity also decrease (p<0.001) during development in rats (significant age effect - (A), Tables II and III).

The effect of treatment is presented in Tables II and III as (T) effect. Treatment is strongly age dependent (interaction A × T, in Tables) only in GSH content (Tables II and III; Figure 1).

Our results showed, that T₄ treatment had opposite effects on GSH content. While in 30 days old animals we found a significant increase (p<0.001) in

GSH content between T_4 treated (300.7 ± 20) and corresponding controls (45.7 ± 5.9) in 60 and 90 days old rats we found decrease in GSH content ($p < 0.01$). Detailed analysis of grand means revealed, that T_4 direct effects should be viewed as clear change of T_4 treated animals in comparison with control and T_4 dissolving buffer treated animals. Furthermore, animals at 30 days of age responded different to treatment in respect to old animals. These results suggest endogenous developmental pathern of antioxidant enzyme expression which could be modified by external factors.

Discussion

From experimental studies, as well as an epidemiological data, it can be inferred that hyperthyroidism is associated with a general increase in tissue oxidative stress. On the other side, great controversy exists as to whether hyperthyroidism is associated with an increase or decrease in the activity of antioxidant enzymes (8, 30). It was shown, that antioxidative defence system is endogenous dynamic system incorporated in homeostatic regulation lead by internal regulatory signals (31).

ROS have been related with many physiological and pathophysiological processes. Under physiological conditions, it is estimated that approximately 80% of stationary oxygen uptake depends on mitochondrial respiratory chain activity (32). However, it's been shown that mitochondrial respiratory chain generates superoxide anion radical ($O_2^{\cdot-}$) at two different places, such as in the proximity of NADH dehydrogenase and of ubiqinon-cytochrome b. Superoxide anion radical is free radical species which is hydrogen peroxide precursor during its generation in mitochondria (33). In that regard, treatment with TH increase activity of several enzymes coupled with mitochondrial respiratory chain, content of cytochrome c, as well as the size and number of mitochondria. Therefore we may conclude, that TH influence on respiration in mitochondria by changing the concentration of some components in electron-transport chain, as well as redox state of its components (34–36).

BAT is anatomically distinct from white adipose tissue and is located in a number of regions of the body. It is particularly abundant in the interscapular, axillary and perirenal regions. The brown adipocyte contains several lipid droplets and the fat-free cytoplasm is occupied almost exclusively with mitochondria packed with cristae (37). Proliferation and hypertrophy of BAT occurs in response to increased thermic need (i.e. cold exposure). This growth is accompanied by increases in total protein, amount of mitochondria (37–39) and alteration in mitochondrial ultrastructure (40). The factors controlling brown fat proliferation are not clearly defined. Norepinephrine (or an intact sympathetic nervous system) is required,

but is not a sufficient agent alone. Thyroid hormone is required as a permissive synergistic agent (41–43) for the BAT adaptive thermic response, but only at low concentrations (44, 45).

Therefore, we choose to examine the effects of induced hyperthyroidism on GSH-dependent antioxidant enzymes, as well as GSH content in the IBAT of different maturated rats, since this tissue, as we mentioned before, are rich with mitochondria and therefore might be significant source of ROS generation under T_4 stimulation.

Changes in GSH-Px and GST activity in 90 day old rats suggest that in maturated rats enzymatic antioxidant activities in the IBAT depend on age ($p < 0.001$, *Tables II and III*) more than treatment itself. The slight rise in activity of GSH-Px and GST in 90 day old rats is followed with statistically significant decrease in total amount of GSH in T_4 treated animals compared with corresponding controls. This distinct fall in GSH content is age and treatment dependent ($p < 0.001$, *Table III*).

There were no changes in GSH-Px and GST activity in 30 day old rats. On the other side, GSH content in 30 day old rats in T_4 treated animals were significantly higher than corresponding controls ($p < 0.001$, *Table III*). The diminished levels of tissue GSH have generally been correlated with the covalent binding of xenobiotics to tissue macromolecules (46). The occurrence of lower concentrations of GSH in older animals can be explained by the following possibilities. Firstly, the actual loss of GSH may be a result of increased rate of oxidation due to higher consumption of oxygen an concomitant higher generation of hydrogen peroxide and hydroperoxides. Secondly, the diminished GSH concentration may be due to either increase degradation or decreased synthesis of GSH. In fact, activity of GSH-dependent antioxidant enzymes have been found to be higher in the T_4 treated animals in comparison to controls, which implies higher consumption of reduced GSH. In the same time, GR activity was not changed. Thirdly, the lower concentration of GSH may be due to increased utilization of GSH in the removal of lipid and other peroxides.

Also, we must take in consideration that during maturation there may be an accumulation of toxic substances which would elevate the activity of enzymes such as GSH-Px and GST, resulting in the intracellular depletion of reduced GSH. Higher concentrations of TH itself in T_4 treated animals, may induce their own removal by GSH-dependent antioxidant enzymes, particularly with GST.

On the other side, quite opposite effects were observed in 30 day old T_4 maturated animals. Statistically significant rise in GSH content ($p < 0.001$, *Table III*) may be explained different in comparison to old rats. Elevated GR activity in T_4 treated 30 day

old rats is probably adaptive response to overall biochemical and physiological processes within the cells, rather than direct effect of antioxidant regulatory elements. This suggests, increased turnover between GSSG and GSH and maintaining of stable redox environment. It has been postulated that redox environment obtained by redox couples is one of developmental determinant (47). One of cellular redox couples is GSH/GSSG and its optimal ratio is considered as developmental causal.

In this investigation, we have demonstrated that during maturation of rats T_4 treated animals exhibit a diminished reducing potential. This observations suggests, that during the period of lower GSH concentrations in hyperthyroid rats IBAT becomes susceptible to oxidative damage due to higher generation of oxidative molecules such as H_2O_2 , hydroperoxides etc. Thus, older animals could be at risk and more vulnerable to deleterious effects of hyperthyroid state.

It can be concluded from presented results, which under normal conditions there are a delicate balance between the rate of formation and the breakdown of ROS in the IBAT which is partially under the control of TH. Alteration in the thyroid state of the body influences the antioxidative defence in the IBAT and can lead to a pathophysiological state. Different response of non-mature rats to thyroxine comparing to older rats, could be attributed to the difference in thyroxine metabolism and developmental phase of regulatory systems maturation including antioxidative. Direct effects of T_4 on mature rats might be summarized as part of its overall catabolic role.

Acknowledgements. This work was supported by the Ministry of Sciences, Technology and Development, Republic of Serbia, Grant No 1669.

EFEKAT TIROKSINA NA AKTIVNOST ANTIOKSIDACIONIH GLUTATION-ZAVISNIH ENZIMA I KOLIČINU GLUTATIONA U INTERSKAPULARNOM MRKOM MASNOM TKIVU PACOVA RAZLIČITE STAROSTI

Zorica S. Saičić, Dejan N. Mijalković, Aleksandra L. Nikolić,
Duško P. Blagojević, Mihajlo B. Spasić, Vojislav M. Petrović

Institut za biološka istraživanja »Siniša Stanković«, Odeljenje za fiziologiju, Beograd

Kratak sadržaj: Ispitivan je efekat tiroksina na aktivnost antioksidacionih glutacion-zavisnih enzima i količinu glutationa (GSH) u interskapularnom mrkom masnom tkivu (IBAT) pacova različite starosti. Mužjaci Mill Hill hybrid hooded pacova starih 15, 45 i 75 dana tretirani su sa L-tiroksinom, T_4 (40 mg/100 g telesne mase), s.c., jedna doza dnevno, tokom 14 dana (do finalne starosti 30, 60 i 90 dana). Efekat T_4 na aktivnost GSH-zavisnih antioksidacionih enzima u IBAT-u se razlikuje u odnosu na starost. Tretman sa T_4 smanjuje aktivnost svih GSH-zavisnih antioksidacionih enzima kod pacova 60 i 90 dana starosti u poređenju sa mladim jedinkama. Količina GSH kod životinja starih 30 i 60 dana je niža u poređenju sa pacovima starih 90 dana. Tretman tiroksinom značajno povećava količinu GSH kod pacova starih 30 dana ($p < 0,001$) u odnosu na odgovarajuće kontrole, dok kod pacova starosti 60 i 90 dana izaziva smanjenje ($p < 0,01$). Različiti odgovor ne-maturiranih pacova na tiroksin u odnosu na maturirane životinje može se pripisati razlikama u metabolizmu tiroksina i razvojnoj fazi regulatornih fizioloških sistema uključujući i antioksidacioni.

Cljučne reči: tiroksin, glutacion-zavisni antioksidacioni enzimi, glutation, interskapularno mrko masno tkivo, pacovi

References

1. Videla LA. Energy metabolism, thyroid calorogenesis, and oxidative stress: functional and cytotoxic consequences. *Redox Report* 2000; 5: 265–75.
2. Goglia F, Moreno M, Lanni A. Action of thyroid hormones at the cellular level: the mitochondrial target. *FEBS Let* 1999; 452: 115–20.
3. Fernandez V, Videla LA. Influence of hyperthyroidism on superoxide radical and hydrogen peroxide production by rat liver submitochondrial particles. *Free Rad Res Commun* 1993; 18: 329–35.
4. Huh K, Kwon TH, Kim JS, Park JM. Role of the hepatic xanthine oxidase in thyroid dysfunction: effect of thyroid hormones in oxidative stress in the rat. *Arch Pharm Res* 1998; 21: 236–40.
5. Giavarotti KAS, Rodrigues L, Rodrigues T, Junqueira VBC, Videla LA. Liver microsomal parameters related

- to oxidative stress and antioxidant systems in hyperthyroid rats subjected to acute lindane treatment. *Free Rad Res* 1998; 29: 35–42.
6. Fernandez V, Llesuy S, Solari L, Kipreos K, Videla LA, Boveris A. Chemiluminescence and respiratory responses related to thyroid hormone-induced liver oxidative stress. *Free Rad Res Commun* 1988; 5: 77–84.
 7. Sies H. Biochemistry of oxidative stress. *Angew Chem Int Ed Engl* 1986; 25: 1058–71.
 8. Asayama K, Dobashi K, Hayashibe H, Megata Y, Kato K. Lipid peroxidation and free radical scavengers in thyroid dysfunction in the rat; a possible mechanism of injury to heart and skeletal muscle in hyperthyroidism. *Endocrinology* 1987; 121: 2112–8.
 9. Morini P, Casalino E, Sblano C, Landriscina C. The response of a rat liver lipid peroxidation, antioxidant enzyme activities and glutathione concentration to the thyroid hormone. *Int J Biochem* 1991; 23: 1025–30.
 10. Petrović VM, Spasić M, Saičić Z, Milić B, Radojičić R. Increase in superoxide dismutase activity induced by thyroid hormones in the brains of neonate and adult rats. *Experientia* 1982; 38: 1355–6.
 11. Mijalković ND. Efekat tiroksina na zaštitu od oksidacionih oštećenja u ciljnim tkivima pacova različite starosti. Magistarska teza. Beograd. Hemijski fakultet, 2002.
 12. Saičić ZS, Mijalković D, Blagojević D, Nikolić A, Spasić MB, Petrović VM. Effect of thyroxine on the antioxidant enzyme activities and glutathione content in the heart of rats. Proceedings of the Second International Conference of the Society for Free Radical Research-Africa, Mauritius: 2001 July 15–19, Plenary lecture. 2001; 27–8.
 13. Saičić ZS, Mijalković D, Nikolić A, Blagojević D, Spasić MB. Efekat tiroksina na antioksidacioni zaštitni sistem u skeletnim mišićima pacova različite starosti. *Medicus* 2003; 16: 10–6.
 14. Dröge W. Aging-related changes in the thiol/disulfide redox state: implications for the use of thiol antioxidants. *Exp Gerontol* 2002; 37: 1331–43.
 15. Warner HR. Superoxide dismutase, aging and degenerative disease. *Free Rad Biol Med* 1994; 17: 249–58.
 16. Kannan R, Kuhlenskamp JF, Ookhtens M, Kaplowitz N. Transport of glutathione at blood-brain barrier of the rat: inhibition by glutathione analogs and age-dependence. *J Pharmacol Exp Ther* 1992; 263: 964–70.
 17. Julius M, Lang CA, Gleiberman L, Harburg E, Difrancesco W, Schork A. Glutathione and morbidity in a community-based sample of elderly. *J Clin Epidemiol* 1994; 47: 1021–6.
 18. Wooten LW, Cascarano J. The effect of thyroid hormone on mitochondrial biogenesis and cellular hyperplasia. *J Bioenerg Biomemb* 1980; 12: 1–11.
 19. Rossi MA, Audi GS, Dianzani MJ. Glutathione peroxidase, glutathione reductase and glutathione transferase in regenerating rat liver. *Med Sci Res* 1987; 15: 109.
 20. De Waziers I, Albrecht R. The effects of vitamin A, nutritional status on glutathione, glutathione transferase and glutathione peroxidase activities in rat intestine. *Experientia* 1987; 43: 394–5.
 21. Takada Y, Oschino N, Okabe T, Kayiyama M. Superoxide dismutase in various tissues from rabbits bearing the Vx-2 carcinoma in the maxillary sinus. *Cancer Res* 1982; 42: 4233–5.
 22. Paglia DE, Valentine WN. Studies on the quantitative characterization of erythrocyte glutathione peroxidase. *J Clin Lab Med* 1967; 70: 74–7.
 23. Tamura M, Oschin N, Chance B. Some characteristics of hydrogen and alkyl-hydroperoxides metabolizing systems in cardiac tissue. *J Biochem* 1982; 92: 1019–31.
 24. Habig WH, Pabst MJ, Jakoby WB. Glutathione-S-transferases. *J Biol Chem* 1974; 249: 7130–9.
 25. Glatzle D, Vuilleumier JP, Weber F, Decker K. Glutathione reductase test with whole blood a convenient procedure for the assessment of the riboflavin status in humans. *Experientia* 1974; 30: 665–8.
 26. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. *Anal Biochem* 1969; 27: 502–22.
 27. Griffith OW. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. *Anal Biochem* 1980; 106: 207–12.
 28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem* 1951; 193: 265–75.
 29. Hinkle DE, Wiersma W and Jurs SG. Applied Statistics for Behavioral Sciences. 5th ed, Boston: Houghton Mifflin Company, 2003.
 30. Fernandez V, Barrientos X, Kipreos K, Valenzuela A, Videla LA. Superoxide radical generation, NADPH oxidase activity, and cytochrome P-450 content of rat liver microsomal fractions in an experimental hyperthyroid state: relation to lipid peroxidation. *Endocrinology* 1985; 117: 496–501.
 31. Blagojević D, Buzadžić B, Korać B, Saičić ZS, Radojičić R, Spasić MB, Petrović VM. Seasonal changes in the antioxidative defense in ground squirrels (*Citellus citellus*): possible role of GSH-Px. *J Environ Pathol Toxicol Oncol* 1998; 17: 241–50.
 32. Scholz R, Bucher TH. Hemoglobin-free perfusion of rat liver. In: Chance B, Easterbrook RW, Williamson JM eds. Control of energy metabolism. Academic Press: New York, 1965: 393–414.
 33. Turrens JF, Boveris A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. *Biochem J* 1980; 191: 421–7.
 34. Roodyn DB, Freeman KB, Tata JR. The stimulation by treatment *in vivo* with triiodothyronine or amino acid

- incorporation into protein by isolated rat liver mitochondria. *Biochem. J* 1965; 94: 628–41.
35. Bronk JR. Thyroid hormone: effects on electron transport. *Science* 1966; 153: 638–9.
 36. Nishiki K, Erecinska M, Wilson DF, Cooper S. Evaluation of oxidative phosphorylation in hearts from euthyroid, hypothyroid and hyperthyroid rats. *Am J Physiol* 1978; 235: C212–9.
 37. Barnard T, Skala J. The development of brown adipose tissue. In: LINDBERG eds. *Brown adipose tissue*. Elsevier: New York, 1970: 33–72.
 38. Desautels M, Zaror-Behrens G, Himms-Hagen J. Increased purine nucleotide binding, altered polypeptide composition, and thermogenesis in brown adipose tissue mitochondria of cold-adapted rats. *Can J Biochem* 1978; 56: 378–83.
 39. Desautels M, Himms-Hagen J. Roles of noradrenaline and protein synthesis in the cold-induced increase in purine nucleotide binding by brown adipose tissue mitochondria. *Can J Biochem* 1979; 57: 968–76.
 40. Desautels M, Himms-Hagen J. Parallel regression of cold induced changes in ultrastructure, composition, and properties of brown adipose tissue mitochondria during recovery of rats from acclimation to cold. *Can J Biochem* 1980; 58: 1057–68.
 41. Barnard T, Mory G, Nechad M. Biogenic amines and the trophic response of brown adipose tissue. In: PARVEZ eds. *Biogenic amines in development*. Elsevier/North-Holland, Amsterdam, 1980; 391–493.
 42. Himms-Hagen J. Thyroid hormones and thermogenesis. In Girardier S, eds. *Mammalian thermogenesis*. Chapman and Hall, London, 1983; 141–77.
 43. Sundin D. GDP binding to rat brown fat mitochondria: effects of thyroxine at different ambient temperatures. *Am J Physiol (Cell Physiol 10)* 1981; 241: C134–9.
 44. Silva JE, Larsen PR. Adrenergic activation of triiodothyronine production in brown adipose tissue. *Nature*, London 1983; 305: 712–3.
 45. Triandafillou J, Gwilliam C, Himms-Hagen J. Role of thyroid hormone in cold induced changes in rat brown adipose tissue mitochondria. *Can J Biochem* 1982; 60: 530–7.
 46. Farooqui MYH, Ahmed AE. The effects of acrylonitrile on hemoglobin and red cell metabolism. *J Toxicol Environ Hlth* 1983; 12: 695–707.
 47. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. *Free Rad Biol Med* 2001; 30: 1191–212.

Received: June 22, 2004

Accepted: August 4, 2004

INFLAMMATORY RESPONSE IN RHEUMATOID ARTHRITIS

Ljiljana Petrović-Rackov, Nada Pejnović, Zoran Mijušković, Gordana Ercegović

*Clinic of Rheumatology and Clinical Immunology
Institute of Medical Biochemistry
Military Medical Academy, Belgrade*

Summary: The aim of the research is to determine the clinical significance of cytokines TNF-alpha, IL-12, IL-15 and IL-18 in evaluation of the activity of rheumatoid arthritis (RA). By comparing the concentrations in 30 patients with high, 14 patients with moderate and 20 patients with mild activity of RA it is established that the patients with high degree of disease activity, have significantly high ($p < 0.01$; $p < 0.05$) concentrations of examined cytokines and rheumatoid factor in blood and synovial fluid as well as C-reactive protein in serum in relation to patients with moderate and mild active disease. We have concluded that the cytokines concentrations can be good indicators of the degree of the general activity of RA. This research can contribute to interpretation of insufficiently well known views of pathogenesis role of cytokines in active disease.

Key words: cytokines, arthritis, rheumatoid factor, C-reactive protein

Introduction

Rheumatoid arthritis (RA) is chronic inflammatory disease of unknown etiology and multifactor pathogenesis, of changing clinical course and unpredictable prognosis in which base is the progressive destructive synovitis and the impairment of the joint structure (1). Symmetric pains and swelling of small peripheral joints, long-term morning stiffness, general symptoms, the occurrence of rheumatoid nodules, rheumatoid factor (RF) in blood and characteristic radiological changes in joints are the primary clinical features of the disease. The appearance of extraarticular manifestations, autoimmunoglobulin antibodies and immune complexes in the circulation with activation of the complement system imply to systemic nature of the disease, which justifies the term rheumatoid disease (2). The most epidemiological, pathophysiological, immunological and genetic aspects of the disease are well known, but the precise starter and factors, which maintain the destructive inflammatory process, still haven't been determined. Because of that it is not

unusual to claim that RA is the disease with many causes or many diseases with one cause (2, 3).

Immunopathological process in synovial tissue develops in five phases (4): in the first phase the presentation and recognition of the unknown antigen is being done by T lymphocyte; in the second phase occurs the proliferation of T and B lymphocytes, migration of inflammatory cells in to the joint and angiogenesis. The cells components of the joint react to the injury by changing the functional profile. Changes occur in endothelium of small blood vessels and hyperplastic reaction of synovia with proliferation of synovial cells – the third immunological phase of the disease. In the fourth phase of the disease the panus is formed. It is metabolically active and autonomous joint tissue. Chondrocytes and osteoclasts are activated. Cytokines interleukine (IL)-1, the tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (INF-gamma) and many others, which are produced by macrophages and activated T cells, stimulate synovial cells to create hydrolytic enzymes, proteinases. The initial damage of the joint occurs. In the fifth immunological phase many mediators such as prostaglandins, activated components of complement, proteases, free oxygen and nitrogen radicals bring to the definitive destruction of joint cartilage, bones and surrounding structures (5).

The tumor necrosis factor-alpha and IL-1 have almost identical biological activity, mutually stimulate

Address for correspondence:

Dr sc. med. Ljiljana Petrović-Rackov
11000 Beograd
Svetozara Markovića 43
tel: 011/3611 788
mobil: 063/361 004
e-mail: ljrackov@eunet.yu

production and act synergistic in the induction of inflammatory reaction (6, 7). Proinflammatory effects IL-18, IL-15 and IL-12 have been examined and demonstrated in experimental conditions *in vitro* and *in vivo* with mice on model of arthritis induced by collagen (8–13). According to us available literature great number of research with patients with RA has not been conducted. It is unknown if the production of cytokines in blood, and especially in synovial fluid (SF) is connected with the severity of RA and if their levels can reflect the disease activity, to imply to progression and foresee the course of the disease. These have just been the basic motives to conduct the research with the aim to determine clinical significance of cytokines for the evaluation of activity of rheumatic arthritis. In this region such research has not been done.

Methods

In four year period, total of 89 patients have been analyzed, 64 patients with RA, newly formed or in the phase of deterioration of the disease. The diagnosis of all patients has been set according to revised criteria for classification and diagnosis of RA (ARA/ACR, 1987). We have analyzed clinical manifestations of patients (P group) and have grouped the in relation of the disease activity in three groups: patients with highly active RA (HiA), 30 patients, patients with moderately active RA (MoA), 14 patients and patients with mildly active RA (MiA), 20 patients. The control group was consisted of 25 subjects with the arthritis of the knee during the deterioration of osteoarthritis (OA), for whom we have presumed not to have deranged immunological parameters in blood and SF. The total evaluation of activity of rheumatic arthritis is determined on the basis of total number of swollen joints (SJ), total number of tenderness joints (TJ), values on visible analogical scale for pain (VAS) and rapidity of erythrocyte sedimentation rate (ESR) by means of is calculated index Disease Activity Score 28 (DAS 28), numerical indicator of the degree of disease activity (14). High disease activity have represented the given values DAS >5.1, moderate >3.2, and mild disease activity have showed given values of DAS >2.6. In both examined groups the analyzes of the samples of serum (S) and SF has been done and the concentrations of C-reactive protein (CRP) (mg/L) have been determined by immunonephelometry method, IgM-RF (IU/mL) Latex nephelometry (DADE Behring, Germany) and concentrations of cytokines (pg/mL) TNF-alpha, IL-12, IL-15 and IL-18 immunoenzymatic (ELISA) methods by using kits for humane interleukines (R&D, USA). The value of ESR (mm/h) was determined by standard laboratory procedure according to Westergreen.

For evaluation of statistical significance of difference between characteristics of observation in control group and group of patients with RA Mann-Whitney U test was administered. For comparing between groups

of patients divided according to the degree of activity both Kruskal-Waliss test and Mann-Whitney U tests were used. The level of significance in all administered methods was on in the limit of 0.05.

Results

Comparing the number of subjects in control group and group of patients with RA in relation to sex, showed that there is highly significant difference, caused by larger number of female patients in the group of patients with RA ($p < 0.01$) (Table I).

In groups with highly and moderately active RA examined patients have had significant increase of serum values RF in relation to the group of patients with mild case of RA ($p < 0.01$) (Table II).

Activity of RA in the group of patients was determined and numerically presented on the basis of values of DAS 28 index. Clinical manifestations have been compared between the two groups of examinees, and between groups of HiA, MoA and MiA, by comparing clinical parameters, individual factors of DAS: average values of number of tenderness joints, swollen joints and average values ESR and VAS.

Values of all examined clinical parameters (SJ, TJ, VAS, DAS), have high significantly differentiated between the groups of patients with different activity of RA, with the highest values in HiA group, smaller in MoA and the least in the group of patients with mild RA activity (Table III). The examined subjects in control group have had significantly lower ($p < 0.01$) average values clinical parameters in relation to patients with RA (results are not show).

Table I General characteristics of the study population

Characteristics	Group	
	Control	Patients
Number patients (% of total number examinees)	25 (28)	64 (72)
Age (yr.)	59.2	57.8
Female	15	45
Male	10	19
Mean duration of disease (m.)	45.2	74.4
Mean duration of presently hardships (m.)	5.4	6.0

Table II The division of the group of patients in relation to disease activity and seropositivity

Group	P		HiA		MoA		MiA	
	N	%	N	%	N	%	N	%
Number of »seropositive« pat.	57	89	30	100	14	100	13	65
Number of »seronegative« pat.	7	11	0	0	0	0	7	35
Total number patients	64	100	30	100	14	100	20	100

Table III Clinical parameters values in groups of patients with RA in relation to disease activity

Group	HiA	MoA	MiA	
Parameters	$\bar{x} \pm SD$	$\bar{x} \pm SD$	$\bar{x} \pm SD$	p
TJ	9.8 ± 6.1	4.2 ± 0.9	2.4 ± 0.5	0.00**
SJ	8.4 ± 5.7	2.8 ± 0.7	1.8 ± 0.6	0.00**
ESR	78.0 ± 24.9	47.4 ± 10.7	27.2 ± 11.3	0.00**
VAS	70.3 ± 13.8	31.4 ± 4.6	12.0 ± 5.7	0.00**
DAS	10.1 ± 5.2	4.7 ± 0.5	2.9 ± 0.1	0.00**

* p < 0.05; ** p < 0.01

Table IV Comparing of mean values CRP and RF in serum and synovial fluid and ESR between control group and group of patients with RA

Group		CRP (mg/L)	CRP (mg/L)	RF (IU/mL)	RF (IU/mL)	SE (mm/h)
		S	SF	S	SF	
Patients	Mean	43.95	25.41	489.96	316.14	55.5
	SD	38.72	21.26	546.71	327.82	29.3
Control	Mean	6.67	4.77	14.08	12.36	14.8
	SD	7.15	4.46	10.02	6.98	9.6
z		5.79	5.74	6.22	5.95	6.44
p		0.00**	0.00**	0.00**	0.00**	0.00**

* p < 0.05; ** p < 0.01

Table V Cytokines concentrations (TNF-alpha, IL-18, IL-15, IL-12) in the serum samples and synovial fluid of the control group and group of patients with RA

Group		TNFα (pg/mL)		IL-18 (pg/mL)		IL-15 (pg/mL)		IL-12 (pg/mL)	
		S	SF	S	SF	S	SF	S	SF
Patients	Mean	5.59	13.96	156.69	281.11	1.77	10.39	11.80	10.52
	SD	3.53	19.36	90.39	317.23	3.03	9.78	8.09	7.58
Control	Mean	2.32	3.45	89.68	112.18	0.59	3.34	4.92	6.08
	SD	0.80	1.22	17.23	84.83	0.20	1.17	2.14	2.11
z		4.66	5.18	4.40	3.24	3.88	5.13	4.77	3.73
p		0.00**	0.00**	0.00**	0.00**	0.00**	0.00**	0.00**	0.00**

* p < 0.05; ** p < 0.01

Comparing mean values of CRP, RF and ESR between control group and group of patients with RA, indicated significant differences in the concentrations CRP, RF and values ESR (p<0.01). RF and CRP values were higher in the samples of synovial fluid and samples of RA patients' serums as well as ESR values (Table IV).

Comparing mean values of TNF-alpha, IL-18, IL-15, IL-12 has showed that the values of these cytokines are significantly higher (p< 0.01) in serum samples and synovial fluid of the patients with RA in relation to samples of the control group (Table V).

Average serum values of CRP were the highest in HiA group, significantly lower (p<0.01) in MoA group and the lowest (p<0.01) in MiA group. Average values of CRP in synovial fluid were the highest in MoA group, then in MiA group while the lowest were in the group with the highest RA activity, but without any significant differences (Figure 1). Mean values of RF in serum samples and in the synovial fluid samples were highest in HiA group, significantly lower in MoA group (p<0.01) and again significantly the lowest in MiA group (p<0.01) (Figure 2).

Comparing the mean values of cytokines of the patients with RA according to disease activity indicates that with all observed parameters exist highly statistically significant differences (p<0.01), which appear because mean concentrations of cytokines were always higher in HiA group in relation to MoA and MiA groups. Only for the IL-12 concentrations in syno-




Figure 1. Concentrations of CRP in serum and synovial fluid samples of the patients according to degree of RA activity




Figure 2. Concentrations of RF in serum and synovial fluid samples of the patients according to degree of RA activity




Figure 3. Concentrations of TNF alpha, IL-15 and IL-12 in serum samples of patients according to the degree of RA activity




Figure 4. Concentrations of TNF-alpha, IL-15 and IL-12 in synovial fluid samples of patients according to the degree of RA activity




Figure 5. Concentrations of IL-18 in serum and synovial fluid samples of patients according to the degree of RA activity

vial fluid the difference was statistically significant ($p < 0.05$) (Figure 3–5).

Intergroup comparisons between three groups according disease activity within the group of patients with RA, has showed the existence of statistically significant difference in all cases and concentration of

cytokines in serum and synovial fluid have always been the highest in HiA and the smallest in MiA. Only situations when the intergroup differences haven't been significant ($p > 0.05$) are with TNF-alpha in serum between HiA and MoA, IL-12 in serum and in synovial fluid where the difference haven't been significant between HiA and MoA.

Discussion

In pathogenesis of RA TH1 immune response prevails. TH1 cells create special profile of cytokines, which together with products of synovocytes disturbs natural balance in cytokines net inside the synovial tissue. It leads at last to immunoinflammatory reaction and joint damage. Many up today researches showed that IL-12 has major role in the differentiation of TH1 cells response, by stimulating differentiation of T cell's precursor (TH0) in TH1 phenotype. In the arisen TH1 reaction IL-12 increases the proliferation of T cells and production of IFN-gamma and other T cells cytokines in synergism with IL-18. Two cytokines create synergistic effect by reciprocal increase expression of T cells receptor and by different mechanism of IFN-gamma genetic expression (on transcription level). They are produced by synovial macrophages. Lately in synovial tissue of patients with RA has been discovered the IL-15, mediator with pleiotropic effects on many immune system cells. In RA IL-15 activates T cells and stimulates their intercells contact with macrophages. That's how it indirectly induces large synthesis of TNF-alpha and other cytokines of the macrophages. With the help of IL-15 activated synovial T cells secrete TNF-alpha directly. Interleukine-15 stimulates the proliferation of T cells, induces the expression of adhesive molecules and has significant effect of chemotaxis. It stimulates the proliferation of B cells with the consequential production of immunoglobulin including RF. It intensifies the cytotoxicity of natural killer cells, activates neutrophils and stimulates the differentiation of osteoclasts and angiogenesis. Interleukine-15 is produced mainly by T cells and macrophages.

The discovery of new proinflammatory cytokine IL-18 is added to the list of mediators which stimulate activity and development of TH1 cell response with ability to induce the production of IFN-gamma in T cells and NK cells. Synergistic effect with IL-12 and IL-15 in the induction of IFN-gamma defines it as the member of the cytokine family, which induce TH1 (IFN-gamma, IL-2, IL-12 and IL-15). Interleukine-18 is the member of IL-1 family, because it shows the structural and functional similarity with this cytokine. It also owns pleiotropic effects and the role in innate and acquired immunity. Interleukine-18 is synthesized by macrophages, dendrital cells, chondrocytes, osteoclasts, keratinocytes, Kupffers cells, adrenal gland cortex cells and pituitary gland cells. The presence of IL-18 is proved in many diseases in human population, but his role in stimulating or repression the disease is

different. In RA it contributes to the development of TH1 response and induces the IFN-gamma and TNF-alpha synthesis in T and NK cells with consequential stimulation of production and secretion of proinflammatory cytokines of monocytes. The most important role of IL-18, pleiotropic proinflammatory cytokine in synovitis is most probably to facilitate and enable the creation of IFN-gamma dominant T cell response, which is induced by IL-12. There will be necessary further research to establish how much is the real contribution of IL-18 in process of immunopathogenesis of RA. The dilemma about the positive and negative effects of IL-18 in inflammation and synovitis and if there is a need to block or not to his effects because of the potentially positive effects still remains. These and other unknown facts invite us for further researches concerning IL-18.

In our research first was done the analyze of clinical manifestations of diseases inside the group of the patients with active RA, by comparing several clinical parameters which form DAS (average values of the number of tenderness joints and number of swollen joints and average values of ESR and VAS). Patients in the group with highly active disease had significantly higher number of tenderness and swollen joints in relation to group with moderate and mild activity of RA. The mean values of ESR and VAS of patients with the most severe case of the disease were significantly higher in relation to mean values in groups with lower degree of RA activity. Average values of DAS index of RA patients were 6.7. The highest DAS value was in HiA group (10.1) while the patients in MoA group (4.7) and MiA (2.9) had significantly lower DAS values. Patients with RA were divided according to the degree disease activity measured by values of DAS index, were significantly different in relation to the severity of clinical manifestations of the disease.

Between the patients with RA and OA as a control group and between the groups of patients divided according to degree of disease activity inside the group of patients with RA we have compared concentrations of TNF-alpha, IL-18, IL-15 and IL-12 in the samples of S and SF. The average values of all 4 cytokines were high significantly different between the control group and group of patients with RA. Patients with erosive arthritis have higher average concentrations of examined cytokines in blood as well in fluid of joint in relation to examinees with OA. This indicates that pathophysiological mechanism and the degree of inflammatory reaction is different in RA and OA. We have confirmed that TNF-alpha, IL-18, IL-15 and IL-12 have significant role in pathogenesis of rheumatoid synovitis.

Comparing the results of patients with different degree of RA activity significant difference was achieved. Average concentrations of TNF-alpha, IL-18, IL-15 and IL-12 in S and SF were highly and statistically different between the groups of patients with high,

moderate and mild active RA. Patients with high active RA had higher average concentrations of all examined cytokines in serum and synovial fluid in relation to patients with moderate and mildly active RA. When we want to look at the intergroup comparisons between groups of HiA and MiA patients, high and statistically significant differences were established in cytokines concentrations, except for the average values of IL-12 in S ($p=0.62$) and SF ($p=0.43$). Concentrations of TNF-alpha of HiA and MoA patients' serum have also been approximately equal ($p=0.11$), while for other examined parameters highly significant differences came up. Comparing mean values of cytokines concentrations between HiA and MiA groups, highly and statistically significant differences came up. Higher cytokines concentrations in more severe disease cases and their lower values in the disease of the lesser activity indicate that levels of TNF-alpha, IL-18, IL-15 and IL-12 in S and in SF influence clinical manifestations and severity of RA and can be good indicators of general activity of RA as well as parameters to evaluation of the disease severity. We can expect high values of cytokines in S as well in SF in the patients with active RA. We have concluded that the concentrations of cytokines can predict with great accuracy the severity of RA. Concentrations of TNF-alpha, IL-18 and IL-15 in SF reflect the degree of general activity of the disease and severity better than their serum values.

In active disease in laboratory analyzes acute phase parameters of inflammation CRP, fibrinogen and speeded ESR were usually increased. For now there isn't specific biohumoral indicator of disease activity, except of RF. On the basis of comparison of concentrations of CRP and RF in serum and synovial fluid, we have tried to estimate if there is general and local activity of the disease. Patients in HiA group had higher average concentrations of CRP and RF in S and RF in SF in relation to MoA and MiA patients. It implies that RF concentrations in blood and ST and CRP concentrations in S were good indicators of the general activity degree and severity of the disease. Local concentrations of CRP in the knee joint haven't showed any difference among patients groups and it isn't the system inflammatory reaction indicator.

Our research has indicated to the importance of determining several cytokines concentrations in blood and synovial fluid in patients with active RA and can contribute to explanation of insufficiently known views of role in pathogenesis and significance of TNF-alpha, IL-12, IL-15 and especially IL-18 cytokines in the active disease. This research confirmed that examined cytokines could be indicators of the degree of RA activity of the same value and specific quality as up to now used standard biochemical parameters. Concentrations of cytokines can be useful for the early assessment of disease activity. The research can serve as the basis for further studies and evaluation of the administered therapy's effect.

INFLAMATORNI ODGOVOR U REUMATOIDNOM ARTRITISU

Ljiljana Petrović-Rackov, Nada Pejnović, Zoran Mijušković, Gordana Ercegović

*Klinika za reumatologiju i kliničku imunologiju
Institut za medicinsku biohemiju
Vojnomedicinska akademija, Beograd*

Kratak sadržaj: Cilj istraživanja je da se utvrdi klinički značaj citokina faktora nekroze tumora-alfa (TNF-alfa), interleukina (IL)-12, IL-15 i IL-18 u proceni aktivnosti reumatoidnog artritisa (RA). Poređenjem koncentracija kod 30 bolesnika sa visoko, 14 sa umereno i 20 bolesnika sa blago aktivnim RA utvrdeno je da bolesnici sa visokim stepenom aktivnosti oboljenja imaju značajno veće ($p < 0,01$; $p < 0,05$) koncentracije ispitivanih citokina i reumatoidnog faktora u krvi i sinovijskoj tečnosti kao i C-reaktivnog proteina u serumu u odnosu na bolesnike sa umereno i blago aktivnim oboljenjem. Zaključili smo da koncentracije citokina utiču na težinu RA i mogu biti dobri pokazatelji stepena opšte aktivnosti RA. Rad može pružiti doprinos razjašnjenju nedovoljno poznatih stavova o patogenetskoj ulozi i značaju određivanja IL-18, IL-15, IL-12 i TNF-alfa u aktivnoj bolesti.

Cljučne reči: citokini, artritis, reumatoidni faktor, C-reaktivni protein

References

1. Firestein SG. Etiology and pathogenesis of rheumatoid arthritis. In: Kelley WN, Ruddy S, Harris ED and Sledge CB, editors. Textbook of Rheumatology. Philadelphia: W.B. Saunders Co 2001; 921–66.
2. van Riel LCMP, Wijnands JHM, van de Putte BAL. Rheumatoid arthritis. Evaluation and management of active inflammatory disease. In: Klippel HJ, Dieppe AP, editors. Rheumatology, 2nd ed. London: Mosby 1998; 14.1–14.12
3. Budd CR, Fortner AK. T lymphocytes. In: Kelley WN, Ruddy S, Harris ED and Sledge CB, editors. Textbook of Rheumatology. Philadelphia: W.B. Saunders Co 2001; 113–29.
4. Gaston HJ. Cellular immunity in RA. In: Klippel HJ, Dieppe AP, editors. Rheumatology, 2nd ed. London: Mosby 1998; 10.1–10.6
5. Szekanecz Z, Koch AE. Cytokines. In: Kelley WN, Ruddy S, Harris ED and Sledge CB, editors. Textbook of Rheumatology. Philadelphia: W.B. Saunders Co 2001; 275–90.
6. Dinarello AC, Moldawer LL. Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis. In: Dinarello AC, Moldawer LL., editors. A Primer for Clinicians. Florida: College of Medicine 1999; 1–88.
7. Kollias G, Douni E, Kassiotis D. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 1999; 58: 132–9.
8. Cordero OJ, Selgado FJ, Mera-Valera A, Nogueira M. Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol Int 2001; 21 (2): 69–74
9. Plater-Zyberk C, Joosten AL, Helsen MM, Sattoune-Roche P, Siegfried C, Alouani S et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 2001; 108: 1825–32.
10. Joosten LA, Helsen MM, van den Berg WB. Blockade of endogenous interleukin 12 results in suppression of murine streptococcal cell wall arthritis by enhancement of interleukin 10 and interleukin 1Ra. Ann Rheum Dis 2000; 59: 196–205.
11. Ortiz AM, Laffon A, Gonzalez AI. CD69 expression on lymphocytes and interleukin-15 levels in synovial fluids from different inflammatory arthropathies. Rheumatol Int 2002; 21: 182–8.
12. Wei XQ, Leung PB, Arthur MLH, McInnes BI, Liew YF. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 2001; 166: 517–21.
13. Liew YF, McInnes. Role of interleukin 15 and interleukin 18 in inflammatory response. Ann Rheum Dis 2002; 61: ii100–ii102.
14. Prevoo LM, Hof AM, Kuper HH, Leeuwen AM, Putte BL, Riel LP. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 1995; 38: 44–8.

Received: February 25, 2004

Accepted: April 7, 2004

THE BASIC HAEMATOLOGICAL MEASUREMENTS IN PERIPHERAL BLOOD FROM WORKERS EXPOSED TO MERCURY VAPOURS

Radmila Maksimović¹, Ljuba Mandić², Slavica Spasić³

¹Medical Centre, Kruševac

²Faculty of Chemistry, University of Belgrade, Belgrade

³Faculty of Pharmacy, University of Belgrade, Belgrade

Summary: In the present study was assessed the influence of occupational exposure to mercury vapours on the basic haematological parameters (erythrocyte, leukocyte and platelet count, haemoglobin concentration, haematocrit, MCV, MCH and MCHC). Studies were carried out on 138 workers involved in the production of chlorine using the mercuric electrolysis method (divided into three groups: permanently, periodically and earlier exposed to mercury vapours), as well as on 38 healthy workers. The shift time - weighted averages for mercury was determined in the workplace air before research; mean value was significantly over maximum tolerated dose. The mercury content in the blood and urine of exposed workers was determined by atomic absorption spectrophotometry. In all three groups 95th percentile values of mercury in blood and urine are significantly over MTD. Peripheral blood cell parameters were determined using an automatic cell counter. In the group exposed to mercury vapours, was found a statistically significant increase of erythrocyte count with a concomitant decrease in MCV. The mean values of haemoglobin concentration, MCHC and platelet count were higher in the group of workers exposed to mercury vapours, but the difference was not statistically significant. There were no significant differences in haematocrit, MCH and leukocytes between the studied groups. Our results indicate that long-term and permanent exposure to mercury vapours induces changes in the important haematological parameters of the peripheral blood.

Key words: mercury, haematological parameters

Introduction

A large group of workers exposed to mercury vapours may be found in the chlor alkali industry, where chlorine and caustic soda are produced using the electrolysis of brine in mercury cells. A typical mercury cell, 10–20 m², may contain up to 3 tons of mercury, and there are often about 100 mercury cells at a plant. Although the process is closed, leakage of mercury occurs as a result of technical faults, and also during repairs and maintenance. The workers of these plants are exposed to mercury mainly in the form of vapour but to some degree also as the dust of mercury salts (1).

It is relatively easy to diagnose mercurialism with an acute or subacute course by such symptoms as metallic taste in the mouth, excessive salivation, gingivitis, stomatitis, diarrhoea and nephritis. CNS symptoms include nervousness, timidity and uncontrolled fierceness. It is much more difficult to detect the initial symptoms of intoxication showing gradual, yet deepening changes in various metabolic processes. At the beginning, they consist of the elimination of the microelements necessary for life (based on competitive interactions) such as Fe, Ca and Zn (2). A recent review of world literature collected by Moszczynsky (3) irrefutable shows the strong, negative influence of mercury on the immune system.

The aim of this investigation was to determinate (on easily accessible material such as the blood of workers exposed to mercury vapours) changes concerning the basic haematological measurements.

Address for correspondence:

Radmila Maksimović
Rasadnik I H4/29, 37000 Kruševac
e-mail: maks1@ptt.yu

Subjects and Methods

Subjects

The study has been performed on 138 workers involved in the production of chlorine using the mercuric electrolysis method, which were divided into three groups:

Group I, GI – workers (N = 33, average age 36.4 ± 7.21 yrs) permanently exposed to mercury vapours for 8.4 ± 4.7 yrs;

Group II, GII – workers (N = 87, average age 33.9 ± 7.60) periodically exposed to mercury vapours for 7.7 ± 5.3 yrs;

Group III, GIII – workers (N = 18, average age 42.3 ± 5.8 yrs) earlier (minimum 5 years ago) exposed to mercury vapours for 10.3 ± 4.9 yrs.

Control group, CG – (N = 38, average age 31.8 ± 9.4 yrs) consisted of healthy workers, not exposed to mercury vapours.

Methods

The metallic mercury concentrations in workplace air were determined using Analyser of mercury vapour »Jerome instrument corporation S«. The mercury content in the blood and urine of workers was determined by atomic absorption spectrophotometer »Perkin-Elmer«. Blood samples were obtained from fasting subjects together with blood samples for determination complete blood counts. The eight haematological parameters were determined using haematological analyser »Coulter counter«.

The results were subjected to statistical analysis by analysis of variance and Student-t test.

Results

Mercury in blood and urine

The air for the determination of the mercury concentrations was taken in different areas of the workplace on morning and during work time. The shift time – weighted averages determined for mercury in the

workplace air before research were 0.045 ± 0.072 mg/m³ (0.006 to 0.293 mg/m³); mean value was significantly over maximum tolerated dose, MTD (0.01 mg/m³).

Maximum tolerated dose for mercury in blood is 0.175 µmol/L and in urine 0.1 µmol/L. Workers in group permanently exposed to mercury vapours have mean value of mercury in blood close to MTD, but mean in urine are significantly over MTD (*Table I*). Mean values in blood in two other groups are below MTD, mean value in urine in group periodically exposed is slightly higher than MTD and in group earlier exposed is below MTD. In all three groups 95th percentile values of mercury in blood and urine are significantly over MTD.

Mercury concentration in blood and urine of workers significantly correlated with mercury concentration in workplace air: blood: $r = 0.415$, $y = 0.0094 + 0.382x$; urine: $r = 0.474$, $y = 0.069 + 0.354x$.

Haematological parameters

There were no significant differences in haematocrit, MCH and leukocytes between the studied groups (*Table II*).

Erythrocytes count was significantly higher in the group permanently exposed to mercury vapours, $4.74 \times 10^{12}/L$ vs. $4.47 \times 10^{12}/L$ in the control group ($t = 2.09$, $p = 0.04$). The other two groups of workers were not statistically different from the control group (*Figure 1*).

There was substantial drop in the mean corpuscular volume (MCV) value from 102.0 fL in the control group to 97.4 fL in the group permanently exposed to mercury vapours ($t = 2.044$, $p = 0.044$). The values in the group of workers periodically exposed to mercury vapours were slightly higher than the values in the other groups with extremely high 95th percentile value (*Figure 2*).

The mean values of haemoglobin concentration, MCHC and platelet count were higher in the group of workers permanently exposed to mercury vapours, but the difference was not statistically significant.

Table I Mercury concentrations in blood and urine of control group and workers exposed to mercury vapours

Group	Blood (µmol/L)		Urine (µmol/L)	
	mean ± SD	5th–95th P	mean ± SD	5th–95th P
CG	0.009 ± 0.0080	0–0.022	0.015 ± 0.033	0–0.078
GI	0.172 ± 0.123	0.055–0.457	0.379 ± 0.388	0.069–1.017
GI	0.102 ± 0.087	0–0.237	0.103 ± 0.098	0.006–0.280
GIII	0.087 ± 0.093	0–0.202	0.045 ± 0.053	0.006–0.132

Table II The values of haematological parameters in the studied groups

Group	Haemoglobin (g/L)		Erythrocytes count ($\times 10^{12}$)	
	mean \pm SD	5 th – 95 th P	mean \pm SD	5 th – 95 th P
CG	141.6 \pm 15.86	111.9 – 160.1	4.47 \pm 0.61	3.58 – 5.40
GI	148.0 \pm 12.05	124.0 – 160.0	4.74 \pm 0.46	3.97 – 5.50
GII	144.7 \pm 11.98	125.7 – 160.0	4.54 \pm 0.49	3.84 – 5.37
GIII	145.0 \pm 15.79	125.6 – 160.0	4.68 \pm 0.60	3.63 – 5.41
Group	Haematocrit (L/L)		MCV (fL)	
	mean \pm SD	5 th – 95 th P	mean \pm SD	5 th – 95 th P
CG	0.45 \pm 0.045	0.39 – 0.50	102.0 \pm 9.91	88.9 – 116.7
GI	0.46 \pm 0.029	0.40 – 0.49	97.4 \pm 9.27	85.7 – 112.3
GII	0.46 \pm 0.029	0.41 – 0.50	103.0 \pm 11.99	89.3 – 122.2
GIII	0.46 \pm 0.042	0.39 – 0.50	100.2 \pm 9.76	87.2 – 114.4
Group	MCH (pg)		MCHC (g/L)	
	mean \pm SD	5 th –95 th P	mean \pm SD	5 th – 95 th P
CG	31.8 \pm 1.49	28.4 – 35.4	313.2 \pm 22.07	275.5 – 350.0
GI	31.3 \pm 2.45	28.0 – 36.0	323.0 \pm 22.38	293.1 – 351.2
GII	32.1 \pm 3.74	27.6 – 37.8	311.9 \pm 23.14	278.9 – 354.5
GIII	31.2 \pm 2.90	27.7 – 35.4	311.6 \pm 18.33	281.4 – 340.4
Group	Leukocytes ($\times 10^9$)		Platelet ($\times 10^9$)	
	mean \pm SD	5 th – 95 th P	mean \pm SD	5 th – 95 th P
CG	7.50 \pm 1.96	4.8 – 11.1	219.4 \pm 33.0	169.7 – 281.0
GI	7.58 \pm 1.57	4.8 – 9.8	240.3 \pm 43.5	171.8 – 300.0
GII	7.52 \pm 1.98	5.0 – 10.3	236.6 \pm 42.4	166.3 – 296.8
GIII	7.60 \pm 2.00	5.0 – 10.9	234.3 \pm 39.9	178.5 – 290.0




Figure 1. Mean value and 5th and 95th percentile values of erythrocyte count in control group and in groups of workers exposed to mercury vapours; * p < 0.05




Figure 2. Mean value and 5th and 95th percentile values of MCV in control group and in groups of workers exposed to mercury vapours; * p < 0.05

Discussion

Elemental mercury has been detected in the urine of workers exposed to mercury vapour. The occurrence of trace amounts of elemental mercury is considered to be due to reduction of mercuric ion by certain types microorganisms present in the urine and direct urinary excretion following glomerular filtration of elemental mercury persisting in the blood. But determinations of the inorganic species of mercury in urine samples can provide information on both recent exposure and the body borden resulting from chronic

exposure to mercury vapour (4). Our results support this assertion. Almost all workers have had increase values of mercury in urine.

Data collected for all studied groups, i.e. groups exposed to mercury vapours and control subjects are generally contained within normal range. However, when we compared group of workers permanently exposed to mercury vapours with control subjects, the mean value of erythrocyte count was significantly higher and mean value of MCV was significantly lower in the group permanently exposed to mercury. The

quantitative health status results obtained after treatment with toxic compounds or heavy metals where studied parameters fall below the physiological values are relatively easy to explain. It is not easy to comment results obtained in the present study. One possible explanation is that concerning differences in the level of physical exercise, which is higher in the group permanently exposed to mercury than the control group consisting of not physically hardworking people. It is known that physical exercise (6–8 h) increases loss of water from the body, which entails a »thickening« of the peripheral blood (5, 6). The blood »thickening« is accompanied by increased water reabsorption in the renal tubules and increased oxygen consumption by the renal tissue, resulting in local hypoxia which increases the erythropoietin synthesis. That effect is revealed by the increased number of erythrocytes (7).

The decrease of MCV in the group permanently exposed to mercury vapour may result from the diminished iron incorporation into erythrocytic cell lineage, as indicated by increased values of serum ferritin, transferrin and TIBC (8, 9). However, in further studies on cases of mercury intoxication, the level of Cu as well as ceruloplasmin activity in the serum should be taken into account. Copper deficiency is frequently the cause of decrease in MCV and MCHC (10).

Our results indicate that long-term and permanent exposure to mercury vapours induces changes in the important haematological parameters of the peripheral blood, but explanation that phenomenon requires further, broader research.

VREDNOSTI OSNOVNIH HEMATOLOŠKIH PARAMETARA U PERIFERNOJ KRVI RADNIKA IZLOŽENIH UTICAJU PARA ŽIVE

Radmila Maksimović¹, Ljuba Mandić², Slavica Spasić³

¹Medicinski centar, Kruševac

²Hemijski fakultet, Univerzitet u Beogradu, Beograd

³Farmaceutski fakultet, Univerzitet u Beogradu, Beograd

Kratak sadržaj: U radu je ispitivan uticaj izloženosti parama žive iz radne sredine na osnovne hematološke parametre (broj eritrocita, leukocita i trombocita, koncentraciju hemoglobina, hematokrit, MCV, MCH i MCHC). U studiju je uključeno 138 radnika koji rade u proizvodnji hlora procesom elektrolize (podeljeni su u tri grupe: stalno izloženi, povremeno izloženi i ranije izloženi uticajima para žive), kao 38 zdravih radnika. Pre studije su određene koncentracije žive u vazduhu radne sredine; srednje vrednosti su bile znatno iznad maksimalne doze tolerancije (MTD). Koncentracije žive u krvi i urinu radnika koji su izloženi živi određena je atomskom apsorpcionom spektrometrijom. U sve tri grupe je vrednost 95-tog percentila bila znatno iznad MTD. Hematološki parametri su određeni uz pomoć automatskog brojača. U grupi koja je stalno izložena parama žive, dobijeno je značajno povećanje srednje vrednosti broja eritrocita, kao i značajno smanjenje vrednosti MCV. Srednje vrednosti koncentracije hemoglobina, MCHC i broja trombocita u grupi radnika koji su stalno izloženi uticaju žive bile su više nego u kontrolnoj grupi, ali ta razlika nije statistički značajna. Između posmatranih grupa nije bilo značajne razlike u vrednostima hematokrita, MCH i broja leukocita. Dobijeni rezultati pokazuju da dugotrajna i stalna izloženost parama žive može da dovede do promena u vrednostima važnih hematoloških parametara.

Cljučne reči: živa, hematološki parametri

References

1. Menke R, Wallis G. Detection of mercury in air in the presence of chlorine and water vapour. *Am Ind Hyg Ass J* 1980; 41: 120–4.
2. Goyer RA. Toxic and essential metal interaction. *Ann Rev Nat* 1997; 17: 37–50.
3. Moszczynski P. Immunological disorders in men exposed to metallic mercury vapour. A review. *Center Eur J Public Health* 1998; 7: 10–4.
4. Yoshida M. Relation of mercury exposure to elemental mercury levels in the urine and blood. *Scand J Work Environ Health* 1985; 11: 33–7.
5. Szygula Z. Erythrocytic system under the influence of physical exercise and training. *Sport Med* 1990; 10: 181–97.
6. Neuhaus D, Gaehtgens P. Haemorheology and long-term exercise. *Spot Med* 1994; 18: 10–21.
7. Schmidt W, Massen N, Tegtbur U, Braumann KM. Changes in plasma volume and red cell formation after marathon competition. *Eur J Appl Physiol* 1989; 57: 490–8.
8. Zolla L, Lupidi G, Bellelli A, Amiconi G. Effect of mercuric ions on human erythrocytes. *Biochim Biophys Acta Biomembr* 1997; 1328: 273–80.
9. Strom S, Johnson RI, Uyeki EM. Mercury toxicity to hemopoietic and tumor colony-forming cells and its reversal by selenium in vitro. *Toxicol Appl Pharmacol* 1979; 49: 431–6.
10. Marek K, Zajac-Nedza M, Rola E, Wocka-Marek T, Langauer-Lewowicka H, Witecki K. Examination of health effects after exposure to metallic mercury vapours in workers engaged in production of chlorine and acetic aldehyde. I. Evaluation of general health status. *Med Pr* 1995; 46: 101–9.

Received: April 2, 2004

Accepted: August 5, 2004

NOVI PROTOKOL ZA LABORATORIJSKO ISPITIVANJE PACIJENATA SA KALKULOZOM URINARNOG TRAKTA

Dragica Milenković¹, Aleksandar Vuksanović¹, Nataša Lalić²,
Sanja Simić-Ogrizović¹, Violeta Dopsaj²

¹Institut za urologiju i nefrologiju,

²Institut za medicinsku biohemiju, Klinički centar Srbije, Beograd

Kratak sadržaj: Kalkuloza urinarnog trakta je bolest koja je još uvek značajan socio-medicinski problem zbog visoke stope recidiva (50–100% u nelečenih pacijenata), kao i mogućnosti pojave hronične bubrežne slabosti (u 20% pacijenata). Iz tih razloga je pravilna klinička evaluacija pacijenata od neprocenjivog značaja. U cilju efikasnijeg i racionalnijeg pristupa u utvrđivanju mogućih uzroka nastanka kamena u urinarnom traktu i izbora najbolje terapije i mera prevencije važno je sprovođenje laboratorijskih ispitivanja prema inoviranom Protokolu koji je usaglašen sa preporukama Evropskog udruženja urologa (EAU) iz 2003. god. U zavisnosti od hemijskog sastava kamena, kliničke kategorije bolesti kao i specifičnih faktora rizika, program ispitivanja može biti: *minimalan* (analiza prvog jutarnjeg uzorka urina i urinokulture; određivanje kalcijuma, albumina, kreatinina i mokraćne kiseline u serumu i analiza sastava kamena) i *proširen* (kvantifikacija svih relevantnih parametara za nastanak kamena i procena bubrežne funkcije u serumu i 24-oro časovnom urinu (ispitivanjem dva uzastopna uzorka urina). Diferencijalna dijagnoza utvrđenog metaboličkog poremećaja, zasniva se na određivanju parat-hormona u serumu, cAMP u urinu i testova opterećenja kalcijumom, amonijum hloridom i [¹³C₂] oksalatom.

Ključne reči: kalkuloza urinarnog trakta, metabolički poremećaj, protokol laboratorijskog ispitivanja, testovi opterećenja

Uvod

Kalkuloza urinarnog trakta je veoma često oboljenje sa prosečnom prevalencijom od 4–10% (1) i godišnjom incidencijom od 0,5% u zemljama Evrope (2). Od ove bolesti nije pošteđeno nijedno geografsko područje, etnička grupa niti jedno životno doba. Klinički je najmanifestnija između treće i šeste decenije života. U osnovi stvaranja kamena je proces kristalizacije u prezasićenom urinu. On nastaje kao rezultat poremećene ravnoteže između promotera (kalcijum, oksalat, mokraćna kiselina i cistin) čiji je stepen ekskrecije u urinu povećan i inhibitora (Mg, citrat, pirofosfat i glikozaminoglikani) čiji je nivo ili inhibicioni potencijal u urinu snižen. Udružena promena pH vrednosti i zapremine urina dovode do povoljnih uslova za stvaranje novih kristala, agregata kristala i velikih kristalnih čestica koje u kasnijem toku prerastaju u vidljiv konkrement (3). Rezultati *in vitro* istraživanja

(4, 5) su potvrđeni i u kliničkim studijama, koje su pokazale značajno snižene vrednosti inhibitora kristalizacije u urinu osoba sa kalkulozom u poređenju sa zdravima (6–9). Prisustvo infekcije izazvane mikroorganizmima koji razlažu ureu, poremećaji u morfoloiji urinarnog trakta (stenoze, dilatacije, oštećenja urotela) i protoka urina (staza, refluks) takodje deluju kao faktori rizika za stvaranje kamena ili pojavu njegovog recidiva.

U proteklih nekoliko decenija načinjen je značajan napredak u lečenju ove bolesti primenom manje invazivnih metoda – ekstra i intrakorporalne dezintegracije kamena. Međutim, rizik od pojave recidiva ostaje i dalje visok, 50–100% u nelečenih i 10–15% u lečenih bolesnika (10). Novostvoreni kamen u urinarnom traktu značajno otežava kliničku sliku i evoluciju bolesti jer povećava mogućnost razvoja arterijske hipertenzije, a u 20% bolesnika i razvoj hronične bubrežne slabosti (11). Visok procenat recidiva, pored toga što je terapijski problem, ukazuje i na nepotpuno utvrđenu etiologiju bolesti kao i na neadekvatnu primenu mera prevencije. Zbog navedenog, pravilna klinička evaluacija pacijenata je od neprocenjivog značaja.

Adresa autora:

Doc Dr Dragica Milenković
Institut za urologiju i nefrologiju
Klinički centar Srbije, Resavska 51, 11000 Beograd

Tabela I Kliničke kategorije kalkuloze urinarnog trakta

KAMEN KOJI NE SADRŽI KALCIJUM	
Infekcijom izazvan kamen (Infection stone)	INF*
Kamen mokraćne kiseline i njenih soli (Uric acid/sodium, ammonium urate stone)	UR
Cistinski kamen (Cystine stone)	CY
KALCIJUMSKI KAMEN	
Prva pojava kamena bez rezidualnih fragmenata (First time stone former without residual stone or stone fragments)	S ^o
Prva pojava kamena sa rezidualnim fragmentima (First time stone former with residual stone or fragments)	S ^{res}
Recidivna kalkuloza umerene težine bez rezidualnih fragmenata (Recurrent stone former with mild disease without residual stone)	R ^{m-o}
Recidivna kalkuloza umerene težine sa prisutnim fragmentima (Recurrent stone former with mild disease with residual stone)	R ^{m-res}
Recidivna kalkuloza teškog stepena sa ili bez rezidualnih fragmenata (Recurrent stone former with severe disease with or without residual stone)	R ^s
Kalkuloza + specifični faktori rizika (Stone forming patient with specific risk factor)	Risk

* Međunarodne skraćenice prema preporukama EAU-a

Tabela II Specifični faktori rizika za pojavu kamena urinarnog trakta

Početak bolesti pre 25. godine života
Prisustvo fosfata u hemijskom sastavu kamen
Jedan funkcionalan bubreg
Udružene bolesti: hiperparatireoidizam, hipertireoza, renalna tubularna acidoza, Crohn-ova bolest, jejun-ilealni by-pass, stanja malapsorpcije, sarkoidoza
Unošenje visokih doza: kalcijuma, vitamina D, C, sulfonamida, triamterena i Indinavir-a.
Morfološke promene urinarnih puteva praćene zastojem mokraće ili veziko-ureteralnim refluksom (urođene ili stećene).

U cilju što efikasnijeg i racionalnijeg pristupa u utvrđivanju mogućih uzroka nastanka urinarnog kamena i/ili pojave njegovog recidiva, važno je, pre svega, utvrditi kojoj kliničkoj kategoriji pripada pacijent. Na osnovu poznatog hemijskog sastava kamena kao i određenih parametara koji ukazuju na težinu bolesti Odbor za zdravstvenu zaštitu Evropskog udruženja urologa (EAU) je 2003. god. preporučio kliničku kategorizaciju pacijenata sa kalkulozom, koja omogućava ciljanu primenu dijagnostičkih protokola i adekvatnu terapiju (12, 13), (v. Tabelu I).

Postoji više parametara koji se javljaju kao faktori rizika za pojavu recidiva. Na osnovu stepena njihovog prisustva može se predvideti težina bolesti i pojava recidivne kalkuloze. Koristeći analizu specifičnih faktora rizika pacijent se može pravilnije svrstati u određenu kategoriju bolesti (Tabela II).

Cilj ovog rada je da prikaže novi Protokol za laboratorijsko ispitivanje pacijenata sa kamenom urinarnog trakta u nas koji je usaglašen sa preporukama Evropskog udruženja urologa iz 2003. godine, kao i da se ukaže na korist od njegovog uvođenja kao standardnog postupka u kliničku praksu.

Protokol laboratorijskih ispitivanja

Ispitivanje pacijenata sa kalkulozom urinarnog trakta sprovodi se u ambulantnim i/ili bolničkim uslovima (kada ne postoji mogućnost adekvatnog transporta 24h uzoraka urina do laboratorije, kao i u slučajevima kada se radi o proširenom programu ispitivanja).

Optimalno vreme za započinjanje ispitivanja je najmanje mesec dana od prestanka bubrežne kolike ili posle uklanjanja kamena. Protokol se ne nastavlja i u slučajevima kada pregled jutarnjeg uzorka urina pokazuje hematuriju ili piuriju.

U zavisnosti od hemijskog sastava kamena, kliničke kategorije bolesti kao i prisustva specifičnih faktora rizika, program ispitivanja može biti *minimalan* i *proširen*.

Minimalan program ispitivanja obuhvata:

1. Pregled prvog jutarnjeg uzorka urina
 - pH, eritrociti, leukociti, nitriti (test trakama)
 - Određivanje specifične težine (test traka/urometar)
 - Pregled sedimenta urina (kristalurija)
2. Urinokultura

Tabela III Granične vrednosti parametara u urinu i serumu

Parametri	24 ^h urin	Serum
pH (dnevni profil)	< 5,8 ili >6,8	
Specifična težina	> 1,010 g/cm ³	
Zapremina	< 2,0 L	
Kalcijum	>5,0 mmol/dU	2,0–2,5 mmol/L
Fosfat	>35 mmol/dU	0,81–1,29 mmol/L
Mokraćna kiselina	>4,0 mmol/dU	119–380 μmol/L
Magnezijum	<3,0 mmol/dU	
Citrat	<2,5 mmol/dU	
Oksalat	>0,5 mmol/dU	
Cistin	>0,8 mmol/dU	
Kreatinin	7,0–13,0 mmol/L (ž) 13,0–18,0 mmol/L (m)	25–100 μmol/L

3. Pregled seruma: kalcijum, albumin, kreatinin, mokraćna kiselina

4. Analiza kamena

Ovaj program ispitivanja se sprovodi kod svih kategorija bolesnika sa kalkulozom urinarnog trakta, a na osnovu analize parametara indikuju se dalja ispitivanja. Vrednosti pH urina veće od 5,8 ukazuju na mogućnost postojanja renalne tubularne acidoze a vrednosti pH preko 7,0 na urinarnu infekciju. Pozitivan nalaz na test trakama za leukocite i nitrite ukazuje takođe na prisustvo infekcije. Ukoliko pregled sedimenta urina pokaže povećan broj eritrocita, moguća je mehanička lezija mukoze urinarnih puteva usled prisustva kamena, infekcije ili glomerulonefritisa. Povećan broj LE (više od 5) u sedimentu urina takođe ukazuje na infekciju. Vrednosti kalcijuma i mokraćne kiseline u serumu iznad gornjih granica referentnih vrednosti postavljaju sumnju na hiperparatireoidizam i hiperurikemiju i zahtevaju dalja metabolička ispitivanja (Tabela III).

Analiza kamena se radi posle njegove spontane eliminacije ili posle primenjene terapije – dezintegracije ili operacije. Prema preporukama Odbora za zdravstvenu zaštitu EAU, referentne metode za ispitivanje sastava kamena su infracrvena spektroskopija ili difrakcija x-zracima.

Proširen program ispitivanja

Ovaj se program sprovodi kod pacijenata koji pripadaju kliničkim kategorijama komplikovane kalkuloze (S-res, R m-res, R-s i Risk, Tabela I).

Pored svih analiza navedenih u *minimalnom programu ispitivanja*, neophodan je i pregled dva uzorka 24^h urina koji se sakupljaju pri uobičajenom režimu ishrane i unosu tečnosti i uzorci se čuvaju na hladnom mestu (+4 °C).

UZORAK I – sakuplja se bez konzervansa ili uz prethodni dodatak 10 mL 5% rastvora timola u izopropanolu (za svaku bocu od 2,0 L)

Određuje se: 1. zapremina urina

2. urea, kreatinin, albumin, mokraćna kiselina, kalijum, fosfat, magnezijum i citrat

UZORAK II: sakuplja se uz prethodni dodatak 15–30 mL 6 mol/L rastvora HCL (za svaku bocu od 2,0 L)

Određuje se: 1. zapremina urina

2. kalcijum i oksalat

Zakišeljavanje urina je neophodno da bi se sprečilo taloženje soli kalcijuma (u formi oksalata i fosfata) kao i oksidacija askorbinske kiseline u oksalat. Urea, kreatinin, mokraćna kiselina, K, Ca, i fosfat u serumu određuju se na dan donošenja prvog 24^h uzorka urina, čime je omogućeno određivanje klirensa kreatinina. Pored navedenih parametara, koji su obavezni, određuju se Na i Cl u serumu i u urinu prvog uzorka koji uz vrednosti uree, fosfata i K ukazuju na navike u ishrani.

Određivanje navedenih parametara u urinu je moguće i iz uzoraka koji se sakupljaju u kraćim vremenskim intervalima (4 ili 6 sati). U tom slučaju se vrednosti prikazuju na gram kreatinina a ne na ukupnu diurezu.

Na osnovu seta parametara dobijenih analizom 24 h uzoraka urina moguće je izračunati indekse zasićenosti urina kalcijum oksalatom i kalcijum fosfatom (14) kao i prediktivni indeks rizika – PRI (15). Vrednosti ovih indeksa daju uvid u stepen poremećene ravnoteže između promotera i inhibitora kristalizacije. Takođe predviđaju mogućnost pojave recidiva, što je od značaja za kliničko praćenje pacijenata sa kalkulozom.

Kada vrednosti ispitivanih parametara odstupaju od referentnih, ispitivanje se ponavlja. Poznato je da na ekskreciju supstanci od značaja za stvaranje urinarnog konkrementa može da utiče i način ishrane bilo da prikrije, smanji ili poveća postojeći metabolički poremećaj. Iz tih razloga, protokol proširenog ispitivanja se ponavlja posle sprovođenja standardne dijetete (2) u trajanju od tri dana, kada se u kontrolnim, bolničkim uslovima postiže stabilizacija metabolizma. Poređenjem vrednosti analiziranih parametara iz uzorka urina I i II pre i posle dijetete, moguće je otkriti one poremećaje u ekskreciji, na koje utiče način ishrane.

Ukoliko se ispitivani parametri u urinu vrata na normalne vrednosti posle standardne dijetete uzrok po-

remećaja su nepravilnosti u ishrani. Održavanje vrednosti urinarnih parametara izvan referentnih granica ukazuje na metabolički poremećaj i zahteva sprovođenje testova opterećenja kalcijumom, amonijum hloridom ili test apsorpcije [$^{13}\text{C}_2$] oksalata.

Test opterećenja kalcijumom

Test opterećenja kalcijumom modifikovan prema Pak-u (17) izvodi se na sledeći način:

I dan: dijeta bez mlečnih proizvoda

18^h – večera

20^h unos 300 mL vode osiromašene kalcijumom

23^h unos 300 mL vode osiromašene kalcijumom

II dan: 07^h – uriniranje, zatim unos 600 mL vode osiromašene kalcijumom

07–09^h prvi period sakupljanja urina (vrednosti posle gladovanja)

09^h – doručak (1 sendvič, puter, džem, 2 šolje voćnog čaja + 1 tbl od 1000 mg kalcijuma

11^h – unos 300 mL vode osiromašene kalcijumom

09–13^h drugi period sakupljanja urina (vrednosti posle opterećenja)

U uzorcima urina I i II određuje se koncentracija kalcijuma (mmol/L) i kreatinina (mmol/L) i izračunava se indeks Ca/Cr.

Testom opterećenja kalcijumom omogućava se razlikovanje tri tipa hiperkalciurije i to:

1. *Apsorptivna hiperkalciurija* koja nastaje kao posledica povećanog stepena apsorpcije kalcijuma iz intestinalnog trakta. Ona može biti nezavisna od unete količine kalcijuma (tip I) i zavisna, kada se pojavljuje samo pri povećanom unosu kalcijuma (tip II).
2. *Renalna hiperkalciurija* koja je rezultat gubitka kalcijuma na nivou distalnih tubula usled poremećaja u njegovoj reapsorpciji. Tada se, zbog povećanja

gubitka kalcijuma urinom javlja sekundarni hiperparatireoidizam.

3. *Resorptivna hiperkalciurija* koja je posledica primarnog hiperparatireoidizma koji se karakteriše značajnom resorpcijom kalcijuma iz koštanog tkiva i njegovom povećanom apsorpcijom iz intestinalnog trakta. Određivanje koncentracije PTH u krvi i cAMP u urinu olakšava diferencijalnu dijagnozu hiperkalciurije.

U 20% pacijenata i pored sprovedenog Protokola laboratorijskih ispitivanja uzrok hiperkalciurije ostaje neotkriven (*idiopatska hiperkalciurija*).

Test opterećenja amonijum hloridom

Indikacija za sprovođenje ovog testa je sumnja na postojanje renalne tubularne acidoze, tj. stanja neadekvatne sekrecije vodonikovih jona na nivou distalnih tubula. Sumnja na postojanje ovog oblika metaboličke acidoze postoji u slučajevima kada se pH vrednost urina ne snižavaju ispod 5,8 u toku nekoliko uzastopnih određivanja dnevnog profila pH (18).

Test se izvodi ambulantno, a pH vrednost urina se određuje isključivo pH-metrom, neposredno po sakupljanju svakog uzorka urina.

Test se izvodi na sledeći način:

08 ^h : doručak + 0,1g NH_4Cl /kg tt + 150 mL voćnog čaja
09 ^h : sakupljanje I uzorka urina i unos 150 mL voćnog čaja
10 ^h : sakupljanje II uzorka urina i unos 150 mL voćnog čaja
11 ^h : sakupljanje III uzorka urina i unos 150 mL voćnog čaja
12 ^h : sakupljanje IV uzorka urina i unos 150 mL voćnog čaja
13 ^h : sakupljanje V uzorka urina

Ukoliko se pH vrednosti urina snize do 5,4 isključuje se postojanje renalne tubularne acidoze, a ukoliko nisu ispod 5,4 da bi se dokazao tip renalne tubularne acidoze treba uraditi gasne analize krvi. Niske vrednosti bikarbonata (ispod 22 mmol/L) i pH krvi (ispod 7,35) ukazuju na kompletanu, dok normalne vrednosti ukazuju na inkompletanu renalnu tubularnu acidozu (v. Tabelu V).

Test apsorpcije [$^{13}\text{C}_2$] oksalata

Hiperoksalurija je važan faktor rizika u nastanku kalcijum oksalatne kalkuloze. Nastaje kao posledica naslednih poremećaja u metabolizmu oksalne kiseline (endogena ili primarna hiperoksalurija) ili usled povećanog unosa oksalne kiseline hranom, kao i zbog povećanog stepena apsorpcije pri različitim pa-

Tabela IV Indeks Ca/Cr

	Pre opterećenja	Posle opterećenja
Normalno	do 0,337	do 0,563
Apsorptivna hiperkalciurija	do 0,337	$\geq 0,564$
Renalna/resorptivna hiperkalciurija	$\geq 0,338$	$\geq 0,564$
Renalna hiperkalciurija: cAMP povećan		
Resorptivna hiperkalciurija: povećan PTH		

Tabela V Diferencijalna dijagnoza renalne tubularne acidoze

Biohemijski parametri	Kompletna	Inkompletna
pH krvi	snižen	normalan
Bikarbonati plazme	sniženi	normalni
Kalijum	snižen	normalan
Hloridi	povišeni	normalni
Ca i fosfor u urinu	povišeni	normalni
Citrat u urinu	snižen	snižen

tološkim stanjima u intestinalnom traktu (egzozena ili sekundarna hiperoksalurija).

Test apsorpcije [$^{13}\text{C}_2$] oksalata se upravo i izvodi kod pacijenata sa dokazanom hiperoksalurijom u cilju razlikovanja osnovnog uzroka nastanka poremećaja i pravilnog izbora načina lečenja. Test se sprovodi u hospitalnim uslovima, pri unosu 2400 mL tečnosti na dan i posle 2-dnevne standardne dijeta (19), na sledeći način:

I dan 08–20^h: sakupljanje urina (+30 mL 2,5 mol/L HCl)

20–08^h: sakupljanje urina (+30 mL 2,5 mol/L HCl)

II dan 08^h: unos 33,8 mg [$^{13}\text{C}_2$] oksalne kiseline u formi natrijumove soli u kapsuli od 50 mg

09^h: doručak

08–14^h: sakupljanje urina (+15 mL 2,5 mol/L HCl)

14^h: ručak

14–20^h: sakupljanje urina (+15 mL 2,5 mol/L HCl)

20–08^h: sakupljanje urina (+30 mL 2,5 mol/L HCl)

Nivo ekskretovanog oksalata obeleženog radioizotopom ugljenika u 24^h uzorcima urina sakupljenih I i II dana određuje se gasnom hromatografijom. Razlika u nivoima veća od 10% smatra se značajnom.

Značaj protokola

Primena novog Protokola obezbeđuje racionalnost i efikasnost u kliničkoj evaluaciji pacijenata sa kalkulozom urinarnog trakta zbog sasvim preciznih indikacija za izvođenje testova laboratorijskih ispitivanja za svaku kliničku kategoriju bolesti. Kontrolisanost uslova pri skupljanju uzoraka materijala za analizu, sprovođenje standardnih dijeta i adekvatno čuvanje uzoraka urina povećavaju pouzdanost rezultata. Poštovanje algoritma ispitivanja omogućava da se na najbrži način utvrdi postojeći metabolički poremećaj, odnosno otkrije egzogeni faktor (greške u ishrani ili patološka intestinalna apsorpcija materija odgovornih za nastanak kamena). Utvrđivanje uzroka bolesti obezbeđuje da se u svakom konkretnom slučaju odredi najadekvatnija terapija, odnosno da se primene mere profilakse u cilju sprečavanja pojave recidiva bolesti.

Izračunavanje određenih indeksa rizika, na osnovu parametara dobijenih primenom ovog Protokola, omogućava precizniju procenu težine bolesti, predviđanje njenog toka kao i praćenje efekata primenjene medikamentozne terapije.

UPDATE ANALYTIC PROGRAM FOR LABORATORY INVESTIGATION IN URINARY TRACT CALCULOSIS

Dragica Milenković¹, Aleksandar Vuksanović¹, Nataša Lalić², Sanja Simić-Ogrizović¹, Violeta Dopsaj²

¹Institute of Urology and Nephrology

²Institute of Medical Biochemistry, Clinical Centre of Serbia, Belgrade

Summary: Urinary tract calculosis due to its high recurrence rate (50–100% in untreated patients) and possibility to cause chronic renal failure in 20% still represents a great social and medical problem. From that aspect, an adequate clinical evaluation in stone forming patients is of paramount importance. An effective and rational attitude in detecting possible causes of stone formation demands the adequate analytic program in biochemical investigations. Presented program is adjusted to the guidelines on urolithiasis, recommended by Board EAU (European Association of Urologists) Healthcare Office, for year 2003. Regarding to known chemical stone composition, category of stone former and presence of an specific risk factor, analytic program could be *minimal* (fasting morning spot urine sample analysis, urinculture and blood analysis (calcium, albumine, creatinine and urate and stone analysis) and *extended* (quantification of all parameters in serum and in two consecutive 24^h urine collections, relevant for stone formation and evaluation of renal function). In order to identify metabolic disorders, a quantification of parathormone in serum, cAMP in urine and absorption/loading tests with calcium, NH_4Cl and [$^{12}\text{C}_2$] oxalate are recommended.

Key words: urinary tract calculosis, metabolic disorder, analytic program, absorption/loading tests

Literatura

1. Gambaro G, Reis-Santos JM, Rao N. Nephrolithiasis: Why doesn't our learning progress. *Eur Urol* 2004; 45: 547–56.
2. Hesse A, Tiselius HG, Jahnen A. Urinary stones: Diagnosis, treatment and prevention of recurrence, 2nd revised and enlarged ed. Basel: Karger 2002; 8.
3. Fleisch H. Role of inhibitors and promoters of crystal nucleation, growth and aggregation in the formation of calcium stone. In: Wikham J E A and Buck AP eds. *Renal tract stones*, Edinburgh, London, Melbourne and New York, Churchill Livingstone 1990; 295–306.
4. Fleisch H. Inhibitors and promoters of stone formation. *Kidney Int* 1978; 13: 361–71.
5. Lieske JC, Deganello S, Toback FG. Cell-crystal interactions and kidney stone formation. *Nephron* 1999; 81 (suppl. 1): 8–17.
6. Hesse A, Wurzel H, Vahlensieck W. The excretion of glycosaminoglicans in the urine of calcium stone patients and healthy persons. *Urol Int* 1986; 41: 81.
7. Milenković D. Procena nivoa magnezijuma, pirofosfata, citrata i glikozaminoglikana u urinu kao faktora rizika u nastanku kalkuloze. Doktorska disertacija, Medicinski fakultet, Beograd, 1991.
8. Milenković D, Petronić V, Hadži Đokić J, Mičić S, Tulić C, Lalić N. Urinary levels of glycosaminoglicans in stone forming subjects. *Br J Urol* 1997; 80 (suppl. 2): 323.
9. Greishar A, Nakagawa Y, Coe F. Influence of urine pH and citrate concentration on the upper limit of metastability for calcium phosphate. *J Urol* 2003; 169: 867–70.
10. Strohmaer WL. Course of calcium stone disease without treatment. What can we expect? *Eur Urol* 2000; 37: 339–44.
11. Marangella M, Bruno A, Vitalo C, Cosseddu D, Tricerri A, Linari F. The occurrence of chronic renal failure in calcium nephrolithiasis. In: Vahlesieck W, Gasser G, Schoneich G Eds.: *Urolithiasis*, Amstredam Excerpta Medica 1990; 15–8.
12. EAU guidelines ed 3, Arnhem: Drukkerij 2003; 19–20.
13. Tiselius HG. Etiology and investigation of stone disease. *Eur Urol* 1998; 33/1 (Curric Urol 2.1): 1–7.
14. Tiselius HG. Solution chemistry and supersaturation in kidney stones: Medical and surgical management. Edds Coe E, Flavus MJ, Pak CYC, Parks JH, Preminger GM. Philadelphia, Lipkot Raven Publishers, 1996; 33–64.
15. Milenković SD, Petronić V, Lalić N, Hadži Đokić J, Mičić S, Tulić C, Kozomara M. Modified predictive risk index for urinary calculosis. In: *Kidney stones* ed Borghi L, Micchi T, Briganti A, Schinchi T, Novarini A. Proceedings of the 8th European symposium on urolithiasis, Parma, Editoriale Bios 1999; 397–9.
16. Tiselius HG. Factors influencing the course of calcium stone disease. *Eur Urol* 1996; 363–70.
17. Pak CYC, Kaplan RA, Bone H, Townsend J, Woters O. A simple test for the diagnosis of absorptive, resorptive and renal hypercalciuria. *New Engl J Med* 1975; 292: 497–500.
18. Chafe L, Gaul MH. First morning urine pH in the diagnosis on renal tubular acidosis with nephrolithiasis. *Clin Nephrol* 1994; 41: 159–162.
19. Von Unruh GE, Langer MA, Paar DW, Hesse A. Mass spectrophotometric-selected ion monitoring assay for an oxalate absorption test applying (12C2) oxalate. *J Chromatogr* 1998; 716: 343–9.

Rad primljen: 15. 08. 2004

Prihvaćen za štampu: 5. 09. 2004

SOMATOSTATIN U OBOLJENJIMA GASTROINTESTINALNOG TRAKTA

Nada Kostić¹, Branislava Brkić¹, Zorica Čaparević¹, Verica Milošević²

¹Kliničko-bolnički centar »Dr Dragiša Mišović – Dedinje«, Beograd

²Institut za biološka istraživanja »Siniša Stanković«, Beograd

Kratak sadržaj: Somatostatin u serumu određen je RIA metodom, kod 50 pacijenata sa cirozom jetre, 15 sa pernicioznom anemijom i atrofičnim gastritisom, 31 sa inflamatornim oboljenjem creva, 32 sa kolorektalnim tumorima i 40 kontrolnih osoba. Kod pacijenata sa cirozom jetre nađene su značajno više vrednosti somatostatina u odnosu na kontrolnu grupu ($p < 0,01$). Pacijenti sa pernicioznom anemijom i ulceroznim kolitisom u akutnoj fazi bolesti imali su značajno niže vrednosti somatostatina ($p < 0,005$). Kod pacijenta sa kolorektalnim tumorima somatostatin je bio značajno niži nego u kontrolnoj grupi ($p < 0,01$). Dobijeni rezultati pokazuju da je jetra uključena u metabolizam somatostatina. Atrofični gastritis, ulcerozni kolitis i M. Crohn, kao i kolorektalni tumori bili su udruženi sa značajnim promenama u nivou somatostatina što sugerise moguću patofiziološku i terapijsku ulogu somatostatina u ovim oboljenjima.

Cljučne reči: somatostatin, ciroza jetre, atrofični gastritis, ulcerozni kolitis, M. Crohn, kolorektalni tumori

Uvod

Somatostatin je tetradekapeptid, prvo izolovan iz hipotalamusa ovce 1973. godine, a kasnije je otkriven u gastrointestinalnom traktu, pankreasu, centralnom i perifernom nervnom sistemu i tireoidnoj žlezdi (1). Poznato je da izaziva inhibiciju većeg broja drugih hormona, kao i inhibiciju sekrecije i motiliteta u gastrointestinalnom traktu. Eksperimentalne studije ukazuju da se somatostatin metaboliše u jetri i bubrezima i dokazana je degradacija somatostatina u izolovanim hepatocitima (2, 3). Ispitivanja u ljudi za sada daju kontradiktorne rezultate.

U većini patoloških stanja kao što su oboljenja želuca, tankog i debelog creva dolazi do odstupanja pojedinih gastrointestinalnih peptida, pa i somatostatina (4). Objavljene studije ukazuju na hipotetički značaj somatostatina u patofiziologiji gastritisa, inflamatornih oboljenja creva i kolorektalnog kancera s jedne strane, i mogućnosti primene u terapijske svrhe (5–7). Cilj ovog rada je bio da se razjasni moguća uloga jetre u metabolizmu somatostatina merenjem njegovih vrednosti u serumu bolesnika sa različitim stepenom ošte-

ćenja jetre, utvrdi veza između razvoja intestinalne me-
taplazije i vrednosti somatostatina, ispita vrednost somatostatina, u bolesnika sa ulceroznim kolitisom i Kronovom bolešću u odnosu na fazu i lokalizaciju bolesti i eventualna odstupanja vrednosti somatostatina u bolesnika sa kolorektalnom neoplazijom.

Materijal i metode

Ispitano je ukupno 50 (35 muškog pola i 15 ženskog pola) bolesnika sa histološki potvrđenom alkoholnom cirozom jetre, prosečne starosti 49 godina. Dobijeni rezultati posmatrani su sa dva aspekta: u odnosu na prisustvo ciroze i u odnosu na stepen hepatalne insuficijencije. Izvršena je podela prema kliničkim kriterijumima na kompenzovani i dekompenzovani oblik ciroze.

Sa oboljenjem perniciozne anemije i atrofičnog gastritisa sa ahlorhidrijom bilo je ukupno 15 bolesnika, prosečne starosti 59 godina. Dijagnoza perniciozne anemije postavljena je na osnovu megaloblastne kostne srži i pozitivnog Schilling testa, a atrofičnog gastritisa gastroscopski uz histopatološki nalaz.

Endoskopskim ispitivanjem uz histopatološku analizu postavljena je dijagnoza ulceroznog kolitisa u ukupno 31 bolesnika, od čega 17 u akutnoj fazi bolesti, a 14 u remisiji. Takođe je praćeno i 32 bolesnika sa M. Crohn različite lokalizacije (21 na tankom, 5 na

Adresa autora:

Prof. dr Nada Kostić
KBC Dr Dragiša Mišović
Heroja Milana Tepića br.1, Beograd
Tel: 367–20–25

debelom crevu i 6 istovremeno na tankom i debelom crevu).

Moguća veza između somatostatina i kolorektalne neoplazije ispitivana je na 42 bolesnika, prosečne starosti 60 godina. Dijagnoza je postavljena kolonoskopski uz histopatološku verifikaciju i to u 16 adenomatozni polip, u 8 vilozni adenom i u 18 adenokarcinom.

Svih 138 bolesnika kao i 40 kontrolnih osoba bilo je hospitalizovano na Klinici za internu medicinu i detaljno ispitano (kompletne biohemijske analize i krvna slika, rendgenska ispitivanja, ultrazvučna dijagnostika i endoskopski pregledi uz histopatološke analize). Izuzimajući grupu sa alkoholnom cirozom jetre, svim ostalim bolesnicima isključena su druga oboljenja, pre svega bubrežna i hepatalna insuficijencija.

Svi ispitanici bili su bez medikamentne terapije i ujutru našte uzimana je krv za određivanje bazalnih vrednosti somatostatina. Analiza je vršena RAI metodom uz korišćenje laboratorijskog, eksperimentalnog test reagensa (dobijenog iz Laboratorije Hammersmith Hospital u Londonu). Referentne vrednosti za somatostatin bile su 17–150 pmol/L.

U statističkoj obradi korišćeni su Studentov t test i druge uobičajene statističke metode.

Rezultati

Alkoholna ciroza jetre

Bazalne vrednosti somatostatina u serumu bile su značajno više kod svih bolesnika sa alkoholnom cirozom jetre u odnosu na kontrolnu grupu ($p < 0,01$) (Tabela I). Vrednosti somatostatina u grupi bolesnika sa dekompenzovanim oblikom ciroze bile su značajno više u odnosu na kompenzovani oblik ($p < 0,05$) (Tabela I).

Tabela I Nivoi somatostatina u plazmi bolesnika sa alkoholnom cirozom jetre

Ispitivane grupe	N	Somatostatin, pmol/L
Kompenzovana ciroza	20	44,0 ± 9,8 ^x
Dekompenzovana ciroza	30	68,6 ± 20,1 ^{xx}
Sve ciroze jetre	50	50,7 ± 30,3 ^{**}
Kontrolna grupa	40	28,0 ± 10,1

** p < 0,01 nivo statističke značajnosti razlika u odnosu na kontrolnu grupu
^x p < 0,05 nivo statističke značajnosti razlika bolesnika sa dekompenzovanim cirozom jetre u odnosu na grupu sa kompenzovanim cirozom jetre
^{xx} p < 0,01 nivo statističke značajnosti razlika bolesnika sa dekompenzovanim cirozom jetre u odnosu na kontrolnu grupu

Perniciozna anemija i atrofični gastritis

Svi bolesnici sa pernicioznom anemijom imali su hronični atrofični gastritis, a u 7 bolesnika histološki je potvrđena i intestinalna metaplazija. Nivoi somatostatina u serumu bili su značajno niži u bolesnika sa pernicioznom anemijom i hroničnim atrofičnim gastritisom u odnosu na kontrolnu grupu ($p < 0,01$). Sve vrednosti u ispitivanih bolesnika bile su ispod normalnih vrednosti za somatostatin. Kod bolesnika sa intestinalnom metaplazijom nađene su značajno niže vrednosti u odnosu na bolesnike sa samo hroničnim atrofičnim gastritisom ($p < 0,01$) (Tabela II).

Tabela II Somatostatin u serumu bolesnika sa pernicioznom anemijom

Grupe bolesnika	N	Somatostatin, pmol/L
Perniciozna anemija	15	9,4 ± 10,6*
Samo atrofični gastritis	8	13,6 ± 12,1
Atrofični gastritis i interstinalna metaplazija	7	3,2 ± 2,3**
Kontrolna grupa	40	49,5 ± 20,1

* značajna razlika ($p < 0,01$) za bolesnike sa pernicioznom anemijom u odnosu na kontrolnu grupu
 ** značajna razlika ($p < 0,01$) podgrupa perniciozne anemije sa i bez intestinalne metaplazije

Ulcerozni kolitis i Kronova bolest

Ispitivanjem su utvrđene značajno više vrednosti somatostatina u obe grupe bolesnika (105,5 ± 21,4 pmol/L) u odnosu na kontrolnu grupu (50,3 ± 10,2 pmol/L) ($p < 0,01$). U odnosu na fazu bolesti vrednosti bazalnog somatostatina bile su značajno niže u akutnoj fazi u odnosu na remisiju ($p < 0,005$). U odnosu na lokalizaciju Kronove bolesti vrednosti somatostatina bile su značajno više u grupi sa promenama na tankom crevu ($p < 0,001$) (Tabela III). Sve ispitivane vrednosti somatostatina bile su unutar referentnih vrednosti za somatostatin.

Tabela III Somatostatin u serumu bolesnika sa ulceroznim kolitisom i M. Crohn

Ispitivane grupe	N	Somatostatin, pmol/L
Ulcerozni kolitis	31	
– u akutnoj fazi	17	8,1 ± 4,4*
– u remisiji	14	39,9 ± 14,7
Kronova bolest	32	
– tanko crevo	21	44,1 ± 15,2**
– debelo crevo	5	28,7 ± 13,2
– oba	6	44,7 ± 2,9
Kontrolna grupa	40	19,5 ± 20,1

* p < 0,005
 ** p < 0,001

Kolorektalni tumori

U grupi bolesnika sa kolorektalnim adenokarcinomom i viloznim adenomom vrednosti somatostatina bile su značajno niže u odnosu na kontrolnu grupu ($p < 0,01$), ali unutar normalnih vrednosti.

Diskusija

Do sada saopšteni kontradiktorni rezultati u literaturi (3, 8) ovo ispitivanje čine aktuelnim. Rezultati povišenih bazalnih vrednosti somatostatina u skladu su sa pretpostavkom da se somatostatin metaboliše u jetri, što ne isključuje njegovu ulogu kao neurotransmitera i lokalnog endokrinog regulatora pa i mogućnosti da se metaboliše na mestima gde se i oslobađa. Povećanje somatostatina u cirozi jetre, a posebno dekompenzovane, moguće je objasniti uticajem intrahepatičneolestaze, portalne hipertenzije i postojanjem intra i ekstrahepatičnih šantova (10). Navedene rezultate treba posmatrati i u svetlu upotrebe somatostatina u farmakološkom tretmanu portalne hipertenzije (11).

Poznato je prisustvo hipergastrinemije kod bolesnika sa pernicioznom anemijom i hroničnim atrofičnim gastritisom, što se objašnjava sekundarno povećanim oslobađanjem gastrina zbog ahlorhidrije, uzrokovane upravo atrofičnim gastritisom, a ne isključuje se ni uloga imunoloških mehanizama (postojanje autoantitela na gastrinske receptore) (14). Niske vrednosti somatostatina mogu se objasniti pre povećanim odnosom G/D ćelija što je i dokazano, a što sugerise da su niske vrednosti pre posledice ahlorhidrije, nego

tipičnog efekta hipergastrinemije, jer je poznato da se somatostatin oslobađa pri niskim antralnim pH (15–17).

Nalaz značajno nižih vrednosti somatostatina u akutnoj fazi bolesti je u saglasnosti sa ispitivanom literaturom (18). Takođe veće vrednosti somatostatina u bolesnika sa intestinalnom lokalizacijom odražavaju mesto oslobađanja somatostatina uzrokovano najverovatnije nekrotičnim promenama. S druge strane od značaja je razmatranje upotrebe somatostatina u bolesnika sa teškim oblicima kolitisa (18, 19).

Poslednjih godina otkriveno je prisustvo receptora za somatostatin i druge peptide kod eksperimentalnog kancera kolona (20). Takođe potvrđena je imunoreaktivnost ćelija serotonina, enteroglukagona, peptida YY i dr. (21, 22). Niže vrednosti somatostatina uz povišene vrednosti gastrina, IGF-1 i drugih peptida uklapaju se u patofiziološki koncept rasta kolorektalnih tumora, gde endokrini sistem očigledno ima određenu ulogu. S obzirom na navedene promene moglo bi se razmišljati o upotrebi neuroendokrinih peptida, pa i somatostatina u dijagnostici i terapiji kolorektalnog kancera (23).

Iz svega izloženog može se zaključiti da pored poznatog opšteg inhibitornog dejstva somatostatina na sekreciju neuroendokrinih tumora, kao i na sekreciju i motilitet gastrointestinalnog trakta, somatostatin očigledno ima ulogu i u patofiziologiji gastritisa, inflamatornih oboljenja creva, kolorektalnog kancera. Ovo je od posebnog značaja kada se razmatraju mogućnosti upotrebe somatostatina u terapijske svrhe.

SOMATOSTATIN LEVELS IN GASTROINTESTINAL DISEASE

Nada Kostić¹, Branislava Brkić¹, Zorica Čaparević¹, Verica Milošević²

¹Clinical Hospital Centre »Dr Dragiša Mišović« »Dedinje«, Belgrade

²Institute for Biological Research »Siniša Stanković«, Belgrade

Summary: Serum levels of somatostatin were determined by RIA method in 50 patients with liver cirrhosis, 15 with pernicious anemia and atrophic gastritis, 31 with inflammatory bowel disease, 32 with colorectal tumors and in 40 control persons. In patients with liver cirrhosis somatostatin levels were significantly higher than in control group ($p < 0.01$). Patients with pernicious anemia and ulcerative colitis in acute phase of the disease had significantly lower levels of somatostatin ($p < 0.01$) ($p < 0.005$). In patients with colorectal tumors somatostatin were significantly lower than in control group ($p < 0.01$). Our results show that the liver is involved in somatostatin metabolism. Atrophic gastritis, ulcerative colitis and M. Crohn, so as colorectal neoplasia were associated with significantly changes in somatostatin levels which suggest the potential pathophysiologic and therapeutic role of somatostatin in those disease.

Key words: somatostatin, liver cirrhosis, atrophic gastritis, ulcerative colitis, M. Crohn, colorectal tumors

Literatura

1. Gerich JE, Paton GS. Somatostatin. *Med Clin North Am* 1978; 62, 375–83.
2. Conlon JM, Whittaker J, Hammond V, Alberti KGM. Metabolism of somatostatin and its analogues by the liver. *Biochim Biophys Acta* 1981; 677: 234–2.
3. Sacks H, Cass TL. Clearance of immunoreactive somatostatin by rat liver. *J Clin Invest* 1981; 67: 419–29.
4. Kostić N. Regulatorni peptidi (patofiziologija i klinički značaj). Zavod za udžbenike i nastavna sredstva, Beograd, 1999.
5. Di Lorenzo C, Lucanto C, Flores AF, Idries S, Hyman PE. Effect of sequential erythromycin and octreotide on antroduodenal manometry. *J Pediatr Gastroenterol Nutr* 1999; 29 (3): 293–6.
6. Eliakim R, Fan QX, Babyatsky MW. Chronic nicotine administration differentially alters jejunal and colonic inflammation in interleukin-10 deficient mice. *Eur J Gastroenterol Hepatol* 2002; 14 (6): 607–14.
7. Sadij-Ouatas Z, Lasfer M, Julien S, Feldmann G, Rayl-Desmars F. Doxorubicin and octreotide induce a 40 kDa breakdown product of p53 in human hepatoma and tumoral colon cell lines. *Biochem J* 2002; 15: 364 (Pt 3): 881–5.
8. Sheppard M, Shapiro B, Pimstone B, Kronheim S. Metabolic clearance and plasma half disappearance time of exogenous somatostatin in man. *Clin Endocrinol Metabol* 1979; 48: 50–6.
9. Kelback H, Tronier B, Bahnsen M, Munkgard S. Fasting plasma somatostatin in alcoholic liver disease. *Scand J Clin Lab Invest* 1983; 43: 597–601.
10. Munkgaard S, Kelbeek H, Tronier B. Elevated plasma somatostatin in cirrhosis of the liver. *N Engl J Med* 1981; 301: 1429–30.
11. Gonzales-Abraldes J, Bosch J, Garcia-Pagan JC. Pharmacological treatment of portal hypertension. *Curr Opin Investig Drugs* 2001; 2 (10): 1407–13.
12. Matrella E, Valatas V, Notas G, Roumpaki H, Xidakis C, Hadzidakis A, et. al. Bolus somatostatin but not octreotide reduces hepatic sinusoidal pressure by a NOindependent mechanism in chronic liver disease. *Aliment Pharmacol Ther* 2001; 15 (6): 857–64.
13. Zhang HB, Wong BC, Zhou XM, Guo XG, Zhao SJ, Wang JH, et. al. Effects of somatostatin, octreotide and pitressin plus nitroglycerine on systemic and portal haemodynamics in the control of acute variceal bleeding. *Int J Clin Pract* 2002; 56 (6): 447–51.
14. Aizupurua HJ, Ungar B, Toch BH. Autoantibody to the gastrin receptor in pernicious anemia. *N Engl J Med* 1985; 313: 479–83.
15. Ligumsky M, Wengrower D, Karmeli F, Rachmilewitz D. Somatostatin release by human gastric mucosa. *Scand J Gastroenterol* 1988; 23: 687–90.
16. Arnold R, Hulst MV, Neuhof CH, Schwarting H, Beker HD, Creutzfeld W. Antral gastrin-producing G-cells and somatostatin producing – D-cells in different states of gastric acid secretion. *Gut* 1982; 23: 285–91.
17. Alonso Falcon F, Codoceo Alquinta R, Polanco Allue I, Aquado Gil A, Fontan Casariego G. Study of gastrointestinal polypeptides controlling gastric acid secretion in patients with primary antibody deficiency. *Rev Esp Enferm Dig* 1999 1; 91 (1): 54–60.
18. van Bergeijk JD, Wilson JH, Nielsen OH, von Triptiz C, Karvonen AL, Lygren I, et. al. Octreotide in patients with active ulcerative colitis with high dose corticosteroids. *Eur J Gastroenterol Hepatol* 2002; 14 (3): 243–8.
19. Su X, Burton MB, Gebhart GF. Effect of octreotide on responses to colorectal distension in the rat. *Gut* 2001; 48 (5): 676–82.
20. Szepeshazi K, Schally AV, Halmos G, Armatis P, Hebert F, Sun B., et. al. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. *Cancer Res* 2002 1; 62 (3): 781–8.
21. Sitohy B, El-Salhy M. Colonic endocrine cells in rats with chemically induced colon carcinoma. *Histol Histopathol* 2001; 16 (3): 833–8.
22. Cox HM, Tough IR, Zandvliet DW, Holliday ND. Constitutive neuropeptide Y Y(4) receptor expression in human colonic adenocarcinoma cell lines. *Br J Pharmacol* 2001; 132 (1): 345–3.
23. Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, et. al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. *Endocrinology*. 1999; 140 (11): 5136–48.

Rad primljen: 10. 07. 2003

Prihvaćen za štampu: 12. 04. 2004

SOMATOSTATIN U OBOLJENJIMA GASTROINTESTINALNOG TRAKTA

Nada Kostić¹, Branislava Brkić¹, Zorica Čaparević¹, Verica Milošević²

¹Kliničko-bolnički centar »Dr Dragiša Mišović – Dedinje«, Beograd

²Institut za biološka istraživanja »Siniša Stanković«, Beograd

Kratak sadržaj: Somatostatin u serumu određen je RIA metodom, kod 50 pacijenata sa cirozom jetre, 15 sa pernicioznom anemijom i atrofičnim gastritisom, 31 sa inflamatornim oboljenjem creva, 32 sa kolorektalnim tumorima i 40 kontrolnih osoba. Kod pacijenata sa cirozom jetre nađene su značajno više vrednosti somatostatina u odnosu na kontrolnu grupu ($p < 0,01$). Pacijenti sa pernicioznom anemijom i ulceroznim kolitisom u akutnoj fazi bolesti imali su značajno niže vrednosti somatostatina ($p < 0,005$). Kod pacijenta sa kolorektalnim tumorima somatostatin je bio značajno niži nego u kontrolnoj grupi ($p < 0,01$). Dobijeni rezultati pokazuju da je jetra uključena u metabolizam somatostatina. Atrofični gastritis, ulcerozni kolitis i M. Crohn, kao i kolorektalni tumori bili su udruženi sa značajnim promenama u nivou somatostatina što sugerise moguću patofiziološku i terapijsku ulogu somatostatina u ovim oboljenjima.

Cljučne reči: somatostatin, ciroza jetre, atrofični gastritis, ulcerozni kolitis, M. Crohn, kolorektalni tumori

Uvod

Somatostatin je tetradekapeptid, prvo izolovan iz hipotalamusa ovce 1973. godine, a kasnije je otkriven u gastrointestinalnom traktu, pankreasu, centralnom i perifernom nervnom sistemu i tireoidnoj žlezdi (1). Poznato je da izaziva inhibiciju većeg broja drugih hormona, kao i inhibiciju sekrecije i motiliteta u gastrointestinalnom traktu. Eksperimentalne studije ukazuju da se somatostatin metaboliše u jetri i bubrezima i dokazana je degradacija somatostatina u izolovanim hepatocitima (2, 3). Ispitivanja u ljudi za sada daju kontradiktorne rezultate.

U većini patoloških stanja kao što su oboljenja želuca, tankog i debelog creva dolazi do odstupanja pojedinih gastrointestinalnih peptida, pa i somatostatina (4). Objavljene studije ukazuju na hipotetički značaj somatostatina u patofiziologiji gastritisa, inflamatornih oboljenja creva i kolorektalnog kancera s jedne strane, i mogućnosti primene u terapijske svrhe (5–7). Cilj ovog rada je bio da se razjasni moguća uloga jetre u metabolizmu somatostatina merenjem njegovih vrednosti u serumu bolesnika sa različitim stepenom ošte-

ćenja jetre, utvrdi veza između razvoja intestinalne me-
taplazije i vrednosti somatostatina, ispita vrednost somatostatina, u bolesnika sa ulceroznim kolitisom i Kronovom bolešću u odnosu na fazu i lokalizaciju bolesti i eventualna odstupanja vrednosti somatostatina u bolesnika sa kolorektalnom neoplazijom.

Materijal i metode

Ispitano je ukupno 50 (35 muškog pola i 15 ženskog pola) bolesnika sa histološki potvrđenom alkoholnom cirozom jetre, prosečne starosti 49 godina. Dobijeni rezultati posmatrani su sa dva aspekta: u odnosu na prisustvo ciroze i u odnosu na stepen hepatalne insuficijencije. Izvršena je podela prema kliničkim kriterijumima na kompenzovani i dekompenzovani oblik ciroze.

Sa oboljenjem perniciozne anemije i atrofičnog gastritisa sa ahlorhidrijom bilo je ukupno 15 bolesnika, prosečne starosti 59 godina. Dijagnoza perniciozne anemije postavljena je na osnovu megaloblastne kostne srži i pozitivnog Schilling testa, a atrofičnog gastritisa gastrokopski uz histopatološki nalaz.

Endoskopskim ispitivanjem uz histopatološku analizu postavljena je dijagnoza ulceroznog kolitisa u ukupno 31 bolesnika, od čega 17 u akutnoj fazi bolesti, a 14 u remisiji. Takođe je praćeno i 32 bolesnika sa M. Crohn različite lokalizacije (21 na tankom, 5 na

Adresa autora:

Prof. dr Nada Kostić
KBC Dr Dragiša Mišović
Heroja Milana Tepića br.1, Beograd
Tel: 367–20–25

debelom crevu i 6 istovremeno na tankom i debelom crevu).

Moguća veza između somatostatina i kolorektalne neoplazije ispitivana je na 42 bolesnika, prosečne starosti 60 godina. Dijagnoza je postavljena kolonoskopski uz histopatološku verifikaciju i to u 16 adenomatozni polip, u 8 vilozni adenom i u 18 adenokarcinom.

Svih 138 bolesnika kao i 40 kontrolnih osoba bilo je hospitalizovano na Klinici za internu medicinu i detaljno ispitano (kompletne biohemijske analize i krvna slika, rendgenska ispitivanja, ultrazvučna dijagnostika i endoskopski pregledi uz histopatološke analize). Izuzimajući grupu sa alkoholnom cirozom jetre, svim ostalim bolesnicima isključena su druga oboljenja, pre svega bubrežna i hepatalna insuficijencija.

Svi ispitanici bili su bez medikamentne terapije i ujutru našte uzimana je krv za određivanje bazalnih vrednosti somatostatina. Analiza je vršena RAI metodom uz korišćenje laboratorijskog, eksperimentalnog test reagensa (dobijenog iz Laboratorije Hammersmith Hospital u Londonu). Referentne vrednosti za somatostatin bile su 17–150 pmol/L.

U statističkoj obradi korišćeni su Studentov t test i druge uobičajene statističke metode.

Rezultati

Alkoholna ciroza jetre

Bazalne vrednosti somatostatina u serumu bile su značajno više kod svih bolesnika sa alkoholnom cirozom jetre u odnosu na kontrolnu grupu ($p < 0,01$) (Tabela I). Vrednosti somatostatina u grupi bolesnika sa dekompenzovanim oblikom ciroze bile su značajno više u odnosu na kompenzovani oblik ($p < 0,05$) (Tabela I).

Tabela I Nivoi somatostatina u plazmi bolesnika sa alkoholnom cirozom jetre

Ispitivane grupe	N	Somatostatin, pmol/L
Kompenzovana ciroza	20	44,0 ± 9,8 ^x
Dekompenzovana ciroza	30	68,6 ± 20,1 ^{xx}
Sve ciroze jetre	50	50,7 ± 30,3 ^{**}
Kontrolna grupa	40	28,0 ± 10,1

** p < 0,01 nivo statističke značajnosti razlika u odnosu na kontrolnu grupu
^x p < 0,05 nivo statističke značajnosti razlika bolesnika sa dekompenzovanim cirozom jetre u odnosu na grupu sa kompenzovanim cirozom jetre
^{xx} p < 0,01 nivo statističke značajnosti razlika bolesnika sa dekompenzovanim cirozom jetre u odnosu na kontrolnu grupu

Perniciozna anemija i atrofični gastritis

Svi bolesnici sa pernicioznom anemijom imali su hronični atrofični gastritis, a u 7 bolesnika histološki je potvrđena i intestinalna metaplazija. Nivoi somatostatina u serumu bili su značajno niži u bolesnika sa pernicioznom anemijom i hroničnim atrofičnim gastritisom u odnosu na kontrolnu grupu ($p < 0,01$). Sve vrednosti u ispitivanih bolesnika bile su ispod normalnih vrednosti za somatostatin. Kod bolesnika sa intestinalnom metaplazijom nađene su značajno niže vrednosti u odnosu na bolesnike sa samo hroničnim atrofičnim gastritisom ($p < 0,01$) (Tabela II).

Tabela II Somatostatin u serumu bolesnika sa pernicioznom anemijom

Grupe bolesnika	N	Somatostatin, pmol/L
Perniciozna anemija	15	9,4 ± 10,6*
Samo atrofični gastritis	8	13,6 ± 12,1
Atrofični gastritis i interstinalna metaplazija	7	3,2 ± 2,3**
Kontrolna grupa	40	49,5 ± 20,1

* značajna razlika ($p < 0,01$) za bolesnike sa pernicioznom anemijom u odnosu na kontrolnu grupu
 ** značajna razlika ($p < 0,01$) podgrupa perniciozne anemije sa i bez intestinalne metaplazije

Ulcerozni kolitis i Kronova bolest

Ispitivanjem su utvrđene značajno više vrednosti somatostatina u obe grupe bolesnika (105,5 ± 21,4 pmol/L) u odnosu na kontrolnu grupu (50,3 ± 10,2 pmol/L) ($p < 0,01$). U odnosu na fazu bolesti vrednosti bazalnog somatostatina bile su značajno niže u akutnoj fazi u odnosu na remisiju ($p < 0,005$). U odnosu na lokalizaciju Kronove bolesti vrednosti somatostatina bile su značajno više u grupi sa promenama na tankom crevu ($p < 0,001$) (Tabela III). Sve ispitivane vrednosti somatostatina bile su unutar referentnih vrednosti za somatostatin.

Tabela III Somatostatin u serumu bolesnika sa ulceroznim kolitisom i M. Crohn

Ispitivane grupe	N	Somatostatin, pmol/L
Ulcerozni kolitis	31	
– u akutnoj fazi	17	8,1 ± 4,4*
– u remisiji	14	39,9 ± 14,7
Kronova bolest	32	
– tanko crevo	21	44,1 ± 15,2**
– debelo crevo	5	28,7 ± 13,2
– oba	6	44,7 ± 2,9
Kontrolna grupa	40	19,5 ± 20,1

* p < 0,005
 ** p < 0,001

Kolorektalni tumori

U grupi bolesnika sa kolorektalnim adenokarcinomom i viloznim adenomom vrednosti somatostatina bile su značajno niže u odnosu na kontrolnu grupu ($p < 0,01$), ali unutar normalnih vrednosti.

Diskusija

Do sada saopšteni kontradiktorni rezultati u literaturi (3, 8) ovo ispitivanje čine aktuelnim. Rezultati povišenih bazalnih vrednosti somatostatina u skladu su sa pretpostavkom da se somatostatin metaboliše u jetri, što ne isključuje njegovu ulogu kao neurotransmitera i lokalnog endokrinog regulatora pa i mogućnosti da se metaboliše na mestima gde se i oslobađa. Povećanje somatostatina u cirozi jetre, a posebno dekompenzovane, moguće je objasniti uticajem intrahepatičneolestaze, portalne hipertenzije i postojanjem intra i ekstrahepatičnih šantova (10). Navedene rezultate treba posmatrati i u svetlu upotrebe somatostatina u farmakološkom tretmanu portalne hipertenzije (11).

Poznato je prisustvo hipergastrinemije kod bolesnika sa pernicioznom anemijom i hroničnim atrofičnim gastritisom, što se objašnjava sekundarno povećanim oslobađanjem gastrina zbog ahlorhidrije, uzrokovane upravo atrofičnim gastritisom, a ne isključuje se ni uloga imunoloških mehanizama (postojanje autoantitela na gastrinske receptore) (14). Niske vrednosti somatostatina mogu se objasniti pre povećanim odnosom G/D ćelija što je i dokazano, a što sugerise da su niske vrednosti pre posledice ahlorhidrije, nego

tipičnog efekta hipergastrinemije, jer je poznato da se somatostatin oslobađa pri niskim antralnim pH (15–17).

Nalaz značajno nižih vrednosti somatostatina u akutnoj fazi bolesti je u saglasnosti sa ispitivanom literaturom (18). Takođe veće vrednosti somatostatina u bolesnika sa intestinalnom lokalizacijom odražavaju mesto oslobađanja somatostatina uzrokovano najverovatnije nekrotičnim promenama. S druge strane od značaja je razmatranje upotrebe somatostatina u bolesnika sa teškim oblicima kolitisa (18, 19).

Poslednjih godina otkriveno je prisustvo receptora za somatostatin i druge peptide kod eksperimentalnog kancera kolona (20). Takođe potvrđena je imunoreaktivnost ćelija serotonina, enteroglukagona, peptida YY i dr. (21, 22). Niže vrednosti somatostatina uz povišene vrednosti gastrina, IGF-1 i drugih peptida uklapaju se u patofiziološki koncept rasta kolorektalnih tumora, gde endokrini sistem očigledno ima određenu ulogu. S obzirom na navedene promene moglo bi se razmišljati o upotrebi neuroendokrinih peptida, pa i somatostatina u dijagnostici i terapiji kolorektalnog kancera (23).

Iz svega izloženog može se zaključiti da pored poznatog opšteg inhibitornog dejstva somatostatina na sekreciju neuroendokrinih tumora, kao i na sekreciju i motilitet gastrointestinalnog trakta, somatostatin očigledno ima ulogu i u patofiziologiji gastritisa, inflamatornih oboljenja creva, kolorektalnog kancera. Ovo je od posebnog značaja kada se razmatraju mogućnosti upotrebe somatostatina u terapijske svrhe.

SOMATOSTATIN LEVELS IN GASTROINTESTINAL DISEASE

Nada Kostić¹, Branislava Brkić¹, Zorica Čaparević¹, Verica Milošević²

¹Clinical Hospital Centre »Dr Dragiša Mišović« »Dedinje«, Belgrade

²Institute for Biological Research »Siniša Stanković«, Belgrade

Summary: Serum levels of somatostatin were determined by RIA method in 50 patients with liver cirrhosis, 15 with pernicious anemia and atrophic gastritis, 31 with inflammatory bowel disease, 32 with colorectal tumors and in 40 control persons. In patients with liver cirrhosis somatostatin levels were significantly higher than in control group ($p < 0.01$). Patients with pernicious anemia and ulcerative colitis in acute phase of the disease had significantly lower levels of somatostatin ($p < 0.01$) ($p < 0.005$). In patients with colorectal tumors somatostatin were significantly lower than in control group ($p < 0.01$). Our results show that the liver is involved in somatostatin metabolism. Atrophic gastritis, ulcerative colitis and M. Crohn, so as colorectal neoplasia were associated with significantly changes in somatostatin levels which suggest the potential pathophysiologic and therapeutic role of somatostatin in those disease.

Key words: somatostatin, liver cirrhosis, atrophic gastritis, ulcerative colitis, M. Crohn, colorectal tumors

Literatura

1. Gerich JE, Paton GS. Somatostatin. *Med Clin North Am* 1978; 62, 375–83.
2. Conlon JM, Whittaker J, Hammond V, Alberti KGM. Metabolism of somatostatin and its analogues by the liver. *Biochim Biophys Acta* 1981; 677: 234–2.
3. Sacks H, Cass TL. Clearance of immunoreactive somatostatin by rat liver. *J Clin Invest* 1981; 67: 419–29.
4. Kostić N. Regulatorni peptidi (patofiziologija i klinički značaj). Zavod za udžbenike i nastavna sredstva, Beograd, 1999.
5. Di Lorenzo C, Lucanto C, Flores AF, Idries S, Hyman PE. Effect of sequential erythromycin and octreotide on antroduodenal manometry. *J Pediatr Gastroenterol Nutr* 1999; 29 (3): 293–6.
6. Eliakim R, Fan QX, Babyatsky MW. Chronic nicotine administration differentially alters jejunal and colonic inflammation in interleukin-10 deficient mice. *Eur J Gastroenterol Hepatol* 2002; 14 (6): 607–14.
7. Sadij-Ouatas Z, Lasfer M, Julien S, Feldmann G, Rayl-Desmars F. Doxorubicin and octreotide induce a 40 kDa breakdown product of p53 in human hepatoma and tumoral colon cell lines. *Biochem J* 2002; 15: 364 (Pt 3): 881–5.
8. Sheppard M, Shapiro B, Pimstone B, Kronheim S. Metabolic clearance and plasma half disappearance time of exogenous somatostatin in man. *Clin Endocrinol Metabol* 1979; 48: 50–6.
9. Kelback H, Tronier B, Bahnsen M, Munkgard S. Fasting plasma somatostatin in alcoholic liver disease. *Scand J Clin Lab Invest* 1983; 43: 597–601.
10. Munkgaard S, Kelbeek H, Tronier B. Elevated plasma somatostatin in cirrhosis of the liver. *N Engl J Med* 1981; 301: 1429–30.
11. Gonzales-Abraldes J, Bosch J, Garcia-Pagan JC. Pharmacological treatment of portal hypertension. *Curr Opin Investig Drugs* 2001; 2 (10): 1407–13.
12. Matrella E, Valatas V, Notas G, Roumpaki H, Xidakis C, Hadzidakis A, et. al. Bolus somatostatin but not octreotide reduces hepatic sinusoidal pressure by a NOindependent mechanism in chronic liver disease. *Aliment Pharmacol Ther* 2001; 15 (6): 857–64.
13. Zhang HB, Wong BC, Zhou XM, Guo XG, Zhao SJ, Wang JH, et. al. Effects of somatostatin, octreotide and pitressin plus nitroglycerine on systemic and portal haemodynamics in the control of acute variceal bleeding. *Int J Clin Pract* 2002; 56 (6): 447–51.
14. Aizupurua HJ, Ungar B, Toch BH. Autoantibody to the gastrin receptor in pernicious anemia. *N Engl J Med* 1985; 313: 479–83.
15. Ligumsky M, Wengrower D, Karmeli F, Rachmilewitz D. Somatostatin release by human gastric mucosa. *Scand J Gastroenterol* 1988; 23: 687–90.
16. Arnold R, Hulst MV, Neuhof CH, Schwarting H, Beker HD, Creutzfeld W. Antral gastrin-producing G-cells and somatostatin producing – D-cells in different states of gastric acid secretion. *Gut* 1982; 23: 285–91.
17. Alonso Falcon F, Codoceo Alquinta R, Polanco Allue I, Aquado Gil A, Fontan Casariego G. Study of gastrointestinal polypeptides controlling gastric acid secretion in patients with primary antibody deficiency. *Rev Esp Enferm Dig* 1999 1; 91 (1): 54–60.
18. van Bergeijk JD, Wilson JH, Nielsen OH, von Triptiz C, Karvonen AL, Lygren I, et. al. Octreotide in patients with active ulcerative colitis with high dose corticosteroids. *Eur J Gastroenterol Hepatol* 2002; 14 (3): 243–8.
19. Su X, Burton MB, Gebhart GF. Effect of octreotide on responses to colorectal distension in the rat. *Gut* 2001; 48 (5): 676–82.
20. Szepeshazi K, Schally AV, Halmos G, Armatis P, Hebert F, Sun B., et. al. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. *Cancer Res* 2002 1; 62 (3): 781–8.
21. Sitohy B, El-Salhy M. Colonic endocrine cells in rats with chemically induced colon carcinoma. *Histol Histopathol* 2001; 16 (3): 833–8.
22. Cox HM, Tough IR, Zandvliet DW, Holliday ND. Constitutive neuropeptide Y Y(4) receptor expression in human colonic adenocarcinoma cell lines. *Br J Pharmacol* 2001; 132 (1): 345–3.
23. Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, et. al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. *Endocrinology*. 1999; 140 (11): 5136–48.

Rad primljen: 10. 07. 2003

Prihvaćen za štampu: 12. 04. 2004

UC 577,1; 61

ISSN 0354-3447

Jugoslav Med Biohem 23: 397, 2004

*Obaveštenja
Technical reports*

SASTANCI U OBLASTI KLINIČKE HEMIJE

- 8–12 maj 2005, Glasgow

**16th IFCC–FESCC
European Congress of Clinical Chemistry
and Laboratory Medicine**

Internet: www.glasgow2005.org

- 24–29 jul 2005, Orlando, FL, USA

**19th International Congress of Clinical
Chemistry and Laboratory Medicine
(IFCC Congress)**

**57th National Meeting
of the American Association
of Clinical Chemistry (AACC)**

Informacije: Secr.: AACC Customer Service, 2101 L
Street NW, Suite 202, Washington, DC
20037–1526, USA

Tel: + (1) 202 587 0717; Fax: + (1) 202 833 4576;
E-mail: custserv@aacc.org
Internet: www.aacc.org

DRUŠTVO MEDICINSKIH BIOHEMIČARA SRBIJE I CRNE GORE

Farmaceutski fakultet
Vojvode Stepe 450
11 221 Beograd

Pristupnicu popuniti štampanim slovima, i zajedno sa kopijom petog primerka dostaviti na navedenu adresu!

**PRISTUPNICA
U ČLANSTVO DMBSCG**

Ime i prezime: _____ Kategorija članstva: _____

Adresa: _____ REDOVNO ČLANSTVO 1 200,00 din

_____ PRIDRUŽENO ČLANSTVO 15 000,00 din

_____ STUDENTI I PENZIONERI – BESPLATNO

Telefon: _____

Datum: _____ Potpis: _____

Članarina se uplaćuje za tekuću godinu na tekući račun DMBSCG broj 255-0006390101000-02, Privredna banka Beograd a.d., Beograd i obezbeđuje prijem časopisa »Jugoslovenska medicinska biohemija« kao i svih obaveštenja o aktivnostima Društva medicinskih biohemičara Srbije i Crne Gore.

JUGOSLOVENSKA MEDICINSKA BIOHEMIJA
je član
Društva biomedicinskih časopisa i biltena SR Jugoslavije



Društvo biomedicinskih časopisa i biltena SR Jugoslavije
Yugoslav Society of Biomedical Journals & Bulletins

Adresa:

Društvo biomedicinskih časopisa i biltena SR Jugoslavije,
Medicinski fakultet, Zavod za farmakologiju, Pregradak 380,
21 000 Novi Sad, Srbija i Crna Gora.
Telefon: (021) 22- 172; Faks: (021) 615-771

Mailing Address:

Yugoslav Society of Biomedical Journals & Bulletins,
Medical School, Department of Pharmacology, P.O.B. 380,
21 000 Novi Sad, Serbia and Montenegro.
Phone: 381- 21- 22 172; Fax: 381- 21- 615 771

UPUTSTVO AUTORIMA

»Jugoslovenska medicinska biohemija« objavljuje originalne naučne i stručne radove iz oblasti kliničke hemije, medicinske biohemije i drugih srodnih disciplina u kojima se primenjuju hemija, biohemija, molekularna biologija i imunohemija za izučavanje normalnih i patoloških procesa u humanom organizmu. Na predlog recenzenata radovi se klasifikuju u sledeće stalne kategorije časopisa: a) lični stav, b) pregledni članci, c) originalni naučni radovi, d) stručni radovi, e) predhodna saopštenja, i f) izlaganja sa naučnih skupova. Časopis objavljuje obaveštenja, prikaze knjiga, izveštaje o radu DMBSCG, IFCC-a i drugih srodnih organizacija, pisma uredništvu, kao i informacije o novinama u oblasti proizvodnje reagensa i instrumenata iz oblasti kliničke hemije.

Svi radovi se šalju Uredništvu Jugoslovenske medicinske biohemije, Zavod za medicinsku biohemiju, Farmaceutski fakultet, Vojvode Stepe 450, 11221, Beograd, Fah 146.

Prispele radove Redakcijski odbor šalje dvojici recenzenata anonimno. Rukopisi koji ne zadovoljavaju utvrđene kriterijume vraciće se autorima na preradu, ako tako predlože recenzenati.

Prvi otisak članka se šalje autoru radi ispravke. Rukopisi se ne vraćaju.

1. Tekst rada

Čitav rad, uključujući sve priloge treba poslati u duplikatu i to original i odgovarajuću fotokopiju rada. Original mora da sadrži sve priloge izrađene na način opisan pod 2. Rad treba da bude ofkucan sa dvostrukim proredom, tako da na jednoj stranici bude najviše 30 redova; s leve strane treba ostaviti beli rub širok oko 4 cm. Pregledni članci i originalni radovi mogu da imaju do 15 kucanih strana, a ostali do osam strana sa svim priložima. Radovi moraju da imaju sledeći sadržaj:

1.1. Naslov rada treba da bude jasan i što kraći, ofkucan na posebnom listu papira s imenima autora koji se navode prvo punim imenom, zatim prezimenom. Ispod toga treba navesti tačan naziv ustanove u kojoj je rad urađen. Na dnu stranice treba napisati adresu autora sa kojim će se vršiti korespondencija.

1.2. Na posebnoj stranici se prilaže kratak sadržaj, koji ne sme da bude duži od 120 reči. Ne sme biti opisan, već mora da sadrži sve bitne činjenice iznete u radu: kratak i precizan prikaz problema, metode rada, bitne rezultate i osnovne zaključke.

1.3. Kratak sadržaj na engleskom jeziku se takođe prilaže na posebnoj stranici papira. Treba da sadrži i naslov rada na engleskom jeziku.

1.4. Ključne reči se navode ispod teksta kratkog sadržaja bilo da je na srpskom ili engleskom jeziku. Treba navesti od 2–5 ključnih reči koje su značajne za brzu identifikaciju i klasifikaciju sadržaja rada.

1.5. Uvod rada treba pisati jasnim jezikom uz navođenje suštine problema i svrhe istraživanja. U uvodu se navode poznati radovi koji su u vezi sa opisanom problematikom.

1.6. U eksperimentalnom delu treba detaljno opisati korišćene materijale i metode. Ako su primenjene metode poznate u literaturi nije ih potrebno detaljno opisivati, već navesti izvorni literaturni podatak. Ako se u radu prikazuje nova metoda ili modifikacija poznate metode potrebno ih je detaljno opisivati. Ako je u radu primenjena statistička analiza rezultata potrebno je navesti koje su metode primenjene.

1.7. Rezultate treba jasno i precizno prikazati. Značajnost rezultata treba obraditi statistički. Rezultate treba izražavati u skladu sa međunarodnim mernim sistemom (SI).

1.8. U diskusiji treba interpretirati dobijene rezultate i njihovo poređenje sa postojećim rezultatima prema navedenoj literaturi. Na osnovu ovako upoređenih rezultata treba iskazati zaključke do kojih se u radu došlo.

1.9. U celini rad treba pisati u trećem licu i izbegavati pasivne glagolske oblike.

2. Tabele i slike

Rad treba da sadrži razuman broj slika i tabela.

2.1. Tabele se pišu na posebnom listu papira. Označavaju se rimskim brojevima. U zaglavlju tabele treba napisati kratak informativan opis (legendu). U tabelama ne treba koristiti skraćeni, osim uobičajeno usvojenih prema nomenklaturi i SI sistemu. U tekstu treba naznačiti mesto gde dolazi odgovarajuća tabela.

2.2. Ilustracije (slike, crteži) se označavaju arapskim brojevima prema redosledu kako se u tekstu pojavljuju (u tekstu treba naznačiti mesto ilustracije). Na posebnom listu papira redom treba navesti sve legende (opise) priloženih ilustracija.

Prilažu se crno-bele fotografije na sjajnom, kvalitetnom papiru. Na poleđini slike treba mekom olovkom napisati broj slike i naslov rada i ime autora. Crteži se izrađuju tušem na paus papiru i prilažu se originalu. Slova i znakovi moraju da budu jasni, jednake veličine i odgovarajućih proporcija za štampu. Na vrhu crteža treba napisati ime prvog autora i pomoću strelice označiti vrh slike ili crteža.

3. Podaci o literaturi

Popis literature se piše na posebnom papiru prema redosledu javljanja u tekstu.

Literatura se u tekstu označava arapskim brojevima u zagradi, prema redosledu pojavljivanja. U popisu citirane literature podatke poređati po redosledu po kojem se prvi put pojavljuje u tekstu. Za naslove časopisa koristiti skraćene prema Index Medicus (List of Journals Indexed). Jugoslovenski časopisi koji se ne indeksiraju u ovoj publikaciji skraćuju se na osnovu Liste skraćenih naslova jugoslovenskih serijskih publikacija. Vankuverska pravila precizno određuju redosled podataka i znake interpunkcije kojima se oni odvajaju, kako je u nastavku dato u pojedinim primerima. Navode se svi autori; ukoliko ih je preko šest, navesti prvih šest i dodati »et. al.«.

Primeri:

Članci u časopisima

- *Standardni članak*
Goate AM, Haynes AR, Owen MJ, Farral M James LA, Lai LY, et al. Predisposing locus for Alzheimer's disease on chromosome 21. *Lancet* 1989; 1: 352–5.
- *Organizacija kao autor*
The Royal Marsden Hospital Bone-marrow Transplantation Team. Failure of bone-marrow graft without preconditioning in posthepatitis marrow aplasia. *Lancet* 1977; 2: 742–4.
- *Nisu navedena imena autora*
Coffee drinking and cancer of the pancreas (editorial). *BMJ* 1981; 283: 628.
- *Volumen sa suplementom*
Magni F, Rossoni G, Berti F. BN-52021 protects guinea pig from heart anaphylaxis. *Pharmacol Res Commun* 1988; 20 Suppl 5: 75–8.
- *Sveska sa suplementom*
Gardos G, Cole JO, Haskell D, Marby D, Pame SS, Moore P. The natural history of tardive dyskinesia. *J Clin Psychopharmacol* 1988; 8 (4 Suppl): 31S–37S.

Knjige i druge monografije

- *Jedan ili više autora*
Eisen HN. *Immunology: an introduction to molecular and cellular principles of the immune response*. 5th ed. New York: Harper and Row, 1974: 406.
- *Urednik(ci) kao autor*
Danset J, Colombani J, eds. *Histocompatibility testing* 1972. Copenhagen: Munksgaard, 1973: 12–8.
- *Poglavlje u knjizi*
Weinstein L, Shwartz MN. Pathologic properties of invading microorganisms. In: Soderman WA Jr, Soderman WA, eds. *Pathologic physiology: mechanisms of disease*. Philadelphia: Saunders, 1974: 457–72.
- *Rad u zborniku radova*
Harley NH. Comparing radon daughter dosimetric and risk models. In: Gammage RB, Knye SV, eds. *Indoor air and human health. Proceedings of the Seventh Life Sciences Symposium: 1984 Oct 29-31; Knoxville (TN)*. Chelsea (MI): Lewis, 1985: 69–78.
- *Disertacije i teze*
Cairns RB. *Infrared spectroscopis studies of solid oxygen*. Dissertation. Berkeley, California; University of California, 1965.

UREDNIŠTVO

INSTRUCTIONS TO AUTHORS

»Jugoslovenska medicinska biohemija« is the journal publishing scientific and specialized articles on all aspects of clinical chemistry, medical biochemistry and related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry are dealing with the study of normal and pathologic processes in human beings. All manuscripts are reviewed and after final decision are classified in the following categories: a) personal view, b) review articles, c) original papers, d) professional papers, e) preliminary reports, and f) review of scientific meetings. There are also different reports and news, book reviews, reports on the activity of the Society of Medical Biochemistry of Serbia and Montenegro, IFCC and other related organizations, letters to the editor, and information about innovations, new reagents and instruments in the field of clinical chemistry.

All manuscripts should be addressed to:

The Editor, »Jugoslovenska medicinska biohemija«, Department of Medical Biochemistry, University School of Pharmacy, Vojvode Stepe 450, 11 221 Belgrade, P.O. Box 146, Serbia and Montenegro.

All manuscripts will be reviewed by two anonymous reviewers. Manuscripts which do not satisfy the proposed criteria will be returned to the author for adaptation to reviewers suggestions. Final decision for publishing will be made by the Editorial Board.

The author will receive first proofs for correction. Manuscripts are not returned.

1. Manuscript Preparation

The complete manuscript, including enclosures, should be sent in two copies (original and a photocopy). Enclosures to original copy should be prepared according to instructions given in section 2. The manuscript should be typed or printed double-spaced (30 lines on a page), with a 4 cm left margin. Review articles and original papers should not exceed 15 pages and other articles 8 pages, including all enclosures. The manuscript has to be arranged as follows:

1.1. The title should be short and clear, and typed on the separate sheet, with full names of authors, followed by the name of institution. Exact postal address of the author to whom communications should be sent is typed at the bottom.

1.2. A summary should be short and clear, typed on the separate sheet, not exceeding 120 words. The summary should point to the problem, methods, results and discussion.

1.3. A short summary in Serbian language should be typed on the separate sheet, beginning with the Serbian title.

1.4. At the end of the Serbian and English summaries up to five key words should be written for indexing purposes.

1.5. Introduction should be clear, pointing to the essence of the problem and the purpose of the study. References related to the problem discussed in manuscript should be cited.

1.6. The experimental part should include description of material and methods used. If methods are widely known, they should not be described, but only references indicated. If the article deals with a new method or modified method, full description should follow. Methods used in statistical analyses should be indicated.

1.7. Results should be precise and clear, statistically processed and expressed according to the International System of Units (SI).

1.8. Results should be discussed and compared to reference results. Conclusions should be drawn on the basis of these comparisons.

1.9. The manuscript should be written in the third person and passive tense avoided.

2. Tables and figures

The number of tables and figures should be rational.

2.1. Tables are typed on separate sheets, with the table number in roman numerals, and title centered above the table and explanatory note below the table. Abbreviations are not used in the tables, except the accepted nomenclature and SI system. Place of tables in the text should be indicated.

2.2. Figures and graphs are submitted on sheets separate from the text, with the figures and graphs number in arabic numerals, and place in the text indicated. Figure and graph legends are typed on sheets separate from the text.

Black and white photographs of good quality are submitted. The first author's name, figure number and top location are indicated on the back of each illustration.

Original drawings, made in India ink on tracing paper, are submitted. Letter symbols and signs should be bright, of equal size and appropriate printing proportions. The first author's name, drawing number and top location are indicated on the back of illustration.

3. References

References are typed on sheets separate from the text and follow the text. References are identified in the text by arabic numerals in parentheses, and numbered consecutively in the order in which they are mentioned in the text. If one reference is cited several times in the text, the same number is indicated in parentheses.

Citations such as »personal communication«, »unpublished data« or »in press« are not accepted. Abbreviations of journals conform to those used in Index Medicus (List of Journals Indexed). After the volume, first and last page of the cited article are indicated,

followed by the year of publication. Vancouver rules precisely determine the order of data and punctuation marks as given in examples. List all authors if six or less; otherwise list first six and add »et al.«.

Periodicals:

- *Example for articles in journals*

Goate AM, Haynes AR, Owen MJ, Farral M James LA, Lai LY, et al. Predisposing locus for Alzheimer's disease on chromosome 21. *Lancet* 1989; 1: 352–5.

- *Example for institution as author*

The Royal Marsden Hospital Bone-marrow Transplantation Team. Failure of bone-marrow graft without preconditioning in posthepatitis marrow aplasia. *Lancet* 1977; 2: 742–4.

- *Example for articles without authors' names*

Coffee drinking and cancer of the pancreas (editorial). *BMJ* 1981; 283: 628.

- *Example for volume with supplement*

Magni F, Rossoni G, Berti F. BN-52021 protects guinea pig from heart anaphylaxis. *Pharmacol Res Commun* 1988; 20 Suppl 5: 75–8.

- *Example for number with supplement*

Gardos G, Cole JO, Haskell D, Marby D, Pame SS, Moore P.

The natural history of tardive dyskinesia. *J Clin Psychopharmacol* 1988; 8 (4 Suppl): 315–375.

Books and monographs

- *Example for one or more authors*

Eisen HN. Immunology: an introduction to molecular and cellular principles of the immune response. 5th ed. New York: Harper and Row, 1974: 406.

- *Example for editor(s) as author(s)*

Danset J, Colombani J, eds. Histocompatibility testing 1972. Copenhagen: Munksgaard, 1973: 12–8.

- *Example for chapter in a book*

Weinstein L, Shwartz MN. Pathologic properties of invading microorganisms. In: Soderman WA Jr, Soderman WA, eds. Pathologic physiology: mechanisms of disease. Philadelphia: Saunders, 1974: 457–72.

- *Example for articles in the proceedings*

Harley NH. Comparing radon daughter dosimetric and risk models. In: Gammage RB, Knye SV, eds. Indoor air and human health. Proceedings of the Seventh Life Sciences Symposium: 1984 Oct 29–31; Knoxville (TN). Chelsea (MI): Lewis. 1985: 69–78.

- *Example for dissertation and thesis*

Cairns RB. Infrared spectroscopic studies of solid oxygen. Dissertation. Berkeley, California; University of California, 1965.

EDITORIAL BOARD